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The rise in America’s drug poisoning rates has been described as a public health crisis and has long 
been attributed to the rapid rise in opioid supply due to increased volumes of medical prescribing in the 
United States that began in the mid-1990s and peaked in 2012. In 2016, the introduction of the “deaths of 
despair” hypothesis provided a more nuanced explanation for the rising rates of drug poisoning deaths: 
increasing income inequality and stagnation of middle-class worker wages, driven by long-term shifts in 
the labor market, reduced employment opportunities and overall life prospects for persons with a high 
school degree or less, driving increases in “deaths of despair” (i.e., deaths from suicide, cirrhosis of the 
liver, and drug poisonings). This focus on economic and social conditions as capable of shaping 
geospatial differences in drug demand and attendant drug-related harms (e.g., drug poisonings) provides 
a larger context to factors potentially underlying the heterogeneous distribution of prescription opioid 
supply across the United States. However, despite the likelihood that economic and social conditions may 
be important demand-side factors that also interact with supply-side factors to produce the rates of fatal 
drug poisonings, little information exists about the effect of area-level socioeconomic conditions on fatal 
drug poisoning rates, and no study has investigated whether socioeconomic conditions interact with 
prescription opioid supply to affect area-level rates of fatal drug poisonings. The overarching goal of this 
dissertation was to test the independent and joint effects of supply- and demand-side factors, 
operationalized as prescription opioid supply and socioeconomic conditions, on fatal drug poisoning in the 
U.S. First, a systematic review of the literature was conducted to critically evaluate the evidence on the 
ecological relationship of prescription opioid supply and socioeconomic conditions on rates of drug 
poisoning deaths. The systematic review provides robust evidence of the independent effect of each 
prescription opioid supply and socioeconomic conditions on rates of drug poisoning deaths. The gap in 
the literature on the joint effects of prescription opioid supply and socioeconomic conditions was clear, 
 
 
with no study examining the interaction between supply- and demand-side factors on rates of fatal drug 
poisonings. Moreover, although greater prescription opioid supply was associated with higher rates of 
fatal drug poisonings in most of the studies, two studies presented contradictory findings, with one study 
showing no effect of supply on drug poisoning deaths and the other showing locations with higher levels 
of prescription opioid supply were associated with fewer drug-related deaths. Three limitations were also 
identified in the reviewed studies that could partially explain the observed associations. First, although 
studies aggregated data on drug poisoning deaths to a range of administrative spatial levels, including 
census tract, 5-digit ZIP code, county, 3-digit ZIP code, and state, no study investigated the sensitivity of 
findings to the level of geographic aggregation. Second, spatial modeling requires the assessment of 
spatial autocorrelation in both the unadjusted and adjusted data, but few studies even assessed spatial 
autocorrelation in the data, and fewer still incorporated spatial dependencies in the model. This is 
important because when spatial autocorrelation is present, the independence assumption in standard 
statistical regression models is violated, potentially causing bias and loss of efficiency. Third, studies 
operationalized prescription opioid supply and socioeconomic conditions using a variety of different 
measures, and no study assessed the sensitivity of findings to the different measures of supply and 
socioeconomic conditions. 
 
Second, the ecological relationship between prescription opioid supply and fatal drug poisonings was 
examined. For this, pooled cross-sectional time series data from 3,109 U.S. counties in 49 states (2006-
2016) were used in Bayesian Poisson conditional autoregressive models to estimate the effect of county 
prescription opioid supply on four types of drug poisoning deaths: any drug (drug-related death), any 
opioid (opioid-related death), any prescription opioid but not heroin (prescription opioid-related death), 
and heroin (heroin-related death), adjusting for compositional and contextual differences across counties.  
Comparisons were made by type of drug poisoning (any drug, any opioid, prescription opioids only, 
heroin), level of geographic aggregation (county versus state), and measure of prescription opioid supply 
(rate of opioid-prescribing per 100 persons and morphine milligram equivalents per-capita). Results 
indicated a positive association between prescription opioid supply and rates of fatal drug poisonings 
consistent across changes in type of drug poisoning, level of aggregation, and measure of prescription 
 
 
opioid supply. However, removing confounders from the model caused the direction of the effect estimate 
to reverse for drug poisoning deaths from any drug, any opioid, and heroin. These results suggested that 
differences in adjustment for confounding could explain most of the inconsistent findings in the literature. 
Finally, a rigorous test of the hypothesis that worse socioeconomic conditions increase risk of fatal drug 
poisonings at the county level, and interact with prescription opioid supply was conducted. This analysis 
used the same pooled cross-sectional time series data from 3,109 U.S. counties in 49 states (2006-
2016). The analysis modeled the effect of five key socioeconomic variables, including three single 
socioeconomic variables (unemployment, poverty rate, income inequality) and two index variables (Rey 
index, American Human Development Index [HDI]) on four types of drug poisoning deaths: any drug 
(drug-related death), any opioid (opioid-related death), any prescription opioid but not heroin (prescription 
opioid-related death), and heroin (heroin-related death). The effect of socioeconomic conditions 
Using a hierarchical Bayesian modeling approach to account for spatial dependence and the variability of 
fatal drug poisoning rates due to the small number of events, the independent effect of socioeconomic 
conditions on rates of drug poisoning deaths and their joint multiplicative and additive effect with 
prescription opioid supply were estimated. Results showed that rates of fatal drug poisonings were higher 
in more economically and socially disadvantaged counties; the five key indicator variables were 
differentially associated with drug poisoning rates; and the American Human Development Index (HDI) 
and income inequality were most strongly associated with fatal drug poisoning rates. Finally, the results 
indicate that both HDI and income inequality interact with county-level prescription opioid supply to affect 
drug poisoning rates. Specifically, the effect of higher prescription opioid supply on rates of fatal drug 
poisonings was greater in counties with higher HDI and more equal income distributions than counties 
with lower HDI and less equal income distributions. Overall, this dissertation increased knowledge about 
the separate and conjoint roles of supply- and demand-side factors in the geospatial distribution of fatal 
drug poisonings in the U.S. The idea that area-level prescription opioid supply are key drivers of 
prescription drug use, misuse, and addiction and the attendant consequences, including nonfatal and 
fatal drug poisonings, has been in the literature for well over a decade. However, no study to date has 
shown that area-level socioeconomic conditions modify the effect of prescription opioid supply on fatal 
drug poisonings. By identifying important contextual factors capable of modifying the effect of prescription 
 
 
opioid supply reductions on mortality, high-risk geographic areas can be prioritized for interventions to 
counter any unintended effects of reducing the prescription opioid supply in an area. As federal and state 
policies continue to target the rising rates of fatal drug poisonings, these findings show that area-level 
socioeconomic conditions may represent an important target for policy intervention during the current 
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The overall mortality rates for drug poisonings rose exponentially in the U.S. from 1979 to 2016 (1). 
Increasing 10-fold, from about 6,100 in 1980 to over 67,000 in 2018 (2), the number of drug poisoning 
deaths per annum has now surpassed the number of deaths due to automobile crashes at their peak, 
more than 55,000 in 1972 (3), and the peak number of deaths from HIV/AIDs, more than the 50,000 in 
1995 (4). Drug poisoning deaths have increased among all age groups over 18 years old and both males 
and females since 1999, but rates are higher for males than females and increasing particularly rapidly for 
25-64 year olds (5, 6).  Although White and Black rates of drug poisoning deaths closely tracked each 
other during the 1980s and 1990s, White mortality increased much faster between 1999 and 2015 (5). 
However, from 2015 to 2017, rates of drug poisonings from all opioids and synthetic opioids have 
increased substantially among nearly all racial/ethnic groups and all age groups (7).  
 
1.1.1. Opioids and drug-related mortality in the US 
Among the over 67,000 drug poisoning deaths in 2018, nearly 47,000 involved an opioid (69%), including 
prescription opioids, heroin, and illicitly manufactured synthetic opioids (i.e., fentanyl and its analogs) (2). 
Whether derived from the opium poppy itself (e.g., morphine) or synthesized in the lab (e.g., fentanyl), 
opioids are a broad class of substances that act on the mu-opioid receptors to produce intense euphoria. 
Located in the central nervous system, mu-opioid receptors are designed to create pleasure sensations 
when they receive naturally produced endorphins in response to pain or other stimuli. Opioids, however, 
overwhelm these receptors to inhibit the communication of pain signals to the brain and produce a much 
more intense euphoria than anything produced by the body naturally. This ability of opioids to relieve pain 
and produce intense euphoria has led them to occupy a controversial role in medicine and society. 
 
1.1.2. Medical and nonmedical use of prescription opioids 
Although it is unfortunate that a physician’s desire to alleviate pain can contribute to a patient developing 
an addiction to or even dying from an opioid pain reliever, 8-12% of chronic pain patients treated with 




per year die from a prescription opioid poisoning (9). Unlike the physiological dependence to prescription 
opioids that develops among patients receiving a high daily dose of opioid pain relievers, addiction to 
prescription opioids—defined by the American Society of Addiction Medicine as the “inability to 
consistently abstain, impairment in behavioral control, craving, diminished recognition of significant 
problems with one’s behavior and interpersonal relationship”(8)—is disproportionately associated with 
several individual- and medication-level factors, including younger age (e.g., 18-30 years) (10), lifetime 
history of psychoactive illicit drug use (11, 12), lifetime psychiatric or substance use disorder (10), a high 
daily dose (≥100 morphine milligram equivalents [MME]) (13, 14), and long-term opioid use (>3 months) 
(13, 15). Moreover, higher rates of prescription opioid poisoning have been documented among patients 
with the following individual- and medication-level factors: older age (>65 years) (16), sleep-disordered 
breathing (17), renal or hepatic impairments (18), lifetime psychiatric or substance use disorder (19, 20), 
prior suicidal thoughts/attempts (21, 22), history of a non-fatal poisoning (20, 23), a high daily dose (14), 
prescribed long-acting opioids (e.g., methadone, extended-release oxycodone) (24-26), combination with 
benzodiazepines (27), and long-term opioid use (>3 months) (28). Although prescription opioid-related 
deaths occur among some patients receiving opioid analgesics during their course of treatment, less than 
half of all prescription opioid-related deaths occurring at the population level can be attributed to legally 
prescribed opioids (20, 29). A study of West Virginia drug poisoning deaths from 1999-2004 found that 
the majority of prescription opioid-related deaths could be attributed to nonmedical use or pharmaceutical 
diversion (20)—the former describing the consumption of a prescription drug either in excess of 
prescribed dose or for non-therapeutic purposes (30) and the latter describing prescription drugs that are 
funneled (i.e., diverted) from legal sources for nonmedical use or sale (31). The most common sources of 
diverted prescription drugs are friends/relatives, doctor prescriptions, dealers, and theft, in that order (32). 
According to data from the 2015 National Survey on Drug Use and Health, 40.8% of people who reported 
nonmedical prescription opioid use reported obtaining them for free from a friend or relative who obtained 
them from doctors, 35.1% reported obtaining the drugs from doctors, and less than 1% reported stealing 
them from physician’s office, clinic, or pharmacy (33). Through illegal prescribing and diverted 
prescriptions, extensive quantities of prescription opioids have become readily available from friends and 




1.1.3. Time trends in opioid prescribing and opioid-related mortality rates 
The dominant narrative about the current drug poisoning crisis traces its root to three coincidental factors 
that changed beliefs about the prescribing of opioid pain relievers. First, two studies (34, 35), of low-
quality but published in prominent journals, reported minimal risk of addiction in patients prescribed opioid 
pain relievers. Second, a rising tide of professional pressures encouraged clinicians to become more 
proactive in identifying and treating chronic pain (36). Third, OxyContin®, an extended release oxycodone 
product released in 1996 was aggressively and deceptively marketed by the pharmaceutical industry (37). 
This narrative fit well with existing data. From 1999 to 2010, the rates of both opioid prescribing and 
opioid-related deaths changed in parallel, with prescribing rates quadrupling from 180 to 782 MME per 
capita and death rates increasing from 1.3 to 5.0 per 100,000 population, respectively (38). Evidence of 
parallel trends in the rates of both the prescription opioid supply and the rates of prescription opioid-
related mortality motivated legislators, high-ranking government officials, and influential policy experts to 
pursue a compendium of interventions to reduce excess or unnecessary prescribing (e.g. prescribing 
guidelines) (39) and identify illegal prescribing (e.g., “pill mills” laws, prescription drug monitoring 
programs) (40-53). Both the prescription opioid supply and the rates of prescription opioid-related 
mortality peaked in 2010—at 782 MME per capita and 3.7 per 100,000 population, respectively—before 
trending slightly downward from 2011 through 2013 (54). Despite initial successes in reducing the rate of 
opioid prescribing (43, 50, 55-58), and possibly prescription opioid-related deaths (52, 59-62), the rise of 
cheap and pure heroin (63)—combined  with the ease of importation and synthesis of manufacturing 
fentanyl and its analogs (64)—led to a rapid increase in the use of illicit opioids (65) and contributed to a 
nearly 6-fold increase in deaths involving heroin or fentanyl and its analogs between 2010 and 2018, from 
6,043 to 34,882, respectively (38). 
 
1.1.4. Geographic variation in the distribution of opioid-related mortality rates 
Over the last three decades, opioid-related mortality spread across the U.S., from the Southwest in 1999, 
through Appalachia in the early 2000s, and into New England and Florida soon after (1). Currently, age-
adjusted mortality rates vary substantially between states, from less than 10 per 100,000 in two states 
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(Nebraska and South Dakota) to greater than 35 per 100,000 in four states (West Virginia, Ohio, New 
Hampshire, and Pennsylvania) (38). Places such as rural New Hampshire and areas of Appalachia, 
including southern Ohio and western Pennsylvania have experienced a disproportionate burden of opioid-
related mortality. Though drug use and its related morbidity and mortality is often perceived to be an 
inner-city problem, and a cumulative preponderance of opioid-related mortality has occurred in 
metropolitan areas, rates in nonmetropolitan areas began to converge with metropolitan rates in 2004 
(66), and by 2015, the nonmetropolitan rate (17.0 per 100,00) surpassed the metropolitan rate (16.2 per 
100,000) (67). However, whether metropolitan or nonmetropolitan, low-income communities and 
communities with multiple social and economic stressors (e.g., high rates of unemployment and poverty) 
bear a disproportionate burden of opioid-related mortality (68-72). 
 
1.1.5. Socioeconomic conditions and drug poisoning deaths 
The relationship between shifting socioeconomic conditions and drug poisoning deaths has received 
considerable attention since the publication of Case and Deaton’s widely-discussed paper (73). This 
model, focused on increasing income inequality and stagnation of middle-class worker wages, posits that 
long-term shifts in the labor market reduced employment opportunities and overall life prospects for 
persons with a high school degree or less, driving increases in “deaths of despair” (i.e., deaths from 
suicides, cirrhosis of the liver, and drug poisonings). This focus on socioeconomic conditions may 
elucidate important demand-side factors that act or interact with supply-side factors to modify the rates of 
drug poisoning deaths. However, surprisingly few studies have investigated the role of socioeconomic 
conditions on drug-related mortality rates (71, 74), and no study to date has investigated whether 
socioeconomic conditions modify the effect of prescription opioid supply on rates of drug poisoning 
deaths. The idea that opioid prescribing rates are causally linked to the drug poisoning crisis in general 
and geospatial distribution of drug poisonings in particular is well accepted in the literature. However, if 
socioeconomic conditions increase prescription opioid demand, the supply of prescription opioids will be 
disproportionately higher in areas with worse socioeconomic conditions. Moreover, an interaction 
between prescription opioid supply and socioeconomic conditions would suggest that the effect of 
prescription opioid supply on fatal drug poisonings will vary based on a location’s socioeconomic 
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conditions, suggesting that area socioeconomic conditions could represent an important policy lever for 
reducing rates of drug poisoning deaths. Despite this, no study has investigated the joint effect of 
socioeconomic conditions and prescription opioid supply on rates of drug poisoning deaths.  
 
1.1.5. Implications for future research 
The dominant narrative about the root causes of the drug poisoning crisis, focused on shifting medical 
norms towards more liberal prescribing practices and profit-oriented corporate actions, led to many public 
health and policy experts to target the “supply side” factors of this crisis (57, 75-81). Focus on the supply 
side of the equation assumes that suppressing the supply of prescription opioids, thereby reducing both 
the incidence of opioid addiction and dependence among chronic pain patients (i.e., iatrogenic 
dependence) and the diversion of prescription opioids to illicit markets, will slow the rising rates of opioid-
related mortality. Based on this assumption, numerous federal, state, and local interventions were 
initiated over the past two decades to suppress excess or unnecessary prescribing (e.g., clinician 
guidelines (39)) and identify illegal prescribing behaviors (e.g., “pill mill” laws (40), prescription drug 
monitoring programs (57, 82, 83)).  With a focus on the supply side of the equation, the metrics of 
success came to center on an intervention’s ability to reduce either the rate of prescribing or the diversion 
of prescription medications (56, 84), instead of a more meaningful population health metric, e.g., rates of 
drug poisonings. Therefore, despite reducing both the prescription opioid supply (43, 50, 55-58) and the 
rates of prescription opioid-related deaths (52, 59-62), the overall rate of opioid-related mortality has 
continued to rise (38).  
 
Given the dominance of supply-side interventions in recent years, reductions in the prescription opioid 
supply are expected to continue over the next several years. However, the effect of these changes in per-
capita prescription opioid supply on opioid-related mortality is less clear. Despite the geographic 
heterogeneity in rates of opioid-related mortality, no study to date has investigated important contextual 
factors that may modify the relationship between per-capita prescription opioid supply and opioid-related 
mortality. The continued rise in opioid-related mortality, despite the reductions in opioid prescribing, raises 
questions about previous assumptions about the relationship between prescription opioid supply and 
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opioid-related mortality, including: 1) Does the effect of prescription opioid supply vary by type of drug 
poisoning death (e.g., drug poisonings from any drug, any opioid, prescription opioid, or heroin)?; and 2) 
Are there factors that interact with prescription opioid supply to affect rates of drug poisoning deaths? 
Given that the majority of prescription opioid-related deaths can be attributed to nonmedical use or 
pharmaceutical diversion (20), these questions require that studies must move outside of clinical samples 
to population-based studies; otherwise, potentially informative factors that contribute to the rates of drug 
poisoning deaths among people outside of clinical care will be overlooked. To answer Question 2, 
studying the substantial temporal and geospatial variability in drug-related mortality rates may help 
elucidate the factors that increase aggregate demand for drugs and interact with supply-side factors to 
modify drug-related mortality rates. Through identifying the contextual factors that may modify the effect 
of prescription opioid supply on mortality, actionable information is gained about the types of geographic 
areas that may experience some unintended consequences from supply-side interventions, providing an 






1.2. Dissertation overview  
This dissertation pursues an explanation for geospatial distribution of drug poisoning deaths in the U.S. It 
is motivated by the idea that no single factor can explain the current drug poisoning crisis and the effect of 
supply-side factors will be best understood in the context of the demand-side factors that act with supply 
to cause drug use, misuse, addiction, and poisonings. Specifically, this dissertation has three primary 
aims. In aim 1, the ecological relationship between each prescription opioid supply and area 
socioeconomic condition on the rates of drug poisoning deaths will be documented in a systematic 
literature review. Aims 2 tests whether county-level rates of drug poisoning deaths are higher in counties 
with greater prescription opioid supply, investigating the sensitivity of results to level of geographic 
aggregation, type of drug poisoning death, and source of prescription opioid supply data. Finally, aim 3 
investigates the effect of socioeconomic conditions on drug poisoning deaths, testing whether prescription 
opioid supply and socioeconomic conditions interact to cause disproportionately higher rates of drug 
poisoning deaths in areas with both factors, compared to areas with higher supply only, worse 
socioeconomic conditions only, or neither.  
 
This dissertation has five chapters. After this introduction, Chapter 2 reports the results from the 
systematic literature review of the ecological relationship between both prescription opioid supply and 
area socioeconomic conditions with rates of fatal drug poisonings (Aim 1). In this systematic review, I 
searched the literature for studies investigating the geographic distribution of drug poisoning deaths, 
effects of contextual, area-level factors on drug poisoning mortality rates, and the range of statistical 
models commonly applied to investigate the geographic patterning of drug poisoning mortality rates.  
 
Chapter 3 presents the results from testing effects relevant to Aim 2. Using repeated cross-sectional 
mortality data obtained through the restricted-use National Vital Statistics System (NVSS) and 
prescription data obtained through the QuintilesIMS Transactional Data Warehouse (TDW) (2006-2016), 
the effect of county-level per-capita prescription opioid supply on drug-related mortality rates is estimated. 
For this analysis, the results from the systematic literature review were used to construct a Directed 
Acyclic Graph (DAG), identifying the set of necessary adjustment variables needed in the model to 
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estimate the total effect of prescription opioid supply on rates of drug poisoning deaths at the county-
level. Based on the DAG, the necessary set of adjustment variables included four county-level 
socioeconomic variables (county distribution of age, race/ethnicity, income, and sex), one place-based 
factor (urbanicity), and three state policies (prescription drug monitoring programs [PDMPs], medical 
marijuana laws [MML], and recreational marijuana laws [RML]). Finally, to model the hierarchical (i.e., 
counties nested within states) and spatial nature of these data, a hierarchical Bayesian approach was 
used to estimate a generalized linear mixed model (GLMM) with a conditional autoregressive (CAR), 
adjusting for spatial autocorrelation of outcome rates between adjacent areas within each state and year. 
Finally, tests of the sensitivity of effect estimates to the level of geographic aggregation and the measure 
of prescription opioid supply are reported. 
 
Chapter 4 presents results of the effects examined in Aim 3. County-level indicators of socioeconomic 
conditions are regressed on the count of drug poisoning deaths for the years from 2006 to 2016 to 
estimate the direct effect of county socioeconomic conditions on drug poisoning deaths. By 
conceptualizing socioeconomic conditions as drivers of demand for prescription opioids, I then test 
whether socioeconomic conditions modify the effect of prescription opioid supply on county-level rates of 
drug poisoning deaths. The identification of interaction between socioeconomic conditions and 
prescription opioid supply would bring together the two most often cited explanations for the rise in drug 
poisoning deaths over the last few decades into a single novel model with multiple interacting factors.  
 
Chapter 5 presents a discussion of findings of this dissertation and future direction for research. The 
findings from this dissertation will challenge the scientific community, policy makers, and the general 
population to move beyond a discussion about any one single cause of the drug poisoning epidemic to 
consider the confluence of factors that have acted together to give rise to the current epidemic. These 
findings will help both understand the factors driving drug poisonings in the U.S. and identify the areas in 
the U.S. where risk is disproportionately distributed, which in turn will inform potential levers for future 
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Background: Drug poisonings are among the leading causes of loss of years in life expectancy in the 
United States (U.S.) in the 21st Century. Changes in the prescription opioid supply and deteriorating 
socioeconomic conditions are among the leading hypotheses for the rapid rise in fatal drug poisonings 
over the past three decades. Understanding the contribution of the prescription opioid supply and 
socioeconomic conditions in areas experiencing the greatest increase in drug poisoning deaths is 
therefore a major public health priority. This study aims to evaluate the ecological relationships between 
prescription opioid supply and socioeconomic conditions on rates of drug poisoning deaths in the U.S. 
and explore the analytical approaches to analyzing the spatial associations between these factors.  
 
Methods: Eligible publications from MEDLINE, EMBASE, PsychINFO, Web of Science, and EconLit 
indexed through February 2019 and additional studies from reference lists were reviewed. Observational 
studies (published in English) from U.S. states that examined an ecological association between area 
prescription opioid supply or economic conditions and fatal drug poisonings were included. Two 
investigators extracted data from and rated the risk of bias of studies using established criteria.  
 
Results: Of 1,267 records, 17 articles met the inclusion criteria. These articles examined prescription 
opioid supply only (n = 6), economic conditions only (n = 9), prescription opioid supply and economic 
conditions (n = 2). Low-strength evidence from 7 studies suggested higher rates of fatal drug poisonings 
in areas with greater prescription opioid supply. Low-strength evidence from 11 studies suggested an 
increase in fatal drug poisonings in locations with worse economic conditions. The results were invariant 
with respect to study design, study population, data sources, and different definitions of fatal drug 
poisonings. Limitations include high risk of bias from inadequate adjustment for potential confounding 
variables and failure statistically to model spatial and temporal autocorrelation was common.  
 
Conclusions: Higher prescription opioid supply and worse economic conditions seems to increase rates 
of fatal drug poisonings. Research is needed to identify whether the effect of prescription opioid supply on 
fatal drug poisonings is modified by a location’s economic conditions.  
CHAPTER 2: PRESCRIPTION OPIOID SUPPLY AND SOCIOECONOMIC DETERMINANTS 




Mortality resulting from drugs (generally referred to as “drug-related mortality” or “drug poisoning deaths”) 
has risen exponentially since 1979 in the United States (U.S.) (1), increasing more than 10-fold, from 
about 6,100 deaths in 1980 to over 67,000 in 2018 (2). This trend was driven by three sequential waves 
of drug poisonings, attributed to three different classes of opioids: in the first wave, mortality attributed to 
prescription opioids (e.g., hydrocodone, oxycodone) increased most rapidly, rising from 1.0 deaths per 
100,000 in 1999 to 3.5 deaths in 2010; in the second wave, mortality attributed to heroin began to rise, 
increasing nearly 5-fold, from 1.0 deaths per 100,000 in 2008 to 4.8 deaths in 2017; and the third wave 
was deaths from synthetic opioids (other than methadone), primarily illicitly manufactured fentanyl and 
fentanyl analogs mixed with heroin, which spiked from 1.8 deaths per 100,000 in 2014 to 9.0 deaths in 
2017 (1, 3).  
 
Two views dominate the narrative about the causes of the current crisis, one devoted to examining 
aspects of the ‘supply side’ of this crisis, focused on the rapid increase in the availability of 
pharmaceutically manufactured opioids brought about by overprescribing opioid analgesics for chronic 
pain (4-8), and the other concentrated on investigating the ‘demand side’ of the crisis, such as worsening 
socioeconomic conditions, increasing income inequality, and stagnation of worker wages (9, 10). Many 
consider that these issues of drug supply and demand are intertwined (11-13). Indeed, the rapid rise of 
opioid prescribing that occurred in the U.S. between the mid-1990s and 2010 has been recognized as a 
driving force of the 250% increase in prescription drug abuse over the same 20-year period (14). 
Policymakers need more systematic understanding on the interlinked supply-demand factors to better 
address the effects of rising rates of opioid prescribing and manage the potential consequences caused 
by unmet demand in the population. However, before expanding investigation to jointly address supply 
and demand factors and develop interventions to target these factors, what is known about each of these 
factors, including the limitations of extant studies, should be clarified. The purpose of this systematic 
review was to synthesize the evidence on the area-level effects of greater access to prescription opioids 
and deteriorating socioeconomic conditions on the geography of drug poisoning deaths in the U.S. 
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2.2.1 Supply: Access to prescription opioids 
Access to prescription opioids increased dramatically in parallel with prescription opioid-related mortality 
between 1999 and 2010, with the quantity of opioids dispensed and rate of prescription opioid-related 
mortality increasing over 400% and 350%, respectively, between 1999 to 2010 (15). Federal and state 
interventions aimed to target the supply side of the market by reducing excess (e.g. prescribing 
guidelines) (16) and illegal prescribing (e.g., “pill mills” laws, prescription drug monitoring programs) (17-
30). Opioid prescribing and prescription opioid-related mortality rates peaked in 2010, before trending 
slightly downward from 2011 through 2013 (31), but overall rates of opioid-related mortality continued to 
rise, driven by a 552% spike in deaths involving heroin and synthetic opioids, particularly fentanyl and 
fentanyl analogs (1, 32). Reductions in the supply of prescription opioids—in part as a result of federal 
and state interventions—may drive some people who use prescription opioids nonmedically and others 
who are dependent on these drugs to switch to a cheaper and more prevalent supply of heroin (30, 33-
38).  This fungibility between prescription opioids and heroin suggest that focusing only on supply-side 
interventions to curb harm from pharmaceutically manufactured opioids may simply lead to a shift in use 
to illicitly manufactured opioids (e.g., heroin, fentanyl and its analogs) (11). Therefore, also identifying the 
demand-side factors that drive opioid use is critical for both understanding the processes that generate 
drug poisoning deaths and developing productive interventions for reducing opioid disorder and other 
attendant harms. 
 
2.2.2 Demand: Population characteristics and place-based measures 
Different regions of the U.S. have exhibited different annual rates and patterns of change in rates of drug 
poisoning deaths (39, 40). Prior research suggests that socioeconomic factors may partly explain these 
patterns. The effect of socioeconomic place-based factors on morbidity and mortality is well documented 
(41-47). Economic insecurities during periods of unemployment reduce access to material resources 
(e.g., food, housing) (48-51) and increase psychosocial stress (49, 50). Financial and psychosocial 
stressors affect health directly or through harmful coping behaviors, including increased smoking (52, 53), 
alcohol consumption (54, 55), and drug use (56, 57). Unemployment is associated with overall mortality 
(42, 45, 47, 58) and drug-related mortality (45, 46, 59). Displaced workers, individuals who lose their jobs 
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as part of plant closing, mass layoff, and other company-level employment reductions, have a 10-15% 
increase in annual death hazard (47) in general and an 85% increase in opioid-related mortality 
specifically (59). Case and Deaton (10) documented a recent spike in mortality rates among less 
educated middle-aged non-Hispanic Whites in the U.S., particularly deaths due to suicide, cirrhosis of the 
liver, and opioid poisonings. They ascribed these deaths to long-term shifts in the labor market that 
reduced employment opportunities and overall life prospects for persons with a high school degree or 
less. Given that Americans have been experiencing long-term declines in health and longevity since the 
1970s (60-69), increased access to prescription opioids may have acted as a catalyst (70), accelerating 
the previously documented declines in the health of Americans over the past four decades. However, like 
the limitations inherent to examining only the supply-side of drug poisoning deaths, demand-only 
analyses will be limited in their understanding of the problem, making it equally critical to blend demand 
and supply analyses. 
 
Therefore, the purpose of this systematic review was to investigate the context specific effects of (i) 
prescription opioid supply and (ii) socioeconomic conditions and structures that may also affect demand 
on the geography of drug poisoning deaths in the U.S. This review will characterize the range of statistical 
models previously applied in this literature to investigate the geographic patterning of drug poisoning 
deaths, investigating whether methodological differences across previous extant studies could plausibly 
affect the results and conclusions of these studies, and conclude with recommendations for future study 
into the distribution of drug-related harms and its causes.  
 
2.3. Methods 
2.3.1. Data Sources and Searches 
This systematic review follows the Preferred Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) guidelines (71). The protocol for this review was developed and published to Prospero, an 
international prospective register of systematic reviews, in February 2018 (Registration number: 
CRD42019121317) and each step was pilot tested to train and calibrate investigators. For full protocol 




2.3.2. Literature search 
In January 2019, five online databases were searched, including MEDLINE, EMBASE, PsychINFO, Web 
of Science, and EconLit, for titles and abstracts of articles that investigated the spatial distribution of drug-
related mortality or the association between area-level factors and drug-related mortality. Appendix Table 
1 contains the search strategies. No time restriction was imposed on searches, but articles were restricted 
to the English language. ClinicalTrials.gov was searched for relevant completed and ongoing studies. 
Review articles and references from the selected studies were manually searched to identify papers. 
Dissertations, peer reviewed articles, and government reports were included. All resulting study titles and 
abstracts were exported to DistillerSR (72), a web interface for conducting the screening and data 
extraction phase of the review. Duplicate entries were removed.  
 
2.3.2. Study Selection 
We included observational studies (e.g., cohort, case-control, cross-sectional, natural experiments) that 
estimated the association between area-level (e.g., Census tract, county, Zip code, state) prescription 
opioid supply or socioeconomic conditions on drug-related deaths in the U.S. For the purposes of this 
systematic review, drug-related deaths were defined using the uniform standards and case definitions 
consistently agreed upon by the Substance Abuse and Mental Health Service Administration (SAMHSA) 
Consensus Panel (73): any death due to the acute exposure to a drug, either alone or in combination with 
other drugs or substances, regardless of intention, and equivalent to the layperson’s concept of a drug 
overdose. Area-level prescription opioid supply were defined as any reported or calculated statistic from 
an administrative dataset on the rate of opioid prescribing or quantity of prescription opioids dispensed in 
a spatially defined area (i.e., census tract, ZIP code, county, state). Area-level socioeconomic conditions 
included any statistics from the U.S. Census Bureau or any other administrative dataset on the social 
(i.e., income inequality), economic (i.e., unemployment, employment-to-population ratio, poverty rate), or 
industry structure (i.e., share of employment attributed to different sectors [e.g., manufacturing]) in a 
spatially defined area. Commentaries or opinion papers without results on geography or drug poisonings 




The first author conducted the initial screening of all titles and abstracts for eligibility, and those 
considered relevant advanced to the full review.  Two investigators independently reviewed all full texts of 
selected articles to identify those that met the inclusion criteria. Agreement between the two investigators 
was required for exclusion of full texts. The two investigators agreed on 85% of the studies; for those with 
discordant initial evaluations, the two investigators resolved all conflicts by discussion, determining 
whether each study fit the previously described inclusion criteria. In each stage of the study selection 
process, the order of studies was randomized to prevent bias due to review fatigue.  
 
2.3.3. Data Extraction and Quality Assessment 
For each included study, an investigator abstracted data using a customized data extraction form in 
DistillerSR (Appendix Document 3). Relevant data included details on the study population (such as 
locations included or excluded, years of data collection), details on the outcome (such as source of 
mortality data, definition of drug-related mortality, type of drugs included or excluded), details on the 
exposure (such as source of data, years of data included, definition of each measure), details on the 
primary unit of analysis (such as point or aggregated data, level of aggregation [e.g., ZIP code, county, 
state]), details of the analytical approach (such as model specification, handling of spatial and temporal 
autocorrelation, handling of potential confounding), and results (such as point estimates and standard 
deviations or confidence intervals, P values). Risk of bias was assessed using the Effective Public Health 
Practice Project Quality Assessment Tool (EPHPP) (74). This tool, which has content and construct 
validity (74, 75), is used to evaluate the risk of bias in both randomized trials and observational studies. 
By answering questions provided by the EPHPP, the investigators assessed ROB within five specific bias 
domains (selection bias, study design, confounders, data collection method, analysis, and overall bias), 





2.3.4. Data Synthesis and Analysis 
The heterogeneity of study populations, years, sources and definitions of exposures and outcomes 
precluded formal meta-analysis. Instead, we performed a qualitative assessment and synthesis using 
methods outlined by the Agency for Healthcare Research and Quality (76). Studies were categorized into 
two groups on their exposure variable: prescription opioid supply or socioeconomic conditions. The 
investigators assessed the overall strength of evidence (SOE), considering 4 domains: study limitations 
(determined by using EPHPP ROB tool), directness (whether evidence linked exposure directly to a key 
question in the review), consistency (degree to which studies found the same direction of effect 
estimates), and precision (degree of certainty surrounding an effect estimate). Based on grades from the 
4 specific domains, we rated the overall SOE for the effect of each exposure on drug-related mortality as 




2.4.1. Literature Search 
Figure 1 depicts the literature search and selection process. The search yielded 1,267 papers and 
another 6 were added from reviewing references included papers (n=1,273). After removing 138 
duplicates, 1,135 unique papers were included in the initial screening stage, and 171 selected for full-text 
review. Of these 171 articles, 17 met the inclusion criteria: 5 studies investigated the effect of prescription 
opioid supply only (77-81), 9 studies investigated the effect of economic conditions only (82-90), and 2 
studies investigated the effect of both prescription opioid supply and socioeconomic conditions on drug-
related mortality (91, 92). Appendix Tables 2 and 3 presents the characteristics of the included studies, 
and their primary findings, and Appendix Table 4 the ROB assessments of the studies. 
 
2.4.2. Definition of outcome variable 
Diagnostic criteria used included the International Classification of Diseases (ICD), 9th revision (85), or 
ICD-10. One study, conducted in New York City, used ICD-9 code 304, deaths from drug dependence, to 
identify drug-related deaths (85). Although this code is generally intended for deaths attributed to chronic 
use or consequence of substance dependence (e.g., dilated cardiomyopathy, aspiration pneumonia) 
rather than acute poisoning, the New York City’s Department of Health gave the vast majority of drug-
related deaths (97%) this code prior to adoption of ICD-10 (93). ICD-10 codes based on both the manner 
and contributing cause of death were used to identify drug poisonings. Manner of death included 
unintentional (X40-X44), intentional (X60-X64), homicide (X85), or undetermined (Y10-Y14). Contributing 
cause codes were used to identify whether deaths were attributed to a natural or semi-synthetic opioid 
(T40.2), heroin (T40.1), or synthetic opioid (T40.4). Data on drug poisonings predominantly came from 
the Multiple Cause of Death (MCOD) files produced by the National Center for Health Statistics of the 
Centers for Disease Control and Prevention (CDC) (78-81, 83, 84, 86, 88, 90-92). Of the six studies that 
did not use the MCOD files, four used data from the Office of the Chief Medical Examiner of New York 
City (82, 85, 89, 90), one used information from the New Jersey Medical Examiner regarding fentanyl-




2.4.3. Prescription opioid supply and drug-related mortality 
Type and source of exposure data. Studies operationalized area-level access to prescription opioid 
supply using one of three approaches: (1) the number of opioid prescriptions dispensed, acquired by 
IQVIA Xponent (formerly Quintiles and IMS Health, Inc.), made available at the county level through the 
CDC (80, 94);  (2) the morphine milligram equivalents (MME) of prescription opioids dispensed in an area, 
available at the 3-digit ZIP code by the U.S. Drug Enforcement Administration (DEA) Automation of 
Reports and Consolidated Orders System (ARCOS) (77-79, 92); or (3) the percentage of prescriptions 
written and submitted to be filled under Medicare Part D for opiate analgesics, compared to non-opioid 
prescriptions, available at the county level from the Centers for Medicare and Medicaid Services (CMS) 
(81). For comparison of three prescription opioid supply datasets, see Appendix Table 5. 
 
Seven studies estimated the effect of prescription opioid supply on drug-related mortality. The years of 
data ranged from 1999 to 2016. Two studies used cross-sectional data from a single year (77, 79) and 
five studies used longitudinal data (78, 80, 81, 91, 92) (Table 1). Among the longitudinal studies, 7 years 
of data were analyzed on average, ranging from 2 (78, 80, 91) to 14 years (81). Three studies analyzed 
data from a single U.S. state (77, 78, 80) and 4 studies analyzed nationally representative data (79, 81, 
91, 92). The units of analysis included county (80, 81, 91, 92), 3-digit ZIP code (77, 78), state (79), and 
national (92). 
 
Findings from the studies varied (Appendix Table 2). Five studies reported a positive association between 
prescription opioid supply and drug-related mortality (77, 79, 81, 91, 92), i.e., a greater area-level supply 
of prescription opioids was associated with higher levels of drug-related mortality. One study found a 
negative association (80), and one study found no association (78).   
 
Most of the studies reporting a positive association between prescription opioid supply and drug-related 
mortality were nationally representative, including data from 48 U.S. states or more, and analyzed at the 
county-level (81, 91, 92). One national study estimated the effect of prescription opioid supply on drug-
related mortality at two different levels of aggregation, at the county- and the national-level. Using data on 
 
 22 
per capita MME from 2000 to 2011 from all 50 U.S. states and Washington D.C., Ruhm (92) found that 
the association with prescription opioid-related mortality rates was approximately 20 percent smaller at 
the county than the national level.  
 
Three studies analyzed data from a single U.S. state: a New Jersey study found 3-digit ZIP codes with 
high quantities of oxycodone dispensed were associated with higher number of fentanyl-related deaths 
(77); a North Carolina study found no association between per-capita MME and unintentional drug 
poisonings at the 3-digit ZIP code level (78); and a New York study found that for every increase in 
prescriptions by 10,000, the number of natural/semi-synthetic drug poisoning deaths decreased by 0.12% 
(80). All three studies had serious risk of bias from inadequate adjustment of confounding: one study 
adjusted for only median income and population share of non-Hispanic white (77), one study only 
adjusted for county age distribution (80), and one study included no adjustment variables (78).  
  
2.4.4. Disadvantaged socioeconomic conditions and drug-related mortality 
Economic conditions were operationalized using both measures of a single socioeconomic feature (single 
component of the economy, e.g., unemployment rate) and composite measures or index measures 
(combination of multiple socioeconomic features). The most common single socioeconomic features were 
unemployment rate (84, 86, 92), median household income (82, 87, 92), poverty rate (84, 87, 92), income 
inequality (82, 89, 90), percent of total income earned by the lowest 70% of households (89, 90), 
employment-to-population ratio (84), median home prices (92), industrial dependencies on specific job 
sectors (88, 91), and change in the share of employment due to manufacturing (83), in that order. Each of 
the four studies using index measures (85, 88, 91, 92) created unique composite measures comprised of 
varying socioeconomic features. For example, Monnat (91) created a composite measure of economic 
distress using a standardized (z-score) factor-weighted index of 6 indicators: (i) percent of households in 
below poverty line; (ii) the ratio of state-to-county median household income; (iii) percentage of 
households receiving public assistance income; (iv) percentage age 25 or older without a four-year 
college degree; (v) percent not-working (unemployed or not in the labor force); and (vi) percent with a 
work disability. In contrast, Hannon et al. (85) summed 4 indicators: (i) poverty rate; (ii) median family 
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income (reverse coded); (iii) percentage of households receiving public assistance income; and (iv) 
unemployment rate. No study used a validated index of area socioeconomic well-being. 
 
Eleven studies investigated the effect of socioeconomic conditions on drug-related mortality (Appendix 
Table 3). The years of data ranged from 1991 to 2016. Two studies used cross-sectional data from a 
single year (89, 90) and nine studies used longitudinal data (82-88, 91, 92). Among the longitudinal 
studies, 8 years of data were analyzed on average, ranging from 2 (91) to 16 years (92). Four studies 
analyzed data from a single U.S. city (New York City) (82, 85, 89, 90), one from a single U.S. county (i.e., 
Orange County, California, U.S) (87), and six analyzed nationally representative data (83, 84, 86, 88, 91, 
92). From smallest to largest levels of aggregation, the units of analysis ranged from the census tract (85, 
87), community district or neighborhood (82, 89, 90), county (84, 86, 88, 91, 92), and state (83, 86).  
 
Findings from the studies were consistent and positive. Methodological differences between the studies 
made it difficult to assess consistency in the magnitude of effect estimates or precision (degree of 
certainty surrounding an effect estimate) of evidence on any single socioeconomic feature or compare the 
strength of the evidence for different socioeconomic features. However, within-study comparison of 
different socioeconomic features was possible. For example, two studies have documented higher 
unemployment rates were associated with greater increases in drug-related mortality than were higher 
poverty rates. Ghertner and Groves (84), adjusting for race/ethnicity, age composition, and metropolitan 
status, found that a 1% increase in a county’s poverty rate and unemployment rate was associated with 
1.7% (95% CI=1.3%, 2.1%) and 4.6% (95% CI=3.6%, 5.6%) increase in drug-related mortality rates, 
respectively. Using a two-way fixed effects model (year, state, and year by state) with robust adjustment 
for confounders, Ruhm (92) found that a 1 standard deviation growth in a county’s poverty rate and 
unemployment rate was associated with a 2.21 (95% CI=1.11, 3.30) and 1.37 (95% CI=0.46, 2.28) per 
100,000 faster growth in drug-related mortality rates, respectively. Applying a similar identification 
approach to Ruhm (92), Hollingsworth et al. (86) investigated the association between unemployment 
rate and drug-related mortality in nationally representative U.S. data at two different levels of aggregation 
(86), finding that the magnitude of association between a 1% increase in unemployment rate and drug-
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related mortality rates increased from 0.19 per 100,000 residents (95% CI=0.09, 0.29) to 0.35 per 
100,000 residents (95% CI=0.13, 0.57) from the county- to the state-level, respectively.  
 
Three nationally representative studies reported the relationship between a county’s industry structure 
and drug-related mortality (83, 88, 91). Two studies by Monnat (88, 91) investigated the association 
between county-level economic dependence on different employment sectors, finding that greater 
dependence on mining and services were associated with higher rates of drug-related mortality and 
greater dependence on manufacturing, public sector employment, and farming were associated with 
lower rates; however, this study did not examine the consequences of changes in the share of 
employment due to different industry sectors nor adjust for potentially confounding policy indicators. 
Charles et al. (83) estimated the effect of change in the share of employment due to manufacturing on 
drug- and opioid-related mortality using a shift-share instrument (95, 96), and found a 1% decline in 
manufacturing employment share of prime age workers between 2000 and 2016 was associated with a 
0.05 per 1,000 and 0.02 per 1,000 increase in drug- and opioid-related deaths, respectively. Evidence 
that manufacturing declines had persistent negative effects on local unemployment rates, hours worked, 
and wages (83) suggest that deteriorating economic conditions are likely mediating the effect of local 
industry structure on rates of drug-related mortality.  
 
Three studies using New York City mortality data from 2000 to 2006 found that higher income inequality 
was associated with higher odds of accidental drug poisoning deaths. Compared with the midpoint of the 
most equitable income decile, Galea et al. (89) found that the unadjusted relative odds of death due to 
drug overdose in the 50th decile were 1.49 (95% CI=1.13, 1.95) and in neighborhoods in the 90th decile, 
the odds were 1.88 (95% CI =1.22, 2.88); similar results were found comparing the midpoint of the lowest 
Gini decile to the 50th and 95th percentile (90). Cerda et al. (82) found analgesic opioid and heroin deaths 
occurred in distinct types of neighborhoods, such that areas with higher median incomes experience 
excess prescription opioid-related deaths, whereas areas with higher income inequality experience 
excess heroin-related deaths. These drug-specific effects are likely to reflect spatially patterned risk 
factors and drug environments that are not shared with other neighborhoods. For example, for 
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prescription opioid-related deaths, the increased odds in neighborhoods with higher median incomes 
likely reflects more permissible norms towards and access to prescription opioids than heroin. Similarly, 
the higher odds of heroin-related deaths in neighborhoods with greater income inequality is consistent 
with the research that shows how residential inequality can give rise to social disorganization, reducing a 
neighborhood’s ability to control crime (97-99).   
 
Associations between composite measures of socioeconomic conditions and drug-related mortality 
uniformly found that lower composite scores were associated with higher levels of drug-related mortality. 
Hannon et al. (85), adjusting for census tract composition (i.e., proportion of population foreign born, ages 
25-34 years, percent male, percent Black), found that a 1 standard deviation increase in poverty index 
(i.e., poverty rate, median family income, percentage of households receiving public assistance income, 
and unemployment rate) was associated with 21.7% (95% CI =13.4%, 30.5%) increase in drug-related 
mortality. Adjusting for a limited set of contextual (i.e., urbanicity) and compositional factors (i.e., racial 
composition, age composition, percent in military or veteran), Monnat found a 1 standard deviation 
increase in an economic distress index (i.e., poverty rate, state-to-county median household income, 
households receiving public assistance, persons aged 25 or older without a 4-year college degree, 
percent not working, unemployed, or not in the labor force, percent work disability) in 2000 was 
associated with a 3.17 per 100,000 (95% CI=1.68, 3.72) population increase in county-level rate of drug-
related mortality in 2014-2016. Ruhm (92) presented results for several single socioeconomic features 
(i.e., poverty rate, median household income, median home price, unemployment rate), as well as the 
estimated percentage of the growth in drug-related mortality rates accounted for by a multiple index 
measure of all studied socioeconomic features. Although the single socioeconomic features were 
uniformly positively associated with drug-related mortality, such that counties experiencing relative 
economic deterioration had higher than average increases in drug-related mortality rates, the index 
estimate exceeded the coefficients for any single socioeconomic feature by 15% or more, suggesting the 




2.4.5. Study Quality and Strength of Evidence 
Table 2.1 summarizes the overall strength of evidence (SOE) regarding the effects of prescription opioid 
supply and socioeconomic conditions on drug-related deaths. In general, the SOE was stronger for any 
drug-related death than specific types of fatal drug poisonings (e.g., prescription opioid- or heroin-related 
deaths). A common limitation across comparisons was the small number of studies investigating the more 
specific types of drug poisoning deaths. Low-grade evidence was available for the association between 
per-capita prescription opioid supply on drug-related deaths. This judgment of low overall SOE for the 
relationship between prescription opioid supply on drug-related deaths was based on the studies with 
serious ROB, which were precise and consistent. Insufficient evidence was available for the relationship 
between per-capita prescription opioid supply and fatal drug poisonings from prescription opioids or 
fentanyl. In addition, low-grade evidence was available for the relationship between socioeconomic 
conditions and drug-related mortality, whereas insufficient evidence was available for the relationships 
between socioeconomic conditions and fatal drug poisonings from any opioid, prescription opioids, or 
heroin.  
 
Overall study quality was low. All studies had methodological shortcomings (Appendix Tables 4). 
Inadequate adjustment for time-invariant and time-varying confounding factors was common, with a 
serious ROB due to confounding found in five of the studies (71%) investigating the effect of prescription 
opioid supply (77-80, 91) and eight of the studies (73%) investigating the effect of socioeconomic 
conditions (82-84, 86, 87, 89-91). Bias due to confounding could arise from either time-invariant 
(baseline) confounding that occurs when one or more factors that causes drug-poisoning deaths also 
causes the baseline exposure (i.e., prescription opioid supply or socioeconomic conditions) or time-
varying confounding, which occurs when post-baseline causes of drug-related mortality affect the 
exposure level after baseline (100). Examples of potential sources of bias due to confounding include 
both compositional (e.g., race/ethnicity composition, age distribution, sex distribution) and contextual 
factors (e.g., urbanicity, economic and social conditions) and potential confounding policies (e.g., 
legalization of recreational or medical cannabis, prescription drug monitoring programs). Although most 
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studies adjusted for some sociodemographic variables, only one study adjusted for state-level policy 
changes (e.g., prescription drug monitoring programs, cannabis legalization) (92).  
 
No modeling of spatial or temporal autocorrelation was also prevalent—found in six of the studies (86%) 
studies investigating the effect of prescription opioid supply (77-79, 81, 91, 92) and seven studies (64%) 
(84, 86, 87, 89, 90, 92, 94) investigating socioeconomic conditions. Spatial modeling requires assessment 
of the strength of spatial autocorrelation, and if data exhibit spatial autocorrelation, then spatial 
dependencies need to be incorporated into the models. The most common statistic for assessing spatial 
autocorrelation is Moran’s I—a metric of spatial dependency, measured on a scale from -1 (perfect 
clustering of dissimilar values) to +1 (perfect clustering of similar values), where values around 0 mean 
that there is no autocorrelation. Three studies, included in this review, found Moran’s I from 0.15-0.56 for 
drug-related mortality (82, 84, 88), 0.62 for unemployment (84), 0.14 for employment-to-population ratio 
(84), and 0.50 for prescription opioid supply (80), all indicating considerable potential confounding from 
shared unobserved effects among counties in close proximity. Higher levels of spatial autocorrelation 
were found in more aggregated data, such that Moran’s I increased from 0.15 at the census-tract level 
(82) to 0.49-0.56 at the county-level (84, 88). Despite evidence of spatial autocorrelation, only four studies 
(80, 82, 85, 88) modeled spatial autocorrelation in the data: two studies (85, 88) included a spatial lag 
variable using a 2-stage least squares approach; one study (82) used a spatial weights matrix, created 
from the nearest neighbors algorithm and a hierarchical linear model; and one study (80) applied an 
Empirical Bayes Smoother and included the smoothed residuals as a covariate in the regression model. 
Romeiser et al. (80) found that failure to account for spatial autocorrelation caused the effect estimates to 
be biased away from the null: for every increase of 10,000 prescriptions, the number of opioid mortalities 
declined from 0.16% to 0.12% after adjustment for spatial autocorrelation and the number of methadone 
mortalities declined from 0.80% to 0.15% after adjustment. Moreover, one study included the average 
rate of opioid prescribing among neighboring counties to account for the potential spillover of 
prescriptions across county boundaries, finding that a 1 standard deviation increase in average opioid 
prescribing of neighboring counties in 2009-2011 was associated with an increase of 1.95 (standard 
error=0.29; P < 0.001) drug-related deaths per county in 2014-2016 (94). These results suggest that the 
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adjustment for spatial autocorrelation is necessary for unbiased effect estimates. However, whether the 
inadequate adjustment for confounding or the failure to account for spatial autocorrelation in the data 
introduces more bias is unclear.  
 
2.5 Discussion 
Understanding the contribution of the prescription opioid supply and socioeconomic conditions in areas 
experiencing the greatest increase in drug-related deaths is a major public health priority. This systematic 
review found low-strength evidence that locations with greater prescription opioid supply and worse 
socioeconomic conditions have higher rates of drug-related mortality. The results of these studies were 
largely invariant with respect to the study design (e.g., cross-sectional versus longitudinal), the years of 
data analyzed, the measure and source of exposure data, the different definitions of drug-related death, 
and the primary unit of analysis (e.g., ZIP code, county, state).  
 
Greater prescription opioid supply was associated with higher rates of drug-related mortality in most of 
the studies (77, 79, 81, 91, 92). Only two studies reported contradictory findings, one study finding no 
association between opioid supply and drug-related mortality (78) and the other showing a negative 
association between prescription opioid supply and drug-related mortality (e.g., locations with higher 
levels of prescription opioid supply were associated with fewer drug-related deaths) (80). Close 
examination of the modeling specifications across all studies revealed that the contradictory finding may 
arise from inadequate adjustment for the sociodemographic differences between units. However, an 
alternative explanation exists—the heterogeneity in results may be due to real differences in the 
association between prescription opioid supply and fatal drug poisonings across populations. Specifically, 
whereas the four nationally representative studies uniformly found that greater prescription opioid supply 
was associated with higher drug-related mortality rates (79, 81, 91, 92), the two studies reporting 
contradictory findings focused on single U.S. states: one study reporting no association between 
prescription opioid supply and drug-related mortality in North Carolina from 2008 to 2010 (78) and the 
other study reporting greater area prescription opioid supply was associated with lower rates of drug-
related mortality in New York from 2013 to 2015 (80). Differences in the association between prescription 
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opioid supply and drug-related mortality rates may vary by location due to differences in the underlying 
distribution of component causes across counties or states (i.e., those causes that interact with 
prescription opioid supply to cause drug-related deaths) (101). For example, if risk of drug poisoning is 
higher in persons who use opioids to cope with physical and psychological trauma than among those who 
use opioids to treat pain then the effect of prescription opioid supply on drug-related mortality will be 
greater in places with a higher prevalence of physical and psychological trauma (e.g., locations with 
concentrated disadvantages, isolation, and hopelessness) and lesser in places with a lower prevalence of 
these interacting factors. However, county- or state-specific differences in the association between 
prescription opioid supply and drug-related mortality are obscured in nationally representative studies that 
report the average association across the entire population of counties or states.  Therefore, the average 
effect of prescription opioid supply on fatal drug poisonings may be positive in nationally representative 
data, despite the effect of prescription opioid supply on fatal drug poisonings being null or negative in 
particular states. 
 
Eleven studies provided evidence of the contribution of disadvantaged socioeconomic conditions to rates 
of drug-related mortality, although effects were of relatively low magnitude. Despite these consistent 
findings, however, the key construct, socioeconomic conditions, was not well defined. Studies used a 
variety of different socioeconomic indicators and indices (or composite measures). The most common 
single indicators were unemployment rate (84, 86, 92), median household income (82, 87, 92), and 
poverty rate (84, 87, 92). Three different indices included: the index of economic conditions (92), poverty 
index (85), and economic distress index (88, 91). Although consistent findings across varying measures 
may be useful for demonstrating robustness, the heterogeneity of measures used across the studies 
precludes meta-analysis of results. The decision to use a single indicator or a composite index of multiple 
socioeconomic conditions involves tradeoffs.  Single-indicator measures are straightforward to interpret 
(e.g., a 1% increase in unemployment versus a 1 standard deviation increase in ‘area deprivation’) and 
data on them are widely available. However, they capture only a limited scope of a location’s 
socioeconomic conditions. Composite indices offer a more complete assessment of local socioeconomic 
conditions, offering a single score that summarizes a complex multi-dimensional issue. However, 
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composite measures lack transparency, entail subjectivity in their construction and difficulties in 
combining heterogeneous measures, and lack the ability present uncertainty (102, 103). Moreover, no 
study identified by this review used a validated deprivation index (e.g., Townsend deprivation index, 
Carstairs index) and little research has been carried out on the validity of the various indicator variables 
and indices. Future research is needed to investigate the validity of the most common indicator variables 
and composite indices of area-level socioeconomic status.  
 
2.5.1. Risk of bias within and across studies 
Studies aggregated fatal drug poisoning data to a range of administrative spatial levels, including, in order 
of size from smallest to largest, census tract, 5-digit ZIP code, county, 3-digit ZIP code, and state. The 
aggregation of data to common administrative levels, while easier to obtain and easier to interpret than 
individual level data, can introduce bias, particularly when the scale and the shape of the units do not 
reflect boundaries that are meaningful for health research. Moreover, the level of geographic aggregation 
can influence the degree to which the effect estimates capture the hypothesized mechanism. For 
example, we might expect the effects of individuals’ use of prescription opioids to be captured in fatal 
drug poisoning counts in the county where individuals live; however, factors both near and far may affect 
an individual’s use of prescription opioids through effects on physician’s prescribing behaviors or 
pharmacists willingness to dispense certain drugs, drug control policy and targeted enforcement efforts, 
changes in drug trafficking, and through the effects on the norms around drug use among the members of 
one’s social network. Whereas the state-level effect estimate of prescription opioid supply—drug 
poisoning death relationship will include any spillover effects of such factors across counties within a 
state, county-level analyses will not. As such, effect estimates can vary substantially at different levels of 
geographic aggregation, even within the same dataset (104-106). For example, two studies found that 
county-level associations were substantially smaller than state- (86) or national-level  estimates (92). 
When undertaking an analysis of areal data, it is best to a priori theory about the most appropriate level of 
action, including at the individual level, to identify the preferred level of geographic aggregation for 
analysis. However, for exploratory research or in the absence of theory, a rule of practice in spatial 
analysis is to analyze area data at the smallest area units for which data are available and, when 
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practical, to model the same relationship at different levels to assess the sensitivity of estimates to unit of 
analysis (107-109). Any inconsistencies in the results estimated at different levels of aggregation will be 
an area to explore in future research. 
 
Spatial modeling requires the repeated assessment of spatial autocorrelation in both the unadjusted and 
the adjusted data (107-109). Standard statistical regression models assume independence of 
observations. When spatial autocorrelation is present, the independence assumption in standard 
statistical regression models is violated, potentially causing bias and loss of efficiency (107-109). Despite 
some studies in this review finding substantial autocorrelation for values of prescription opioid supply (84), 
socioeconomic conditions (84), and rates of fatal drug poisonings (84, 94), few studies assessed spatial 
autocorrelation in the data (80, 82, 84, 85, 88) and fewer still incorporated spatial dependencies into the 
models (80, 82, 85, 88).  
 
2.5.2. Do supply- and demand-side factors interact to cause drug poisoning deaths? 
No study has investigated whether socioeconomic conditions interact with prescription opioid supply to 
cause drug-related mortality rates. Despite the widespread success of supply-side interventions in 
curbing opioid prescribing in the U.S., the overall rates of opioid-related mortality have continued to rise. 
Prescription opioid volume peaked in 2011 at 240 billion MME and have declined by 29% to 171 billion 
MME in 2017 (110), but the number of deaths involving prescription opioids including methadone 
increased by 145%, from 18,777 in 2011 to 46,155 in 2017. Since 2011, however, the number of 
prescription opioid related deaths without synthetic opioids increased by a modest 9%, from 16,111 
deaths in 2011 to 17,689 in 2017, whereas prescription opioid-related deaths with synthetic opioids 
spiked by 245%, from 18,777 to 46,155 deaths in 2011 and 2017, respectively (111). As such, the 
increases in in deaths involving prescription opioids is driven by the use of fentanyl, particularly illicitly 
manufactured fentanyl and fentanyl analogs, mixed with heroin (1, 32). The spike in illicit-opioid related 
deaths has given rise to considerable concern that decreases in an area’s prescription opioid supply, 
without addressing factors related to opioid demand, may drive some people who are physically 
dependent or addicted to prescription opioids to switch to a cheaper and more prevalent supply of illicit 
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opioids (30, 33-38). Given that a single antecedent (e.g., prescription opioid supply) is unlikely sufficient 
to explain a complex phenomenon such as the current drug poisoning crisis, the effect of prescription 
opioid supply on drug-related mortality rates may be modified by county level differences in the 
distribution of factors that drive drug use, such as concentrated disadvantage. Therefore, incorporating 
demand-side socioeconomic conditions may elucidate important factors that interact with supply-side 
factors to modify the rates of drug-related mortality. Through identifying contextual factors that modify the 
effect of prescription opioid supply on mortality, resources can be more efficiently distributed to counter 
any unintended effects of reducing the supply of prescription opioids in an area. 
 
2.5.3. Strengths and Limitations 
The protocol for this review was pre-registered and the methodology applied during this review was 
systematic. Although we required studies to be published in English, our review of references from the 
identified studies did not identify any non-English publications that met our eligibility criteria. Moreover, 
the wide search of 5 different databases and the review conducted by two independent investigators are 
likely to have identified all relevant articles. Nevertheless, whether the positive association between 
socioeconomic conditions and drug-related mortality, reported by all studies included in this review, was 
due to the robustness of the effect or publication bias is unclear. However, methods to detect publication 
bias require a meta-analysis, and the heterogeneity of study populations, years, and exposures and 
outcomes precluded a formal meta-analysis. 
 
2.5.4. Conclusions 
Results indicated consistent evidence that locations with higher levels of prescription opioid supply and 
worse socioeconomic conditions have higher rates of drug poisoning deaths. Methodological variations 
across studies in the type of drug poisoning deaths examined, geographic unit used to aggregate data, 
and measures of prescription opioid supply and socioeconomic conditions, impede comparison of findings 
across studies. To improve the comparability of future findings, studies should present results from a 
range of models for the most common indicator variables (e.g., unemployment, median household 
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income, poverty rate, income inequality) and indices of area socioeconomic conditions, and assess the 
sensitivity of effect estimates to different levels of data aggregation and different sets of covariate factors.  
Finally, given the lack of information on whether supply- and demand-side factors interact to cause drug 
poisoning deaths, further studies are needed that examine whether the effect of prescription opioid supply 
on fatal drug poisonings is modified by economic conditions.  
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2.7 Figures and tables 
Figure 0.1. Process of selecting studies examining the association between area-level prescription 
opioid supply and area-level socioeconomic conditions with drug-related mortality rates 
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Table 0.1. Strength of evidence for the effects of prescription opioid supply and socioeconomic conditions on drug-related mortality 
Outcome Studies, 
n 
SOE Domains References 
ROB Directness Consistency Precision SOE  
Per-capita opioid supplya 
   Any drug poisoning deathc,d 5 Serious Direct Consistent Imprecise* Low 77, 78, 80, 90, 91 
   Prescription opioid poisoning deathc,e 1 Serious Direct Unknown  Unknown Insufficient 79 
   Fentanyl poisoning deathc,f 1 Serious Direct Unknown Imprecise* Insufficient 76 
        
Socioeconomic and social conditionsb 
   Any drug poisoning deathc,d 6 Serious Direct Consistent Imprecise* Low 82-84, 87, 90, 91 
   Opioid poisoning deathc,g 6 Serious Direct Consistent Imprecise* Low 81, 82, 85, 88, 
89, 91 
   Prescription opioid poisoning deathc,e 1 Serious Direct Unknown Unknown Insufficient 86 
   Heroin poisoning deathc, 2 Serious Direct Consistent Imprecise* Insufficient 86, 91 
ROB = risk of bias; SOE = strength of evidence 
* Imprecision based on a broad confidence interval or a confidence interval that crosses the decisional threshold. 
a Per-capita prescription opioid supply came from three sources: QuintilesIMS TDW; Medicare Part D; or Automation of Reports and Consolidation Orders System (ARCOS). 
b Socioeconomic and social conditions include distribution of residents below the federal poverty level, median household income, median home price, unemployment rate, 
employment-to-population ratio, reduction in manufacturing jobs, income inequality, neighborhood conditions (e.g., percent of dilapidated housing structures, proportion of 
acceptably clean sidewalks, percentage of houses vacant or boarded up), and composite indices of area economic conditions. 
c Drug poisoning deaths may include unintentional poisonings, intentional poisonings, homicidal poisonings, and poisonings with unclear intent  
d Any drug includes opium, prescription opioids, heroin, and synthetic opioids 
e Prescription opioids includes natural and semi-synthetic opioids 
f Fentanyl deaths are restricted to synthetic opioids and its analogs 





Background and aims: Greater area-level prescription opioid supply is associated with more drug 
poisoning deaths in many, but not all studies. Heterogeneity across studies may arise from 
methodological variation in modeling this association. This analysis aimed to investigate three potential 
sources of this heterogeneity (type of drug poisoning death, geographic unit used to aggregate data, and 
measures of prescription opioid supply) and two potential sources of bias (inadequate adjustment 
potential confounders, inadequate modeling of spatial autocorrelation of nearby counties). 
Methods: Hierarchical Bayesian models were used to estimate the associations between county-level 
prescription opioid supply and drug poisoning deaths were measured in 3,109 U.S. counties from 2006-
2016. Comparisons were made by type of drug poisoning deaths (any drug, any opioid, prescription 
opioid, heroin), level of geographic aggregation (county versus state), and measure of prescription opioid 
supply (rate of opioid-prescribing per 100 persons and morphine milligram equivalents per-capita). 
Results from unadjusted models were compared to models adjusted for potentially confounding 
compositional and contextual differences across counties. Results from conditional autoregressive 
models that adjust for nonindependence in the data from spatial and temporal autocorrelation were 
compared to models without adjustment for autocorrelation.  
Results: County-level analyses showed that in descending order, prescription opioid supply was most 
associated with drug poisoning deaths from opioids only (adjusted rate ratio [aRR]=1.21; 95% credibility 
interval (CI)=1.18, 1.23), prescription opioids only (aRR=1.20; 95% CI=1.17, 1.23), any drug (aRR=1.17; 
95% CI=1.16, 1.19), and heroin (aRR=1.14; 95% CI=1.08, 1.20). County-level analyses produced 
estimates smaller in magnitude than state-level estimates. Results were similar across the two different 
state-level measures of prescription opioid supply. Removing confounders from the model caused the 
direction of the effect estimates to reverse for drug poisoning deaths from all drugs, all opioids, and 
heroin. 
CHAPTER 3:  PRESCRIPTION OPIOID SUPPLY AND DRUG-RELATED MORTALITY: AN 




Discussion: Results indicate a positive association between prescription opioid supply and drug 
poisoning deaths consistent to changes in type of drug poisoning, level of aggregation, and measure of 
prescription opioid supply. Inadequate adjustment for confounding in previous studies likely explains 
previous inconsistencies in the literature. Replication offers an important tool to disentangle potential 




Drug poisoning deaths in the United States (U.S.) have increased by more than 400% over the past two 
decades, from 16,849 deaths in 1999 to over 67,000 in 2018 (1). This increase was primarily driven by a 
triple wave of drug poisoning deaths from three classes of opioids: the first wave was deaths from 
pharmaceutically manufactured opioids in 1999, rising 4-fold, from 2,749 deaths in 1999 to 10,943 in 
2010; the second wave was deaths from heroin beginning in 2007, rising 6-fold, from 2,399 deaths in 
2007 to 15,482 in 2017; and, finally, the third wave was deaths from synthetic opioids other than 
methadone, most frequently illicitly manufactured fentanyl (IMF) or fentanyl analogs mixed with heroin (2-
4), which began rising in 2013 and spiked over 10-fold, from 3,007 deaths in 2013 to 28,466 in 2017 (5). 
During the same period, the prescription opioid supply in the US has changed dramatically.  
   
According to data from the Drug Enforcement Administration (DEA), quantities of opioid analgesics, 
measured in morphine milligram equivalents (MMEs) dispensed in the U.S, increased slowly throughout 
the 1990s, from about 50 billion MMEs in 1992 to 92 billion MME in 2000, and then increased markedly 
over the next decade, peaking in 2010 at 250 billion MME (6). This rise in the quantity of prescription 
opioids dispensed in the U.S. coincided with the first wave of prescription opioid-related deaths. Evidence 
of parallel trends in the rates of prescription opioid supply and of prescription opioid-related mortality in 
part motivated the federal government and states to implement a series of interventions whose purposes 
were to target the supply-side of the market by reducing excess or unnecessary prescribing (e.g. 
prescribing guidelines) (7), identifying illegal prescribing (e.g., “pill mills” laws, prescription drug monitoring 
programs) (8-21), and developing abuse-deterrent formulations of commonly misused prescription opioids 
(e.g., OxyContin, Opana) (22). In 2010, the rates of both opioid prescribing and prescription opioid-related 
deaths peaked—at 782 MME per capita and 3.7 deaths per 100,000 population, respectively—before 
starting to trend slightly downward from 2011 through 2013 (23). Despite these declines, however, the 
overall rates of drug poisoning deaths attributed to opioids continued to increase faster than ever, driven 
by a 522% spike in deaths attributed to heroin during the second wave and illicitly manufactured fentanyl 
and its analogs during the third wave of this crisis (24). This rise in drug poisoning deaths from illicitly 
manufactured opioids overlaps with the first wave of deaths from pharmaceutically manufactured opioids 
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that preceded it (25, 26). That federal and state policy, implemented in part to reduce nonmedical 
prescription opioid use and disorder, increased demand for illicit opioids is well supported by both 
qualitative (27) and quantitative research (22, 28-31). Adaptations in the illicit opioid market both enabled 
a portion of the population dependent on prescription opioids to transition from one source of opioids (i.e., 
pharmaceutically manufactured opioid pills) to illicitly manufactured opioids (26, 32) and introduced 
opioids to an at-risk, opioid-naive, population (33). However, the complexities of the drug poisoning crisis 
make assigning causal status to the role of the prescription opioid supply on drug poisoning deaths 
difficult based on national time trends, particularly given considerable geographic variation in opioid 
prescriptions and drug-related mortality in the U.S.  
 
Rates of drug poisoning deaths are spatially heterogenous in the U.S., varying substantially from one 
geographic region to another and over time—increasing first in the Southwestern states and Appalachia 
in the 1990s, followed by dramatic increases in New England and Florida in the early 2000s, and 
nationwide increases in the years after (34). Previous spatial studies on the relationship between 
prescription opioid supply and drug poisoning deaths have been inconsistent: five studies reported a 
positive association (35-39), one study found a negative association (40), and one study found no 
association at all (41). The inconsistencies in this literature may arise from either methodological 
differences or methodological deficiencies. Methodological differences across the studies include: (1) 
sources and definitions of data on the primary exposure variable (i.e., prescription opioid supply); (2) 
inclusion and exclusion of different drug types in the definition of the primary outcome variable (i.e., fatal 
drug poisoning); and (3) data analysis at different levels of aggregation (i.e., 3-digit ZIP code, county, 
state, nation). Methodological deficiencies across studies include: (1) insufficient adjustment for 
potentially confounding compositional and contextual differences across counties and (2) inadequate 
modeling of spatial dependencies in the data arising from the shared experiences, social norms, and 
exposures of nearby counties compared to those farther away. 
 
First, previous studies have used three different datasets to assess area-level prescription opioid supply, 
including the DEA Automation of Reports and Consolidated Orders System (ARCOS) (35, 36, 38, 41), 
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IQVIA Xponent data made available by the Centers for Disease Control and Prevention (CDC) (39, 40), 
and Medicare Part D prescription data from the Centers  for Medicare and Medicaid (CMS) (37). 
Depending on the dataset, prescription opioid supply is defined as either the quantity of opioids, in grams, 
distributed to hospitals, retail pharmacies, and practitioners for dispensing (ARCOS) or the opioid 
prescribing rate (number of opioid prescriptions per 100 residents) (from IQVIA and CMS). Comparability 
of the quantity of opioids distributed (in grams) and the rate of opioid prescribing requires that a constant 
quantity of opioids (in grams) is dispensed per prescription across the country (42, 43) and over time (44-
46). However, given geographic and temporal differences in the average MME per prescription exist, the 
measurement of area-level prescription opioid supply, and the effect estimates derived from them, may 
vary depending on the dataset used.  
 
Second, case definitions for drug poisoning deaths have included and excluded different drug classes: 
four studies included all opioids, both pharmaceutically manufactured and illicitly manufactured opioids 
(35, 37-39, 41), one study included natural and semi-synthetic prescription drugs only (e.g., oxycodone, 
hydrocodone) (40), and one included synthetic drugs only (e.g., fentanyl) (36). Given that changes in the 
prescription opioid supply may be more closely linked to drug poisonings involving prescription opioids 
(e.g., natural/semi-synthetic opioids) than those involving heroin, variations in the case definitions could 
cause study findings to diverge.  
 
Third, although research has shown that the level of data aggregation affects both the accuracy and the 
level of uncertainty of effect estimates (47-49), previous studies have analyzed drug poisoning mortality 
data at either the county (37-40), 3-digit ZIP code (36, 41), or state level (35), and no study to date 
addressed the sensitivity of findings to level of data aggregation while holding other sources of variation 
constant. 
 
Methodological problems concerning inadequate adjustment of potential confounding and modeling of 
spatial autocorrelation were common among previous studies on this topic. First, inadequate adjustment 
for potential confounding is common. Although most studies adjusted for some set of sociodemographic 
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and economic variables, the vast majority of studies have failed to adjust for fixed and time-varying 
compositional and contextual differences across counties that are common causes of both prescription 
opioid supply and fatal drug poisonings and may confound the effect estimates, such as age distribution, 
racial/ethnic composition, poverty levels, or urbanicity (35-37, 39-41, 50), and only one study to date has 
adjusted for potential confounding from competing laws and policies (e.g., prescription drug monitoring 
programs, cannabis legalization for medical or recreational use) (38). Inadequate adjustment for 
confounding and differential adjustment for potential confounding factors across studies severely limit the 
reliability and comparability of estimated associations reported in prior research. Second, despite 
previous studies reporting moderate to high levels of spatial autocorrelation in the distribution of both 
prescription opioid supply (51) and rates of fatal drug poisonings (40, 51-53), only one study to date has 
incorporated spatial dependencies into their model (40). Failing to appropriately address spatial 
autocorrelation is likely to underestimate standard errors and bias parameter estimates (54-57).  
 
Determining what caused previous results to diverge, methodological differences or deficiencies, remains 
unclear. To better understand the effect of prescription opioid supply on drug poisoning deaths, this study 
aimed to provide an empirical answer to the following question: Did areas with greater supply of 
prescription opioids, measured as the per-capita rate of opioid prescribing, experience higher rates of 
drug poisoning deaths between 2006 and 2016 than areas with less supply? To address the 
methodological deficiencies in the literature, a directed acyclic graph (DAG) was constructed to provide a 
transparent approach for identifying the necessary set of adjustment variables to minimize confounding, 
and a geospatial approach was applied to model the effect of prescription opioid supply on fatal drug 
poisonings, accounting for both the county-level variation in the level and rate of growth in drug poisoning 
deaths and spatial autocorrelation in poisoning deaths across counties and states. To investigate the 
influence of methodological differences on this effect estimate, several sensitivity tests were conducted to 
investigate the consistency of results across different type of fatal drug poisoning (deaths attributed to any 
drug, any opioid, prescription opioid, or illicit opioids), levels of data aggregation (county- versus state-
level effect estimates), and measures of prescription opioid supply (comparing IQVIA [per-capita rate of 
opioid prescribing] to quantity of MME per capita [ARCOS]). Finally, results were replicated after removing 
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adjustment variables and removing adjustment for autocorrelation from the model to investigate the 






3.3.1. Study population 
This ecological time-series study aimed to estimate the association between prescription opioid supply 
and drug poisoning deaths in the U.S. This study used data from 3,109 counties in 49 U.S. states and 
Washington D.C., collected over 11 years from 2006 to 2016, resulting in 34,199 space-time units. Alaska 
was excluded from this analysis due to frequent changes in their county boundaries during the study 
period. Since most counties have some policy-making authority over health service administration and 
public health spending, counties were determined to be the appropriate level of aggregation for this 
analysis—preferred over lower levels of aggregation (e.g., ZIP codes, census blocks) that are often ill-
defined and drawn for purposes unrelated to health (e.g., efficient delivery of mail, census enumeration) 
and preferred over higher levels of aggregation (e.g., states) can results in the loss of substantial within-
state variation in opioid prescribing, drug-related mortality, and potential confounding factors (34, 40, 58-
62). For these reasons, the primary analysis was conducted at the county level, with secondary 
replication at the state level.  
 
3.3.2  Measures 
Drug poisoning deaths 
Annual county-level counts of drug poisoning deaths for the period of January 1, 2006 to December 31, 
2016 came from the restricted-use National Vital Statistics System (NVSS) Multiple Cause of Death 
(MCOD) files. The MCOD files provide information from death certificates on a single underlying cause of 
death (UCD), and up to 20 additional causes. This analysis focused on drug-related deaths, identified 
using International Classification of Diseases, 10th Revision (ICD-10) UCD codes: X40-X44 (accidental 
poisoning), X60-X64 (intentional poisoning), X85 (assault by poisoning), and Y10-Y14 (undetermined 
poisoning). The inclusion of all underlying causes of death, including both intentional and unintentional 
poisonings, aims to mitigate the possibility of differential misclassification of intent by medical examiners 




Four outcomes were examined in this study. Drug-related deaths were identified using UCD codes: X40-
X44, X60-X64, X85, and Y10-Y14. Among drug-related deaths, one or more opioid categories are listed 
as ICD-10 “T-codes” as immediate or contributory causes of death. Opioid-related deaths were defined as 
drug-related deaths with one or more opioid categories listed as ICD-10 “T-codes” as immediate or 
contributory causes of death, including: opium (T40.0), heroin (T40.1), natural and semisynthetic opioids 
(T40.2), methadone (T40.3), synthetic opioids other than methadone (T40.4), or other and unspecified 
narcotics (T40.6). Consistent with recent CDC guidelines (68), prescription opioid-related deaths were 
drug-related deaths with natural and semisynthetic opioids (T40.2) and methadone (T40.3) listed as ICD-
10 T-codes, but not heroin (T40.1). Heroin-related deaths were drug-related deaths with heroin (T40.1) 
listed as ICD-10 T-codes.  
 
Prescription opioid supply 
Data on county-level supply of prescription opioids were obtained from outpatient prescribing records 
from IQVIA Xponent, provided by the CDC for years 2006 to 2016 (69). IQVIA Xponent is based on a 
sample of approximately 59,000 (non-hospital) retail pharmacies, which dispense nearly 88% of all retail 
prescriptions in the U.S. Prescription data is recorded on initial or refill prescriptions dispensed at a 
sampled pharmacy and paid for by commercial insurance, Medicaid, Medicare, or self-payment. Data 
from mail order prescriptions and drugs dispensed through methadone maintenance treatment programs 
are not included in these data. Prescribing rates per 100 persons were calculated as the total number of 
opioid prescriptions dispensed each year in a county (numerator) over the annual resident population 
estimates as derived from the Population Estimates Program, U.S. Census Bureau. 
 
Two state-level measures of prescription opioid supply were used: 1) per-capita opioid prescribing from 
IQVIA Xponent and 2) per-capita MME from the U.S. DEA ARCOS (70). ARCOS measures total grams 
purchased by hospitals, retail pharmacies, practitioners, and teaching institutions, capturing the legal 
supply of prescription drugs at the dispenser level prior to reaching consumers. To account for the 
differences in analgesic effects produced by different types of opioids, grams in each of 10 commonly 
prescribed opioids (codeine, dihydrocodeine, hydrocodone, hydromorphone, levorphanol, meperidine, 
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morphine, oxycodone, oxymorphone, tapentadol) were converted into morphine milligram equivalents 
(MME) (71). Finally, state- and year-specific MME rates were calculated as the total MME dispensed each 
year and state (numerator) over the annual resident population estimates as derived from the Population 
Estimates Program, U.S. Census Bureau. 
 
Potentially confounding variables 
Covariates were included into the model for two purposes: to enhance the small area predictions (72) and 
to adjust for potential confounding of the effect of prescription opioid supply on fatal drug poisonings. To 
identify the set of adjustment variables for estimating the total effect of per-capita prescription opioid 
supply on fatal drug poisonings, extant literature was used to construct a Directed Acyclic Graph (DAG) 
for this analysis (Figure 3.1). Next, the DAG was imported into DAGitty v3.0 (73) to identify the minimum 
set of adjustment variables necessary for inclusion in the model to minimize bias (74, 75). Given the DAG 
in Figure 3.1, the minimal sufficient adjustment set for this analysis includes three demographic variables 
(county distribution of age, race/ethnicity, and sex), three socioeconomic variables (median household 
income, proportion of families in poverty, and unemployment rate), two place-based factors (population 
density and urbanicity), and three state policies (prescription drug monitoring programs [PDMP], medical 
marijuana law [MML], recreational marijuana law [RML]). 
 
Time-varying measures of three demographic, six socioeconomic factors, and one place-based measure 
were annually collected from the Census Bureau’s state and county level estimates of population and 
income characteristics (including data from the American Community Survey), were compiled by 
GeoLytics (East Brunswick, New Jersey). GeoLytics bases its estimates on U.S. Census Bureau reports 
and limited population estimates, then expands on those to provide an extensive list of population-based 
variables (76). Annual county population share of the following measures were obtained from GeoLytics: 
age composition (percent of the population aged 0-19, 20-44, 45-64, and greater than or equal to 65 
years); racial/ethnic composition (non-Hispanic Whites, non-Hispanic Blacks, Hispanics, other nonwhite 
non-Hispanics); percent male; adult unemployment rate; percent of families in poverty; median household 
income; and population density (thousands of people per square mile). To improve interpretation, the 
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three demographic variables (county distribution of age, race/ethnicity, and sex), three socioeconomic 
variables (median household income, proportion of families in poverty, and unemployment rate) were 
standardized to have a mean of 0 and a standard deviation of 1, using the z-score formula to subtract the 
mean of each variable from each county-year observation and dividing by the variables standard 
deviation. 
 
County size and metropolitan status came from the USDA Economic Research Service’s nine-level 
categorical Rural-Urban Continuum codes. The Rural-Urban Continuum codes (RUCC) form a 
classification scheme that distinguishes between large and small metropolitan counties and 
nonmetropolitan counties by degree of urbanization and adjacency to metro area or areas (77). Large 
metropolitan areas with densely populated center with population ≥ 1,000,000 and include the 
surrounding economically integrated areas (RUCC = 1). Small metropolitan areas are similar, except that 
the center has between 250,000 to 999,999 people (RUCC = 2) or 50,000 and 249,999 (RUCC = 3). All 
other areas are defined as nonmetropolitan counties (RUCC = 4 to 9). Nonmetropolitan counties are 
classified by degree of urbanization and adjacency to metro area or areas: urban with population ≥ 
20,000, adjacent to (RUCC = 4) or not adjacent to a metropolitan area (RUCC = 5); urban with population 
2,500-20,000 and adjacent to (RUCC = 6) or not adjacent to a metropolitan area (RUCC = 7); and rural 
with population <2,500 adjacent to (RUCC = 8) or not adjacent to a metropolitan area (RUCC = 9).  
 
Three measures of the state-level legal environment related to drug use were adjusted for in the analysis. 
The first variable indicates whether a state had a prescription drug monitoring program (PDMP) that 
required prescribers and dispensers to review the patient prescribing history prior to prescribing or 
dispensing controlled substances. Prescription drug monitoring programs with mandatory provider review 
was chosen over a state-level variable indicating any PDMP or PDMP with some other operational 
feature (e.g., frequency of reporting, interstate sharing of prescription data) based on two conclusions 
from a recent systematic review (78). First, an association between PDMP with mandatory provider 
review and drug poisoning deaths has been consistently reported in the literature, whereas evidence on 
whether PDMPs in generals or PDMPs with other operational features are associated with drug poisoning 
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deaths is mixed. Second, half of the studies that have shown PDMP implementation to be associated with 
increasing rates of heroin-related deaths considered PDMP with mandatory provider review (65, 79), with 
the other studies using either a binary variable coding PDMP as present or absent (80) or a latent class 
variable based on PDMP features (81). The second and third variables indicate whether a state has 
legalized cannabis use for medical or recreational purposes. Medical marijuana legalization (MML) and 
recreational marijuana legalization (RML) was enacted in 25 states and 3 states by 2016 (Alaska was not 
included in this analysis). To account for any potential confounding from these state-level policies, the 
status of these laws and the fraction of the year in which they were enacted at the state level were 
adjusted for in the model. For PDMP with mandatory provider review, data on month and year of 
enactment came from the National Alliance for Model State Drug Laws (NAMSDL) (82) and the 
Prescription Drug Abuse Policy System (PDAPS) (83). MML and RML enactment dates were determined 
by a team of legal scholars, policy analysts, and economists after reviewing state policies (84), and used 
in previous work on MML (85, 86) and RML (87, 88).  
 
3.3.3. Statistical analysis 
For this study, both a county- and state-level analysis were performed, where the outcomes are counts of 
various types of drug poisoning deaths, and the key explanatory variable is per-capita rate of opioid 
prescribing.  
 
To account for the hierarchical and spatial nature of the data, a spatiotemporal Hierarchical Bayesian 
statistical model was used to model the effect of prescription opioid supply on counts of drug poisoning 
deaths. Hierarchical Bayesian models employ multiple levels of modeling, specified in a hierarchical 
order, to estimate the posterior distributions of the model parameters using the Bayes method. The 
Bayesian spatiotemporal modeling approach borrows strengths across both counties and years to 
produced smoothed yearly county level estimates, allowing examination of spatial and temporal variation 
in rare outcomes such as counts of drug poisoning deaths (89, 90).  Previous studies have found county-
level measures of prescription opioid supply and drug poisoning deaths exhibit strong spatial 
autocorrelation (40, 51-53). Although time-varying covariates account for some spatial and temporal 
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autocorrelation (91), any residual spatial autocorrelation remaining after accounting for covariates can 
introduce bias and inefficiencies (91-93). In a Bayesian spatiotemporal model, the spatially structured and 
unstructured random effects are used to model the inherent spatial autocorrelation in the data, the 
correlated and uncorrelated time effects model the time dependent structure of the data, time varying 
covariates model the extra uncertainty in the data due to measured potential confounding factors, and a 
space-time interaction effect models the residual spatiotemporal variation that is not accounted for by the 
county random effects. To account for this residual spatial autocorrelation, spatially structured random 
effects were introduced into the model (94, 95). 
 
Since all the dependent measures are count outcomes, the number of fatal drug poisonings within 
counties are assumed follow a Poisson distribution. Let !!,# denote the observed count of fatal drug 
poisonings occurring in the "th county and #th state during year $ under a heterogenous Poisson process: 
!!,#|&!,#~()"**)+(&!,#) 
Where, 
log1&!,#2 = log	(5!,# , 7!,#) 
7!,# denotes the expected number of fatal drug poisonings under the assumption that statewide overdoses 
are distributed among counties in direct proportion to the population and 5!,# is interpreted as the relative 
risk of residing in the "th county during year $. Counties with 5!,# > 1 will have higher counts than expected 
based on their population, and counties with 5!,# < 1 will have fewer counts than expected. Therefore, the 
log relative rate is: 
log	(5!,#) = 	; + =$ + >?((@!!,#A + B′!,#D + ∅!# + F!# + G! + H! 
; is the statewide intercept and =	is the state temporal trend in fatal drug poisonings over time. B′!,# is a 
matrix of potentially confounding space- and time-varying covariates (identified in Figure 2.1) and D is a 
vector of fixed-effects estimates of the association of those covariates with drug poisoning 
deaths.	>?((@!!,# is the county rate of opioid prescribing and A is the effect estimate of the association 
between prescription opioid supply on fatal drug poisonings (the effect estimate of interest). To account 
for spatial autocorrelation of the geographic units, the model included a conditional autoregressive (CAR) 
random effect, using a first-order adjacency matrix of counties, weighted as one if counties share a 
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boarder (90, 96). The CAR random effect (∅!,#) deals with the lack of independence among spatial units, 
and avoids biases due to small area effects (97). Models also included a nonspatial county random effect 
(F!,#) to control for overdispersion that can arise when areas have low or zero counts (98). Finally, G! is a 
county-specific CAR random effect that allows for spatially variant rates of change above or below the 
statewide trend =, and H! is a county-level random effect that allows for variation around the intercept ;. 
The posterior distribution of the parameters in the hierarchical Bayesian model were estimated via 
Integrated Nested Laplace Approximation (INLA) in R using the R-INLA package (99). This method will 
approximate the median estimate and 95% credible interval (CI) of the posterior distribution that can be 
interpreted like the point estimate for the incidence rate ratio (RR) and 95% confidence interval in 
standard, frequentist, regression.  
 
Multiple different model specifications were tested, including different count data specifications for the 
data generating process (i.e., negative binomial and zero-inflated Poisson), different functions for time, 
state and year fixed effects, and a county-specific random slope for time. The model fit was examined 
using the Deviance Information Criterion (DIC). Better fitting models should have lower DIC and small 
effective number of parameters to estimate (91, 100). The best fitting model included the set of pre-
determined time-varying covariates, a state fixed effect to account for potential endogeneity of 
prescription opioid supply within states, and year fixed effects to adjust for the secular trends in 
prescription opioid supply and drug-related mortality.  
 
Finally, to investigate the effect of two potential sources of bias (i.e., insufficient adjustment for 
confounding and inadequate spatial dependence in the data), the fully adjusted spatial model (Model 1), 
described above, was compared to three additional models: Model 2 removes the adjustment for spatial 
autocorrelation, keeping the adjustment variables in the model; Model 3 removes the adjustment 
variables, keeping the adjustment for spatial autocorrelation; and Model 4 removes both the adjustment 
variables and the adjustment for spatial autocorrelation. For this analysis, the non-spatial models (Models 
2 and 4) are fit excluding data on the spatial relationships in the data, whereas the unadjusted models 
(Models 3 and 4) are fit excluding all covariates from the model. Model 4 is most comparable to the 
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previous study finding no association between prescription opioid supply and fatal drug poisonings (41). 
Model 3 is most comparable to the previous study finding a negative relationship between prescription 
opioid supply and fatal drug poisonings (40). 
 
3.3.4. Sensitivity analyses 
Two sensitivity analyses were conducted to investigate three potential sources of bias. First, opioid 
prescribing rates were missing for 3,500 county-years of the 34,199-total county-years of data (10%). 
Therefore, a two-stage approach was used to predict missing opioid prescribing rate and to evaluate its 
effects on drug-related mortality at the county-level (101). Specifically, in the first stage, the same model 
used in the county-level analysis above was fit with opioid prescribing rate as the outcome variable. From 
this model, five samples were obtained from the posterior distribution for each missing observation. In the 
second stage, the original dataset is completed with each of the five sets of imputed values and the 
model is fit once for each imputation set and the fit models are put together by computing the average 
model using Bayesian model averaging (102). The primary advantage of this approach is it allows for 
uncertainty propagation from stage one to stage two of the modeling framework. Appendix Tables 6 to 9 
compare the results from the imputation models with those from models that excluded missing counties 
(i.e., complete case analysis) for deaths attributed to any drug, any opioid, prescription opioids, and illicit 
opioids. Given that minimal differences between these models were found, complete case analysis was 
reported. 
 
Second, the recent rise in illicitly manufactured fentanyl complicates the measurement of prescription 
opioid- and heroin-related deaths in the later years. Prior to the 2013 rise of illicitly manufactured fentanyl 
and fentanyl analogs mixed with heroin (2-4), synthetic opioid-related deaths were largely attributed to 
pharmaceutically manufactured fentanyl, dispensed from pharmacies or hospitals and included in the 
primary exposure variable (i.e., prescription opioid supply). With the 2013 rise of illicitly manufactured 
fentanyl and fentanyl analogs mixed with heroin (2-4), the likely source of synthetic opioid-related deaths 
transitioned from prescription opioids, dispensed from pharmacies or hospitals and included in the 
primary exposure variable (i.e., prescription opioid supply), to a fully illicit opioid supply, for which a 
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measure of supply does not exist. Because the quantity and distribution of illicitly manufactured fentanyl 
increased substantially between 2010 and 2016, it stands to reason that the likelihood a synthetic opioid-
related death is attributed to a measurable prescription opioid or unmeasurable and fully illicit opioid 
source will vary by location and year. To mitigate potential differential misclassification of synthetic opioid-
related deaths by year or region, synthetic opioid-related deaths were excluded from both prescription 
opioid-related deaths (restricted to deaths attributed to natural and semi-synthetic opioids or methadone) 
and heroin-related deaths in the primary analysis. However, sensitivity tests investigated the consistency 
of effect estimates to measures of heroin- and prescription opioid-related deaths that both included and 





The median drug-related mortality rate across the 3,109 counties was 10.6 per 100,000 residents (Table 
3.1). Median rates for deaths attributed to any drug, any opioid, and any prescription opioid continuously 
increased from 2006 to 2016. For heroin-related deaths, median rates were much lower, with few 
counties recording any heroin-related deaths from 2006 to 2010 and only 25% of counties having a rate 
of 2.0 per 100,000 people or more in 2016. Median rates of opioid prescribing first increased from 74.3 
per 100 population in 2006 to 85.2 in 2010, and then dropped to 72.8 per 100 population in 2016. 
 
3.4.1. Association of per-capita prescription opioid supply with drug poisoning deaths 
Table 3.2 reports the county-level association between rate of opioid prescribing and drug poisoning 
deaths attributed to any drugs, any opioid, prescription opioids, and heroin, with covariate coefficients 
reported in Appendix Table 10. The covariate coefficients should be interpreted with caution, as they 
represent ecological relationships, not individual-level risk factors or potential causal pathways. 
Covariates significantly associated with drug poisoning deaths included: demographic characteristics 
(e.g., racial and ethnic distribution, urbanization), socioeconomic factors (e.g., median home value, 
unemployment rate), and legal environment (e.g., good Samaritan laws, prescription drug monitoring 
programs). These results are consistent with previously reported county-level associations of 
socioeconomic (38, 39, 51-53, 103-106) and legal environments (78, 107, 108) with drug-related 
mortality.   
 
3.4.2. Results by type of fatal drug poisoning 
Table 3.2 summarizes the association between opioid prescribing rate and drug poisoning deaths 
attributed to all drugs, all opioids, prescription opioids, and illicit opioids. Opioid prescribing rate was 
associated with a positive increase of similar magnitude for all outcomes, with 1 SD higher opioid 
prescribing rate associated with a minimum of 17% higher (rate ratio [RR]=1.17; 95% CI=1.16, 1.19) rate 
of drug-related mortality and a maximum of 21% higher (RR=1.21; 95% CI=1.18, 1.23) rate of opioid-




3.4.3. Results by level of aggregation 
Table 3.3 focuses on how the association between opioid prescribing rate and drug poisoning deaths 
varies by different levels of geographic aggregation for different types of poisoning deaths. Though all 
effect estimates were positive, magnitudes of the estimates were similar for drug-related mortality rates at 
the county- and state-level, about 5% larger at the county-level than the state-level for opioid- and 
prescription opioid-related deaths, and about 4% smaller at the county-level than the state-level for 
heroin-related deaths.  
 
3.4.4. Results by measure of prescription opioid supply 
Figure 3.2 shows a linear relationship between the two state-level measures of prescription opioid supply, 
opioid prescribing rate per 100 people and per-capita MMEs from 2006 to 2016. Table 3.4 shows how the 
estimated effect of prescription opioid supply varies with the two different measures of supply. Whereas 
the associations between each measure of prescription opioid supply were similar for opioid-related 
mortality (median=1.15), MME per-capita was more associated with prescription opioid-related mortality 
than opioid prescribing rate, but less associated with both drug-related deaths and heroin-related deaths. 
The range of associations between each measure of prescription opioid supply and the different types of 
fatal drug poisonings were more varied using MME per capita than opioid prescribing rate. For example, 
the adjusted rate ratios between MME per capita and drug poisoning deaths ranged from about null 
(RR=1.03; 95% CI=0.87,1.21) for heroin-related deaths to a RR of 1.21 (95% CI=1.12, 1.31) for 
prescription opioid-related deaths. In contrast, opioid prescribing rate was similarly associated with all 
types of fatal drug poisonings, with adjusted RR ranging from 1.14 (95% CI=1.09, 1.20) prescription 
opioid-related deaths to 1.21 (95% CI=1.11, 1.33) for heroin-related deaths.  
 
3.4.5. Comparison of estimates from the fully adjusted spatial model to estimates from non-spatial 
and unadjusted models 
Table 3.5 summarizes estimates from models both with and without adjustment for potentially 
confounding variables included and with and without adjustment for spatial autocorrelation. Model 1 is the 
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preferred model and repeats the results from Table 3.2, with all the adjustment variables included and 
adjustment for spatial autocorrelation. Removing adjustment for spatial autocorrelation (Model 2) 
increases the estimates slightly, e.g., 1 SD higher rate of prescription opioid supply is associated with a 
17% higher (RR=1.17; 95% CI=1.16, 1.19) rate of drug-related mortality in the preferred model versus a 
20% higher (RR=1.20; 95% CI=1.18, 1.22) rate in the model without adjustment for spatial 
autocorrelation. Removing the adjustment for potentially confounding variables instead (Models 3 and 4), 
the estimate for drug-related mortality is attenuated by approximately 30%, from an RR of 1.17 (95% 
CI=1.16, 1.19) in the preferred model to an RR of 0.90 (95% CI=0.89, 0.91) and an RR of 0.89 (95% 
CI=0.88, 0.90) in the unadjusted spatial model and the unadjusted non-spatial model, respectively. The 
differences between Model 1 and the non-spatial and unadjusted models were largest for drug-, opioid-, 
and heroin-related deaths and smallest for prescription opioid-related deaths. 
 
3.4.6. Sensitivity analysis: Inclusion of synthetic opioid deaths with prescription opioid-related 
deaths versus illicit opioid-related deaths 
Appendix Table 11 shows the associations between opioid prescribing rate and two different measures of 
prescription opioid- and heroin-related deaths, one measure that includes deaths attributed to synthetic 
opioids and one measure that excludes synthetic opioid-related deaths. Apart from the county-level 
association between opioid prescribing rate and prescription opioid-related deaths, for which similar 
associations were observed whether synthetic opioid-related deaths were included or excluded in the 
definition, the inclusion of synthetic opioid-related deaths led to smaller estimates both for prescription 
opioid- and for heroin-related deaths. For example, the state-level association between opioid prescribing 
rate and prescription opioid-related deaths declined from an RR of 1.14 (95% CI=1.09, 1.20) to an RR of 
1.11 (95% CI=1.06, 1.16) after including synthetic opioid-related deaths. Although a similar reduction in 
the magnitude of the association occurred after including deaths from synthetic opioids with heroin-
related deaths at the county level, the state-level association between opioid prescribing rate and heroin-






Greater area-level supply of prescription opioids was consistently associated with higher rates of drug 
poisoning deaths across different types of drug poisonings, levels of aggregation, and measures of 
prescription opioid supply. Although the results indicated a consistent and positive association between 
prescription opioid supply and drug poisoning deaths, findings from previous studies on this topic have 
varied in both the magnitude and the direction of the relationship. To investigate the potential source of 
this heterogeneity in the literature, a transparent and rigorous analysis strategy was applied, varying first 
the definition of the outcome, the level of aggregation, and the type of measure of the main predictor and 
testing next the role of insufficient adjustment for potential confounding and inadequate modeling of 
spatial autocorrelation. Although results were similar across these methodological sources of variation, 
removing adjustment variables from the model caused the estimates to attenuate and reverse in direction, 
such that greater prescription opioid supply was associated with lower rates of drug poisoning deaths, 
suggesting that previous inconsistencies in the literature may be a consequence of unadjusted 
differences in the distribution of potentially confounding county-level sociodemographic factors or state-
level drug policy environment across units. 
 
There are a number of underlying mechanisms that could explain the consistent association between 
higher prescription opioid supply and all types of drug poisoning deaths. The most direct explanation is 
that higher prescription opioid supply within an area increases use opportunities, thereby increasing the 
likelihood of opioid use disorder, and the population potentially at risk of dying from a drug poisoning. 
Widespread availability of prescription opioids is well documented in the U.S. and has been associated 
with higher levels of medical and nonmedical use (26, 109). Opioid addiction is estimated to develop in 2-
10% of all patients (110) and 8-12% of chronic pain patients (111) prescribed an opioid for pain relief, but 
opioid poisoning deaths are rare among patients, affecting less than 1% of patients per year (112). Prior 
studies indicate that nonmedical use and diversion are responsible for the vast majority of opioid 
poisoning deaths (113-115). One study investigating the prescription record of persons dying from 
prescription opioid poisonings in West Virginia found that 95% of decedents had one or more indicators of 
substance abuse, including: 63% of deaths involved one or more prescription drug not prescribed to the 
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decedent, 21% of decedents received 5 or more prescribed controlled substances during the year prior to 
their deaths, and 16% listed a contributory illicit drug (113). After remaining relatively stable for over a 
decade, drug poisonings involving heroin began to rise, increasing 5-fold, from 1.0 deaths per 100,000 in 
2008 to 4.8 deaths in 2017 (2, 5). Many studies attributed the sudden rise in heroin use and attendant 
heroin poisoning deaths to the expanded pool of susceptible people, with some people who use 
prescription opioids, whether for medical or nonmedical purposes, finding their preferred drug too costly 
or difficult to obtain may transitioning to the cheaper, more accessible, and more potent alternative (i.e., 
heroin) (21, 27, 65, 78-80, 116). These findings imply that greater supply of prescription opioids in some 
locations not only increase access to diverted drugs for nonmedical use and the population at risk of 
dying from a prescription opioid poisoning but also the population at risk of dying from a heroin poisoning. 
However, it is possible that the effect of prescription opioid supply on drug poisonings may attenuate over 
time considering the shifting profile of the epidemic. Future research with more complete data, including 
local measures of heroin supply and illicitly manufactured fentanyl, will be essential to understanding the 
changing role of opioid supply on drug poisonings.  
 
Beyond highlighting the need for adequate adjustment of confounding from compositional and contextual 
differences between counties in future investigations, the finding that removing confounders from the 
model caused the direction of the prescription opioid supply—drug poisoning death to reverse for fatal 
poisonings from all drugs, all opioids, and heroin, but not deaths due to prescription opioids suggest that 
inadequate adjustment for confounding is likely to explain previous heterogeneity of results. Moreover, 
differences in the effects of confounding on the association between prescription opioid supply and 
prescription opioid-related deaths, compared to all other types of fatal drug poisonings, suggest an 
additional mechanism by which prescription opioid supply may affect prescription opioid-related deaths 
versus all other types of fatal drug poisonings. While future research should investigate specific 
mechanism in more detail, the results here are consistent with heroin substituting for prescription opioids 
in certain locations. In general, if prescription opioid supply is associated with higher rates of prescription 
opioid-related deaths in all locations, but associated with heroin-related deaths only after adjustment for 
compositional and contextual differences between counties, then these compositional and contextual 
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differences between counties may be markers for differences in the geospatial distribution of illicit drug 
markets, which in turn creates differential access to heroin across geographies. Examining the relative 
magnitude of the effect estimates for the different types of fatal drug poisonings, the results suggest that, 
after adjustment for potential confounding, the effect of area-level prescription opioid supply was similar 
across all types of drug poisoning deaths and not isolated to prescription opioid-related deaths. While 
these data do not allow a test of the individual-level mechanism explicitly, these results are consistent 
with a pathway between prescription opioid supply and drug poisoning deaths driven by diversion and 
nonmedical use of prescription opioids. 
 
The pattern of greater area-level prescription opioid supply being associated with higher rates of drug 
poisoning deaths persists across different types of drug poisonings, levels of data aggregation, and 
measures of prescription opioid supply. Although a 1 SD increase in prescription opioid supply was 
consistently associated with an approximately 20% increase in rates of drug poisoning deaths, ranging 
from a 17% increase in drug- and heroin-related deaths to a 21% increase in opioid-related deaths, the 
magnitude of the associations was found to vary by level of aggregation for different types of poisoning 
deaths, such that magnitudes of the estimates were similar for drug-related mortality rates at the county- 
and state-level, larger at the county-level than the state-level for opioid- and prescription opioid-related 
deaths, and smaller at the county-level than the state-level for heroin-related deaths. This finding might 
suggest that prescription opioid supply increases drug poisoning deaths from all opioids and prescription 
opioids to a greater extent through corresponding local mechanisms than through statewide processes, 
e.g., prescription opioid-related deaths are more likely to involve a locally dispensed drug than one 
dispensed in a different county within the state. In addition to varying across levels of aggregation, the 
two state-level measures of prescription opioid supply, rate of opioid prescribing per 100 persons from 
IQVIA Xponent and per-capita MME from ARCOS, varied in their effect on different types of drug 
poisoning deaths. These heterogeneous effects across different types of drug poisonings suggest that 
opioid prescribing rate and per-capita MME capture different aspects of the relationship between 
prescription opioid supply and drug poisonings. The effect estimates suggest that per-capita MME from 
ARCOS captures the unique aspects of prescription opioid supply that increase prescription opioid-
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related deaths but not heroin-related deaths. Compared to the rate of opioid prescribing per-capita, which 
captures only the number of opioid prescriptions dispensed, per-capita MME captures the strength of 
opioid prescriptions dispensed in an area, by using a conversion factor to account for differences in dose 
across drugs. Previous studies of people who use opioids nonmedically have reported a preference for 
higher strength opioids, indicated by higher MME conversion factors, such as oxycodone (MME 
conversion factor=1.5), hydromorphone (MME conversion factor=4), and fentanyl (MME conversion 
factor=2.4) over hydrocodone (MME conversion factor=1) or morphine (MME conversion factor=1) 
containing products (117, 118). Given that higher dosages of opioids are associated with higher risk of 
drug poisoning and death (119-121), per-capita MME may better capture this direct link between higher 
dosage and higher risk than overall rate of opioid prescribing, which might potentially reflect overall 
opportunities to access prescription opioids for nonmedical use. Future research on the effect of 
prescription opioid supply on drug poisonings could consider potential indicators of nonmedical use and 
diversion, e.g., the proportion of patients receiving prescriptions from multiple providers or the rate of 
prescriptions for high strength opioids.   
 
Although the consequences of inadequate adjustment for potential confounding are well known, spatial 
dependencies causing spatial autocorrelation can lead to biased, inefficient, or inconsistent findings (91-
93) and these dependencies need to be incorporated into models estimating the ecological effect of 
prescription opioid supply on drug poisoning deaths. Despite previous studies reporting moderate to high 
levels of spatial autocorrelation in the distribution of both prescription opioid supply (51) and rates of fatal 
drug poisonings (40, 51-53), only one study to date has incorporated spatial dependencies into their 
model (40). To address concerns about inadequate adjustment for confounding and insufficient modeling 
of spatial autocorrelation in the literature, a DAG was used to determine the necessary set of adjustment 
variables to minimize bias and a spatiotemporal hierarchical Bayesian statistical model was applied to 
account for both the temporal (repeated over time) and the spatial structure (counties nested within 
states) of these data. DAGs provide a transparent approach to identifying adjustment variables, making 
explicit the assumptions underlying the model. Future studies will benefit from updating or modifying the 
current DAG, based on future research, to improve confounder control, and by building upon this 
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spatiotemporal modeling approach, using the proposed estimation strategy to address potential bias and 
inefficiencies from spatial autocorrection in the study data. 
 
This study is not without limitation. First, analyses addressed ecological relationships, not the effect of 
prescription opioid intake of individuals in the counties. Second, the associations found at one level of 
aggregation may not reflect association at other geographic units. To minimize this concern, the analysis 
was conducted at two different levels of aggregation. However, within-county heterogeneity of 
prescription opioid supply, drug poisoning deaths, and confounding factors may exist. While future studies 
may consider replicating this analysis in more disaggregated data, boundaries at lower levels of 
aggregation (e.g., ZIP codes, census blocks) are often ill defined and lack theoretical justification or 
meaning beyond administrative boundaries (e.g., efficient delivery of mail, census enumeration). Third, 
administrative mortality data may misclassify cause of death and not reliably identify the drugs involved in 
a fatal opioid poisoning. However, our findings were robust to four different definitions of drug poisoning 
deaths, including the broadest definition—drug-related mortality—that included both intentional and 
accidental deaths and those where an opioid was not specified on the death certificate. Fourth, despite 
using a DAG to identify potential confounders, residual confounding may remain. Although we considered 
county fixed effects to address time-fixed sources of confounding, the emphasis on avoiding bias comes 
at a considerable loss to efficiency. Based on these trade-offs, the random-effects estimator was 
preferred to the fixed-effects estimator. Fifth, prescription opioid supply was operationalized using two 
rather crude measures: opioid prescribing rate per 100 persons and MME per-capita. Although other 
measures of high-risk prescribing exist (e.g., proportion of population receiving prescriptions for opioids 
from four or more prescribers in a year, proportion of patients with high daily MME), the choice of 
measures was made to align with previous studies investigating the relationship between prescription 
opioid supply and drug poisoning deaths, all except one which have used one of these two measures. 
 
Although area-level prescription opioid supply is a commonly used metric for identifying high risk 
communities and evaluating the effect of policies, previous evidence on the relationship between 
prescription opioid supply and population health outcomes, in particular fatal drug poisonings, has been 
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mixed. The results of this study suggest that greater prescription opioid supply increases rates of fatal 
drug poisonings attributed to all types of drugs, all opioids, prescription opioids only, and heroin. While the 
effect of prescription opioid supply on prescription opioid-related deaths may be the direct effect of 
medical use of opioid pain relievers, the effect of prescription opioid supply on rates of heroin-related 
deaths may operate through increasing demand for heroin, with access to heroin markets differing across 
counties. Despite the results here indicating an association between area-level prescription opioid supply 
and fatal drug poisonings, they do not suggest that supply reductions will lower the rate of fatal drug 
poisonings. Improved understanding of the diverse supply dynamics and causal mechanisms driving the 
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3.7 Figures and Tables. 
Table 0.1. Characteristics of 3,109 counties in 49 US States and Washington, D.C., 2006-2016 
Characteristics 
County  State 
Median (IQR)  Median  (IQR) 
Population ≥ 12 year of age 20,281 (8,836 - 
52,197) 
 4,340,759 (1,802,854 - 
6,825,358) 
Population density (per mile2) 44.7 (17.2 - 112.4)  102 (237.7 - 
10,951.9) 
Age (%)      
    0-19 years 26.6 (24.4 - 29.0)  26.8 (25.6 - 28.3) 
    20-44 years 31.9 (30.0 - 33.8)  32.6 (31.6 - 33.9) 
    45-64 years 25.4 (23.6 - 26.9)  25.7 (24.9 - 26.6) 
    ≥ 65 years 15.4 (13.1 - 18.1)  14.5 (13.3 - 15.8) 
Sex (%)      
    Male 49.3 (48.6 - 50.0)  49.1 (48.8 - 49.7) 
    Female 50.8 (50.0 - 51.4)  50.1 (50.3 - 51.3) 
Race/ethnicity (%)      
    Non-Hispanic white 82.1 (63.6 - 92.3)  72.2 (58.9 - 80.9) 
    Non-Hispanic black 1.8 (0.3 - 10.1)  7.2 (2.6 - 15.4) 
    Hispanic 2.3 (1.0 - 6.8)  7.4 (3.5 - 11.9) 
    Other race/ethnicity 3.7 (1.6 - 9.6)  7.5 (4.5 - 11.0) 
Socioeconomic status      
    Median household income $38,242 ($32,416 - 
$45,782) 
 $48,504 ($4,579 - 
$55,104) 
    Families living below the poverty line (%) 11.4 (8.1 - 15.7)  9.8 (8.1 - 12.1) 
    Unemployed (%) 6.0 (4.4 - 8.5)  6.2 (4.7 - 8.2) 
Opioid prescribing rate (per 100 persons)b     
     2006 74.3 (51.7-100.2)  77.5 (62.0-87.4) 
     2010 85.2 (59.6-116.7)  85.0 (68.5-98.0) 
     2016 72.8 (50.0-98.9)  66.9 (58.7-80.1) 
      
Characteristic No. (%)  No. (%) 
Areas with medical marijuana lawsc      
     2006 306 (9.9)  10 (20.0) 
     2010 444 (14.3)  14 (28.0) 
     2016 924 (29.7)  25 (50.0) 
Areas with a mandatory review PDMPc     
     2006 0 (0.0)  0 (0.0) 
     2010 0 (0.0)  0 (0.0) 
     2016 998 (32.1)  16 (32.0) 
PDMP = Prescription drug monitoring program; IQR = interquartile range 
a Alaska was excluded from the analysis due to changes in the boundaries of multiple counties over the analytical period  
b Per-capita prescription opioid rates were compiled by IQVIA Xponent, provided by the Centers for Disease Control (CDC), 
calculated as the total number of opioid prescriptions dispensed in a county in a given year and county (numerator) over the annual 
resident population estimates derived from the Population Estimates Program, U.S. Census Bureau. 




Table 0.2. County-level association between rate of opioid prescribingg and drug-related deatha attributed to any drug, any 
opioid,b prescription opioids,c and heroind in 3,109 counties in 49 U.S. Statese and Washington, D.C., 2006-2016 
 
 




 Heroin-related deatha,d 
Medianf (95% CI)  Medianf (95% CI)  Medianf (95% CI)  Medianf (95% CI) 
Opioid prescribing rateg  (1 SD) 1.17 (1.16-1.19)  1.21 (1.18-1.23)  1.20 (1.17-1.23)  1.14 (1.08-1.20) 
Random effects            
    County 0.002 (0.002-0.002) 0.007 0.006-0.007 0.007 0.006-0.007 0.002 0.002-0.002 
    Spatial 0.15 (0.13-0.19)  0.38 0.30-0.46  0.44 0.36-0.54  0.15 0.13-0.19 
    Noise 0.05 (0.04, 0.06)  0.10 0.07-0.13  0.12 0.09-0.15  0.05 0.04-0.06 
    !h  0.76   0.79   0.79   0.76  
SD = standard deviation; CI = credibility interval; Median = rate ratio, computed as the exp(!) of the median posterior estimate.  
a Drug-related deaths were identified using International Classification of Diseases, 10th Revision (ICD-10) underlying cause of death (UCOD) codes for 
unintentional poisoning (X40-X44), intentional poisonings (X60-X64), homicidal poisoning (X85), poisonings with unclear intent (Y10-Y14). 
b Opioid poisoning deaths were drug poisoning deathsa identified using International Classification of Diseases, 10th Revision (ICD-10) multiple cause of death 
codes (MCOD) for opium (T40.0), heroin (T40.1), natural or semi-synthetic opioid (T40.2), methadone (T40.3), synthetic opioid (T40.4), and unspecified narcotic 
(T40.6).  
c Prescription opioid-related deaths were drug poisoning deathsa identified using International Classification of Diseases, 10th Revision (ICD-10) multiple cause of 
death codes (MCOD) for natural and semisynthetic opioids (T40.2) and methadone (T40.3) 
d Heroin-related death were drug poisoning deathsa identified using International Classification of Diseases, 10th Revision (ICD-10) multiple cause of death codes 
(MCOD) for heroin (T40.1) 
e Alaska was excluded from the analysis due to changes in the boundaries of multiple counties over the analytical period  
f Models adjusted for the following county-level covariates: population density (1,000s of people per square mile); age distribution (% 0-19 years, % 20-44 years, % 
45-64 years); racial/ethnic distribution (% non-Hispanic white, % non-Hispanic black, % Hispanic); gender distribution (% male); median household income; % of 
families in poverty; % of people ages 16 years or older unemployed. Models were also adjusted for State’s status on medical marijuana laws, must access 
prescription drug monitoring program, and state and year fixed effects. 
g Per-capita prescription opioid rates were compiled by IQVIA Xponent, provided by the Centers for Disease Control (CDC), calculated as the total number of 
opioid prescriptions dispensed in a county in a given year and county (numerator) over the annual resident population estimates derived from the Population 
Estimates Program, U.S. Census Bureau. 
h  Proportion of random-intercept variance that is CAR spatial
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Table 0.3. Association between per-capita opioid prescribing ratea and deaths attributed to 
any drug,b any opioid,c prescription opioids,d and heroine using different definitions of 
“areas” to aggregate data in 3,109 counties in 49 U.S. Statesf and Washington, D.C., 2006-
2016 
 County  State 
 Mediang (95% CI)  Mediang (95% CI) 
Outcome: Drug-related deathb      
    Per-capita opioid prescribing ratea 1.17 (1.16-1.19)  1.09 (1.06-1.12) 
      
Outcome: Opioid-related deathb,c      
    Per-capita opioid prescribing ratea 1.21 (1.18-1.23)  1.15 (1.11-1.19) 
      
Outcome: Prescription opioid-related deathc,d     
    Per-capita opioid prescribing ratea 1.20 (1.17-1.23)  1.14 (1.09-1.19) 
      
Outcome: Heroin-related deathd,e      
    Per-capita opioid prescribing ratea 1.14 (1.08-1.20)  1.18 (1.08-1.29) 
a Per-capita prescription opioid rates were compiled by IQVIA Xponent, provided by the Centers for Disease Control 
(CDC), calculated as the total number of opioid prescriptions dispensed in a county in a given year and county 
(numerator) over the annual resident population estimates derived from the Population Estimates Program, U.S. 
Census Bureau. b Drug poisoning deaths were identified using International Classification of Diseases, 10th Revision 
(ICD-10) underlying cause of death (UCOD) codes for unintentional poisoning (X40-X44), intentional poisonings 
(X60-X64), homicidal poisoning (X85), poisonings with unclear intent (Y10-Y14). c Opioid poisoning deaths were drug 
poisoning deathsa identified using ICD-10 multiple cause of death codes (MCOD) for opium (T40.0), heroin (T40.1), 
natural or semi-synthetic opioid (T40.2), methadone (T40.3), synthetic opioid (T40.4), and unspecified narcotic 
(T40.6). d Prescription opioid-related deaths were drug poisoning deathsa identified using ICD-10 MCOD for natural 
and semisynthetic opioids (T40.2) and methadone (T40.3). e Heroin opioid-related death were drug poisoning deathsa 
identified using ICD-10 MCOD for heroin (T40.1). f Alaska was excluded from the analysis due to changes in the 
boundaries of multiple counties over the analytical period. g Models adjusted for the following area-specific 
covariates: population density (1,000s of people per square mile); urbanicity, age distribution (% 0-19 years, % 20-44 
years, % 45-64 years); racial/ethnic distribution (% non-Hispanic white, % non-Hispanic black, % Hispanic); gender 
distribution (% male); median household income; % of families in poverty; % of people ages 16 years or older 
unemployed. Models were also adjusted for State’s status on medical marijuana laws, must access prescription drug 
monitoring program, year fixed effect, unit-specific random trend. County-level models included state fixed effect and 
modelled spatial autocorrelation using a conditional-autoregressive (CAR) spatial random effect. Median estimates an 





Table 0.4. Association between state prescription opioid supply on deaths attributed to any 
drug,a any opioid,b prescription opioids,c and heroind using different sources of prescription 
opioid supply in 49 US Statese and Washington, D.C., 2006-2016 
 Opioid prescribing rate 
per 100, IQVIA 
Xponent 
 Morphine milligram 
equivalents (MME) per-
capita, ARCOS 
 Medianf (95% CI)  Medianf (95% CI) 
Outcome: Drug-related deatha      
    Per-capita opioid prescribing rate 1.09 (1.06-1.12)  1.04 (1.03-1.05) 
      
Outcome: Opioid-related deatha,b      
    Per-capita opioid prescribing rate 1.15 (1.11-1.19)  1.07 (1.06-1.08) 
      
Outcome: Prescription opioid-related deatha,c     
    Per-capita opioid prescribing rate 1.14 (1.09-1.19)  1.10 (1.08-1.12) 
      
Outcome: Heroin-related deatha,d      
    Per-capita opioid prescribing rate 1.18 (1.08-1.29)  0.90 (0.87-0.94) 
a Drug poisoning deaths were identified using International Classification of Diseases, 10th Revision (ICD-10) 
underlying cause of death (UCOD) codes for unintentional poisoning (X40-X44), intentional poisonings (X60-X64), 
homicidal poisoning (X85), poisonings with unclear intent (Y10-Y14).b Opioid poisoning deaths were drug poisoning 
deathsa identified using ICD-10 multiple cause of death codes (MCOD) for opium (T40.0), heroin (T40.1), natural or 
semi-synthetic opioid (T40.2), methadone (T40.3), synthetic opioid (T40.4), and unspecified narcotic (T40.6). c 
Prescription opioid-related deaths were drug poisoning deathsa identified using ICD-10 MCOD for natural and 
semisynthetic opioids (T40.2) and methadone (T40.3). e Alaska was excluded from the analysis due to changes in the 
boundaries of multiple counties over the analytical period. f Models adjusted for the following area-specific covariates: 
population density (1,000s of people per square mile); urbanicity, age distribution (% 0-19 years, % 20-44 years, % 
45-64 years); racial/ethnic distribution (% non-Hispanic white, % non-Hispanic black, % Hispanic); gender distribution 
(% male); median household income; % of families in poverty; % of people ages 16 years or older unemployed. 
Models were also adjusted for State’s status on medical marijuana laws, must access prescription drug monitoring 
program, year fixed effect, unit-specific random trend. County-level models included state fixed effect and modelled 
spatial autocorrelation using a conditional-autoregressive (CAR) spatial random effect. Median estimates an 
incidence rate ratio, computed as the exp(!) of the median posterior estimate. CI=credibility interval; 





Table 0.5. Association between state prescription opioid supplya on deaths attributed to any drug,b any opioid,c prescription 
opioids,d and heroine in 49 U.S. Statesf and Washington, D.C., 2006-2016, using various sets of adjustments for confounding and 
spatial autocorrelation 
a Per-capita prescription opioid rates were compiled by IQVIA Xponent, provided by the Centers for Disease Control (CDC), calculated as the total number of 
opioid prescriptions dispensed in a county in a given year and county (numerator) over the annual resident population estimates derived from the Population 
Estimates Program, U.S. Census Bureau. b Drug-related deaths were identified using International Classification of Diseases, 10th Revision (ICD-10) underlying 
cause of death (UCOD) codes for unintentional poisoning (X40-X44), intentional poisonings (X60-X64), homicidal poisoning (X85), poisonings with unclear intent 
(Y10-Y14). c Opioid poisoning deaths were drug poisoning deathsb identified using International Classification of Diseases, 10th Revision (ICD-10) multiple cause 
of death codes (MCOD) for opium (T40.0), heroin (T40.1), natural or semi-synthetic opioid (T40.2), methadone (T40.3), synthetic opioid (T40.4), and unspecified 
narcotic (T40.6). d Prescription opioid-related deaths were drug poisoning deathsb identified using ICD-10 MCOD for natural and semisynthetic opioids (T40.2) and 
methadone (T40.3). e Heroin-related deaths were drug poisoning deathsb identified using ICD-10 MCOD for heroin (T40.1). f Alaska was excluded from the 
analysis due to changes in the boundaries of multiple counties over the analytical period. g Models adjusted for the following county-level covariates: population 
density (1,000s of people per square mile); age distribution (% 0-19 years, % 20-44 years, % 45-64 years); racial/ethnic distribution (% non-Hispanic white, % non-
Hispanic black, % Hispanic); gender distribution (% male); median household income; % of families in poverty; % of people ages 16 years or older unemployed. 
Models were also adjusted for State’s status on medical marijuana laws, must access prescription drug monitoring program, and state and year fixed effects. h  
Models adjusted for spatial autocorrelation of the geographic units by including a conditional autoregressive random effect that used the first-order adjacency 
matrix of counties, weighted as one if counties share a boarder. The conditional autoregressive (CAR) random effect deals with the lack of independence among 
spatial units and avoids biases due to small area effects. Models also included a nonspatial county random effect (to control for overdispersion that can arise when 
areas have low or zero counts) and a county-specific CAR random effect that allows for spatially variant rates of change above or below the statewide trend, and a 
county-level random effect that allows for variation around the intercept. f Median estimates an incidence rate ratio, computed as the exp(!) of the median posterior 




Drug-related deathb  Opioid-related deathc  Prescription opioid-
related deathd 
 Heroin-related deathe 
Medianf (95% CI)  Medianf (95% CI)  Medianf (95% CI)  Medianf (95% CI) 
Per-capita prescription opioid ratea (1 SD)           
M1: Adjustedg, spatial modelh 1.17 (1.16-1.19)  1.21 (1.18-1.23)  1.20 (1.17-1.23)  1.14 (1.08-1.20) 
M2: Adjustedg, non-spatial model 1.20 (1.18-1.22)  1.23 (1.20-1.25)  1.22 (1.19-1.25)  1.13 (1.07-1.20) 
M3: Unadjusted, spatial modelh 0.90 (0.89-0.91)  0.76 (0.45-0.77)  1.14 (1.12-1.16)  0.21 (0.20-0.22) 









Ancestor of exposure and outcome 






Figure 0.2. Relationship between two state-level measures of prescription opioid supply, per-
capita rate of opioid prescribing from IQVIA Xponentaa and per-capita morphine milligram 
equivalents (MME) from the Automation of Reports and Consolidated Orders System 
(ARCOS)b, in 49 US Statesc and Washington, D.C., 2006-2016 
a IQVIA Xponent is based on a sample of approximately 50,000 (non-hospital) pharmacies, which dispense nearly 90% of all retail 
prescriptions in the United States. Mail order pharmacy data are excluded. Opioid prescriptions include buprenorphine, codeine, 
fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, propoxyphene, tapentadol, and tramadol. 
Cough and cold formulations containing opioids and buprenorphine products typically used to treat opioid use disorder were not 
included, and methadone dispensed through methadone maintenance treatment programs were not included. 
b Automation of Reports and Consolidated Orders System (ARCOS) is a comprehensive drug reporting system which monitors the 
flow of controlled substances from their point of manufacture through commercial distribution channels to point of sale or distribution 
at the dispensing retail level (hospitals, retail pharmacies, practitioners, and teaching institutions). Included in this measure of per-
capita morphine milligram equivalents are the following: codeine, dihydrocodeine, hydrocodone, hydromorphone, levorphanol, 
meperidine, morphine, oxycodone, oxymorphone, tapentadol (buprenorphine and methadone excluded).  







Background and aims: Prescription opioid supply as a risk factor for fatal drug poisoning is well 
documented at the county level, but less is known about the role of socioeconomic conditions, which may 
underlie drug demand and play a critical role in this relationship. The current study assesses the degree 
to which different measures of the geographic distributions of socioeconomic conditions moderate to the 
effect of prescription opioid supply on drug poisoning mortality rates.  
Methods: In this pooled cross-sectional study of 3,109 counties in 49 states and Washington D.C., United 
States (2006-2016), hierarchical Bayesian Poisson space-time models were used to analyze the 
association between county-level socioeconomic conditions (unemployment, poverty rate, income 
inequality, Rey index [comprised of percent of adults unemployed, blue-collar workers, and with at least a 
high-school diploma], American Human Development Index [HDI]) and counts of  four types of fatal drug 
poisonings based on whether the death involved any drug (drug-related death), any opioid (opioid-related 
death), any prescription opioid but not heroin (i.e., natural and semi-synthetic opioid or methadone 
[prescription opioid-related death]), and heroin (heroin-related death). These models were fit to estimate 
the independent effect of each of the five key socioeconomic measures on fatal drug poisoning risk and 
their joint multiplicative effect with prescription opioid supply (opioid prescriptions per 100 persons), 
adjusting for population density, age distribution, race/ethnic distribution, gender distribution, education, 
and drug law environment.  
Results: Rates of fatal drug poisoning were higher in counties with more unequal income distributions 
(rate ratios [RR] ranged from 1.09 to 1.13 for prescription opioid- and heroin-related deaths, respectively), 
higher in counties with higher levels of the Rey index (RR ranged from 1.02 to 1.07 for heroin- and opioid-
related deaths), lower in counties with higher levels of HDI (RR ranged from 0.75 to 0.92 for drug- and 
heroin-related deaths, respectively), mixed in counties with higher poverty rates (RR ranged from 0.90 to 
1.04 for heroin- and prescription opioid-related deaths, respectively), and unaffected by levels of 
unemployment. There was super-multiplicative interaction between income inequality and HDI with 
CHAPTER 4: A COUNTY-LEVEL ECOLOGICAL STUDY OF FATAL DRUG POISONINGS, 
SOCIOECONOMIC CONDITIONS, AND PRESCRIPTION OPIOID SUPPLY: A BAYESIAN 
MODELING APPROACH  
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prescription opioid supply. Counties with more equal income distributions and higher HDI experienced the 
greatest change in fatal drug poisoning rates across the prescription opioid supply distribution, going from 
the lowest rates of drug poisoning deaths at 2 SD below the mean prescription opioid supply to the 
highest rates at 2 SD above the mean supply.  
Discussion: Independent of other sociodemographic covariates, rates of fatal drug poisonings were 
higher in more socioeconomically disadvantaged counties. Associations varied across the five key 
socioeconomic variables, with HDI and income inequality most strongly associated with fatal drug 
poisoning rates, and evidence for interaction was seen by prescription opioid supply with both HDI and 
income inequality. The results provide insight into the way factors related to community vulnerability and 
resiliency may shape the geospatial distribution of fatal drug poisonings in the U.S. By identifying the 
factors that shape location vulnerability and resiliency, programs and policies can be developed to 
strengthen and empower communities to address existing vulnerabilities and facilitate future community 







Drug use is the 6th leading cause of death and disability in the United States (U.S.) (1), responsible for 
more than 67,367 lives lost in 2018 (2), a four-fold increase in lives lost from 1999 (1). Drug-related 
mortality led to notable reductions in U.S. life expectancy from 2015 to 2017 (3). Opioids are the principal 
driver of these trends, responsible for over two out of every three drug-related deaths in 2018 (2). 
However, primary type of opioid driving the trend has varied over time in what has been called a triple 
wave epidemic (2, 4). In the first wave, begun in 1999, prescription opioid-related deaths quadrupled, 
from 2,749 deaths in 1999 to 10,943 in 2010. In the second wave, beginning in 2007, heroin-related 
deaths rose 6-fold, from 2,399 deaths in 2007 to 15,482 in 2017. In the third wave, beginning in 2013, 
deaths from synthetic opioids other than methadone, most frequently illicitly manufactured fentanyl (IMF) 
or fentanyl analogs mixed with heroin (4-6), spiked 10-fold, going from 3,007 deaths in 2013 to 28,466 in 
2017 (7). 
 
A major focus of attempts to understand and reverse the rapid rise in fatal drug poisonings has focused 
on the ‘supply side’ of this unprecedented health crisis. During much of the last three decades, the rates 
of opioid-related mortality changed in parallel to opioid prescribing rates in the U.S., with opioid 
prescribing rates quadrupling from 180 morphine milligrams equivalents (MME) in 1999 to 782 MME per 
capita in 2010 (8). Previous studies have documented parallel increases in nonmedical use (9), 
emergency department visits (10), and treatment admissions for opioids analgesics (11). Recognition of 
these national trends motivated numerous state and federal interventions aimed at mitigating prescription 
opioid-related harm by reducing excessive or unnecessary prescribing (e.g. prescribing guidelines) (12) 
and identifying illegal prescribing (e.g., “pill mills” laws, prescription drug monitoring programs) (13-26). 
However, recent years have seen a marked increase in the number of papers documenting the potential 
unintended consequences of supply-side interventions on heroin use and heroin-related deaths (27-30). 
Supply-side intervention—such as prescription drug monitoring programs or abuse deterrent drug 
formulations—causes the market supply of pharmaceutically manufactured opioids to decline, while 
leaving drug demand unaffected. Like all markets, illicit drug markets innovate in response to the 
changing conditions, providing a ready supply of low cost, high purity, heroin to meet the unmet demand 
 
 81 
for prescription opioids created by a supply-side intervention (31-33), and some people who use 
prescription opioids, whether for medical or nonmedical purposes, finding their preferred drug too costly 
or difficult to obtain may transition to heroin (26, 27, 34-38). This suggests that investing in supply-side 
interventions, without an adequate understanding of the mix of factors that closely link drug demand to 
supply, may offset the intended reductions in prescription opioid-related deaths with unintended increases 
in heroin-related deaths. As such, an improve understanding of supply-demand dynamics is needed. 
 
Socioeconomic conditions are considered important determinants of the geographic distribution of 
demand and resulting drug-related mortality in the U.S. (39-48). Economic insecurities during periods of 
unemployment reduce access to material resources (e.g., food, housing) (49-52) and increase 
psychosocial stress (50, 51), affecting marital relationships (53, 54) and childhood well-being (55-57). 
Financial and psychosocial stressors may affect health directly or through harmful coping behaviors, such 
as increased smoking (58, 59), alcohol consumption (60, 61), and suicidal behaviors (62-64). 
Unemployment increases overall mortality (65-68) and substance use-related mortality in particular (65, 
69). While at the in individual-level, people who lose their jobs as part of plant closing, mass layoff, and 
other company-level employment reductions have a 10-15% increase in annual death hazard—an implied 
loss in life expectancy of 1-1.5 years for a 40 year old person (67), at the population-level, counties with 
automotive assembly plant closures have 85% higher increase in opioid poisoning deaths five years after 
plant closure than counties without a plant closure (70). Extrinsically, greater exposure to harmful 
socioeconomic conditions may exacerbate vulnerabilities to addiction through greater exposure to 
psychosocial stress associated with home and neighborhood environments, and reduced access to vital 
resources including adequate health care. Despite this work shows that supply- and demand-side factors 
are inextricably intertwined with drugs being an escape from psychosocial stress (58-61), limited 
opportunities and significant barriers to employment (71), and concentrated disadvantage (72, 73), much 
more attention has been devoted to addressing the ‘supply side’ than the ‘demand side’ of the current 
drug poisoning crisis. By ignoring the underlying drivers of drug demand and its potential interaction with 
drug supply, much uncertainty still exists about the relationship between prescription supply and fatal 
drug poisonings. This is problematic for both research and policy because the effect of prescription opioid 
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supply on drug poisoning risk will vary by location due to differences in the underlying distribution of 
component causes across counties or states (i.e., those causes that interact with prescription opioid 
supply to cause drug-related deaths) (74). This suggests that the effect of interventions targeted on 
prescription opioid supply reductions will be very context specific, with similar interventions producing very 
different outcomes when implemented in different circumstances (75).  
 
Although prior research has provided insight into socioeconomic conditions that may affect fatal drug 
poisoning rates, at least three gaps in the literature remain. First, to the best of our knowledge, all 
research to date on prescription opioid supply has focused on their average effects across populations, 
disregarding socioeconomic conditions as an important potential source of heterogeneity. The effect of 
greater access to prescription opioid supply likely varies by area socioeconomic conditions, as both more 
area deprivation and as less perceived opportunity for economic advancement may affect the motives for 
prescription opioid use in local populations. This suggests that, even in areas with the same access to 
prescription opioids, areas with less area deprivation and as greater perceived opportunity for economic 
advancement might see lower rates of prescription opioid use and prescription opioid-related deaths than 
more deprived areas with less opportunity for advancement, as they may perceive greater risk associated 
with use (e.g., risk of losing a job, eviction, loss of family) than people living in more deprived areas. 
Moreover, in areas with little economic opportunity, indicated by high unemployment rate, individuals in 
the aggregate have more time to engage in drug use and less money to spend on alcohol and illicit drugs, 
but may have access to prescription opioids through safety-net health insurance coverage. This may not 
only increase the risk of poisoning among people prescribed prescription opioids but it may also increase 
the sale of prescription opioid to supplement income, potentially increasing the prescription opioid supply 
for nonmedical use in these areas. 
 
Second, measures of local socioeconomic conditions vary widely across studies. Because each measure 
captures a distinct aspect of local socioeconomic conditions (e.g., income, poverty, employment), the 
interpretation of findings will vary  among studies depending on the socioeconomic measure used. The 
most commonly used area socioeconomic measures include: unemployment rate (42, 45, 76), median 
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household income (39, 46, 76), and poverty rate (42, 46, 76). Moreover, some studies constructed 
composite socioeconomic measures by combining information about several socioeconomic measures 
(44, 76-78). Despite the potential for findings to vary depending on the socioeconomic measure used, no 
study has compared the consistency of results across these most frequently used socioeconomic 
measures that may indicate or underly demand. Third, inadequate adjustment for time-invariant and time-
varying confounding factors is common in the literature, raising concerns about unmeasured and residual 
confounding (39-42, 45-47). For example, although most studies adjusted for some sociodemographic 
variables, only one study adjusted for state-level policy that are common causes of both prescription 
opioid supply and fatal drug poisonings and may confound the effect estimates (e.g., prescription drug 
monitoring programs laws, legalization of cannabis for medical or recreational use) (76).  
 
To address these gaps in knowledge, this study investigated the hypothesis that worse economic and 
social conditions increase risk of fatal drug poisonings at the county level, and interact with prescription 
opioid supply, such that the effect of prescription opioid supply on fatal drug poisonings is higher in 
counties with more deleterious economic and social conditions than counties with more salubrious 
conditions. Because each socioeconomic variable captures a unique aspect of an area’s socioeconomic 
well-being, we investigated the sensitivity of results to five county-level socioeconomic measures, 
including three single socioeconomic features (unemployment rate, poverty rate, income inequality) and 
two validated indices (Rey index and American Human Development Index). Results from the systematic 
literature review (Chapter 2) were used to construct a Directed Acyclic Graph (DAG) and identify the 
minimum set of necessary covariates needed in the model to minimize bias. This study used nationally 
representative data from 49 U.S. states and Washington D.C. from 2006 to 2016, to investigate the 
following two hypotheses: 1) fatal drug poisoning rates are concentrated in more socioeconomically 
disadvantaged counties; and 2) risk of higher prescription opioid supply on fatal drug poisoning rates is 





4.3.1. Study population 
This study analyzed ecological county-level data from 3,109 counties in 49 U.S. states and Washington 
D.C., collected over 11 years from 2006 to 2016, resulting in 34,199 space-time units (due to frequent 
changes in county boundaries during the study period, Alaska was excluded). The relationship between 
socioeconomic conditions and fatal drug poisonings was analyzed at the county level because counties 
have policy-making authority over health service administration and public health spending, whereas 
lower levels of aggregation (e.g., ZIP codes, census blocks) are often drawn for purposes unrelated to 
health (e.g., efficient delivery of mail, census enumeration), making them unlikely targets for future 
intervention, and higher levels of aggregation (e.g., state) conceal substantial within-state heterogeneity 




Outcomes: Fatal drug poisonings 
Annual county-level counts of fatal drug poisonings for the period of January 1, 2006 to December 31, 
2016 were obtained from the restricted-use National Vital Statistics System (NVSS) Multiple Cause of 
Death (MCOD) files. The MCOD files provide information from death certificates on a single underlying 
cause of death (UCD) and up to 20 contributing causes. Drug poisoning deaths are identified with the 
International Classification of Diseases, 10th Revision (ICD-10), according to the UCD codes: X40-X44 
(accidental poisoning), X60-X64 (intentional poisoning), X85 (assault by poisoning), and Y10-Y14 
(undetermined poisoning). Among deaths with drug poisoning as the underlying cause, the type of opioid 
is indicated by the following ICD-10 multiple-cause-of-death “T-codes”: T40.0 (opium), T40.1 (heroin), 
T40.2 (natural and semisynthetic opioids), T40.3 (methadone), T40.4 (synthetic opioids other than 
methadone, including fentanyl and fentanyl analogs), or T40.6 (other and unspecified narcotics).  
 
Four types of drug poisoning deaths were calculated for this study. Drug-related deaths (otherwise called 
fatal drug poisonings) were identified using ICD-10 UCD codes: X40-X44, X60-X64, X85, and Y10-Y14. 
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Opioid-related deaths (otherwise called opioid drug poisonings) were fatal drug poisonings involving one 
or more opioid, including: opium, heroin, natural and semisynthetic opioids, methadone, synthetic opioids 
other than methadone (including fentanyl and fentanyl analogs), or other unspecified narcotic. Consistent 
with recent CDC guidelines (86), prescription opioid-related deaths (otherwise called prescription opioid 
poisoning) were fatal drug poisoning deaths involving only natural and semisynthetic opioids or 
methadone and not heroin. Heroin-related deaths (otherwise called heroin poisonings) were fatal drug 
poisoning deaths involving heroin alone or in combination with any other drugs.  
 
Exposure: County-level socioeconomic conditions 
Five key variables measured county-level socioeconomic conditions. Three single measures were used to 
assess local labor markets and income distribution: 1) unemployment rate, calculated as the number of 
employed persons divided by the sum of employed and unemployed persons 16 years or older and not 
institutionalized;  2) poverty rate, number of  households below federally defined poverty line (a threshold 
that varies by size and age composition of the household) divided by the total number of households; and 
3) income inequality according to the Gini coefficient, the most widely used summary measure of income 
inequality (87-92). The Gini coefficient measures the equality of the income distribution on a scale of 0 to 
1, with 0 representing perfect equality of distribution of income (i.e., every resident in the county has the 
same income) and 1 perfect inequality (i.e., one resident earned all the income in a county). Annual 
county-level estimates of both the unemployment rate and the poverty rate were collected from the 
Census Bureau’s state and county level estimates of population and income characteristics (including 
data from the American Community Survey) and supplied by GeoLytics (93), whereas the Gini coefficient 
were extracted from the American Community Survey (94-96). 
 
Because no single economic measure captures all aspects of a location’s economic well-being, two 
composite measures of socioeconomic deprivation were also used: (i) the Rey index (97) and (ii) the 
American Human Development Index (HDI) (98). The Rey index is defined as the first component of a 
principal component analysis of four area-level input variables: median household income, the 
unemployed rate, the percent blue-collar workers in the labor force, and the percent of people greater 
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than or equal to 18 years old with at least a high-school diploma (97). The Rey index is highly correlated 
with two commonly used indices, the Townsend (99) and the Carstairs indexes (100), but is more 
sensitive to disadvantage in rural areas than either the Townsend or the Carstairs indexes (101). 
Previous studies have shown that the index has discriminant validity, exhibiting strong positive 
associations with mortality rates (97, 102) and rates of colorectal cancer screening (an indicator of 
healthcare utilization across the urban-rural continuum) (101). The second composite measure, the 
American Human Development Index, is the most widely used measure of human development (103). 
Based in Sen’s capability approach (104), the human development paradigm proposes that economic 
resources are just a means to an end (i.e., well-being), which is better captured by the idea that 
development is about widening people’s opportunities and improving their well-being rather than 
economic growth alone (e.g., production, wealth, and spending) (105). Therefore, the HDI aims to create 
a composite rating of overall well-being based on health, education, and income (98). Health is assessed 
using life expectancy at birth. Access to knowledge is measured as a weighted average of two variables: 
school enrollment for the population ages 3 to 24 years and educational degree attainment (high school 
diploma or more) for those ages 25 years and older, with one-third weight applied to the enrollment 
variable and a two-thirds weight to the degree attainment variable. Finally, a reasonable standard of living 
is operationalized using median earnings of all full- and part-time workers ages 16 years and older. The 
variables for both the access to knowledge and the standard of living dimensions are from the U.S. 
Census Bureau’s American Community Survey. Since all measures are reported on different scales (e.g., 





with all indices ranging from 0 to 10, 10 being the highest score possible and scores close to 0 indicating 
a greater distance from the maximum possible index score. To calculate the HDI, the health, education, 
and earning scores are added together and divided by three to yield the final score, which ranges from 0 
to 10. Higher scores denote areas with higher levels of well-being and expanded opportunities.  The HDI 
has good internal consistency (106) and found to be a valid measure of well-being (107). 
 
Prescription opioid supply 
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Prescription opioid supply was defined as the opioid prescribing rates per 100 persons. Data on county-
level opioid prescribing rate were derived from outpatient prescribing records from the IQVIA Xponent 
database, released for public use by the CDC, for years 2006 to 2016 (108). IQVIA Xponent provides 
weighted estimates of the number of opioid prescriptions dispensed from a sample of approximately 
59,000 (non-hospital) retail pharmacies, which dispense nearly 88% of all U.S. retail prescriptions. Data 
on prescriptions obtained by mail order, those dispensed directly by clinicians, or dispensed from a 
methadone maintenance treatment program are not included. Prescribing rates per 100 persons were 
calculated as the total number of opioid prescriptions dispensed each year in a county (numerator) over 
the annual resident population estimates as derived from the Population Estimates Program, U.S. Census 
Bureau. Because opioid prescribing rates were missing for 3,500 county-years of the 34,199-total county-
years of data (10%), a two-stage approach was used to predict opioid prescribing rate and to evaluate its 
effects on drug-related mortality at the county-level (109). In the first stage, the same model used in the 
primary county-level analysis was fit with opioid prescribing rate as the outcome variable. From this 
model, five samples were obtained from the posterior distribution for each missing observation. In the 
second stage, the original dataset is completed with each of the five sets of imputed values and the 
model is fit once for each imputation set and the fit models are put together by computing the average 
model using Bayesian model averaging (110). Minimal differences were found between the imputed 
model and the complete case analysis using listwise deletion of observations with missing data (See 
Appendix Tables 6-9). Although standard errors may be larger with complete case analysis than with 
imputation because less information is used, the two methods produced similar standard errors for this 
analysis. Given that listwise deletion produces results that are approximately unbiased and efficient under 
most circumstances (e.g., data missing completely at random) and more robust (i.e., less biased, more 
efficient) to violations of the missing at random assumption than imputation models (111), counties 
missing data on per-capita prescribing rate were excluded from the dataset. 
 
Potentially confounding variables 
Adjustment variables were determined using a Directed Acyclic Graph (DAG). DAGs provide a visual 
representation of the data-generating process and a transparent approach for identifying the minimum set 
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of adjustment variables necessary to minimize bias (112, 113). All DAGs were constructed using DAGitty 
v3.0 (114). For example, to identify the set of adjustment variables for estimating the total effect of 
unemployment on fatal drug poisonings, all common causes of unemployment and fatal drug poisonings 
were mapped onto the DAG in Figure 4.1, identifying the minimal sufficient adjustment set for an 
unbiased effect of unemployment on fatal drug poisonings, including: four demographic variables (county 
distribution of age, race/ethnicity, education, and sex), one place-based factor (urbanicity), and three 
state policies (medical marijuana law [MML], recreational marijuana law [RML], and prescription drug 
monitoring programs [PDMP]). Appendix Figures 1 to 4 show the DAGs for poverty rate, income 
inequality, the Rey index, and HDI. 
 
Time-varying data on the confounding demographic and place-based covariates were supplied by 
GeoLytics (93). Annual population share of the following measures were adjusted for in the models: age 
composition (percent of the population aged 0-19, 20-44, 45-64, and greater than or equal to 65 years); 
racial/ethnic composition (non-Hispanic Whites, non-Hispanic Blacks, Hispanics, other nonwhite non-
Hispanics); percent male; education (percent of people ages 24 years or older with a college degree); and 
population density (thousands of people per square mile). 
 
Urbanicity was indicated by Rural-Urban Continuum codes (RUCC), a classification scheme that 
distinguishes between large and small metropolitan counties and nonmetropolitan counties by degree of 
urbanization and adjacency to metro area or areas (115). Large metropolitan areas are defined as 
densely populated center with population ≥ 1,000,000, including in the surrounding economically 
integrated areas (RUCC = 1). Small metropolitan areas are defined similarly, except that the center has 
250,000 to 999,999 people (RUCC = 2) or 50,000 to 249,999 (RUCC = 3). All other areas are defined as 
nonmetropolitan counties (RUCC = 4 to 9), classified by degree of urbanization and adjacency to metro 
area: urban with population ≥ 20,000, adjacent to a metro area (RUCC = 4) or not adjacent to a 
metropolitan area (RUCC = 5); urban with population 2,500-20,000 and adjacent to a metro area (RUCC 
= 6) or not adjacent to a metropolitan area (RUCC = 7); and rural with population <2,500 adjacent to a 




Three measures of the state-level legal environment related to drug use were adjusted for in the analysis. 
The first variable indicates whether a state had a prescription drug monitoring program (PDMP) that 
required prescribers and dispensers to review the patient prescribing history prior to prescribing or 
dispensing controlled substances. Prescription drug monitoring programs with mandatory provider review 
was chosen over a state-level variable indicating any PDMP or PDMP with some other operational 
feature (e.g., frequency of reporting, interstate sharing of prescription data) based on two conclusions 
from a recent systematic review (27). First, an association between PDMP with mandatory provider 
review and fatal drug poisonings has been consistently reported in the literature, whereas evidence on 
whether PDMPs in generals or PDMPs with other operational features are associated with fatal drug 
poisonings is mixed. Second, half of the studies that have shown PDMP implementation to be associated 
with increasing rates of heroin-related deaths considered PDMP with mandatory provider review (34, 36), 
with the other two studies either coding PDMP as present or absent (35) or coding PDMPs using a latent 
class variable based on their operational features (28). The second and third variables indicate whether a 
state has legalized cannabis use for medical or recreational purposes. Medical marijuana legalization 
(MML) and recreational marijuana legalization (RML) was enacted in 25 states and 3 states by 2016 
(Alaska was not included in this analysis). To account for any potential confounding from these state-level 
policies, the status of these laws and the fraction of the year in which they were enacted at the state level 
were adjusted for in the model. For PDMP with mandatory provider review, month and year of enactment 
came from the National Alliance for Model State Drug Laws (NAMSDL) (116) and the Prescription Drug 
Abuse Policy System (PDAPS) (117). Enactment date of MML and RML was determined by a team of 
legal scholars, policy analysts, and economists after reviewing state policies (118), and used in previous 
work on MML (119, 120) and RML (121, 122).  
 
4.3.3. Statistical analysis 
The effect of economic and social conditions on fatal drug poisonings was estimated using a county-level 
analysis. The outcomes were four types of fatal drug poisonings (i.e., drug poisonings attributed to all 
drug, all opioids, prescription opioids, and heroin). The key explanatory variables were five measures of 
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county socioeconomic conditions. The county-by-year mortality counts were modelled using a 
spatiotemporal Hierarchical Bayesian Poisson specification to estimate the posterior distributions of the 
model parameters. By borrowing strength across both counties and years to produce smoothed yearly 
county level estimates, the Bayesian spatiotemporal modelling approach allows examination of spatial 
and temporal variation in rare outcomes such as counts of fatal drug poisonings (123, 124). To account 
for spatial autocorrelation, a conditional autoregressive (CAR) random effect was included using a  first-
order adjacency matrix of counties (125, 126). The CAR random effect accounts for potential spatial 
spillover effects and lack of independence among spatial units, while effectively avoiding biases due to 
small area effects by smoothing extreme outliers estimated among small populations in sparsely settled 
counties (127). Models also included a nonspatial county random effect that helps control for 
overdispersion that can arise with Poisson models when a preponderance of areas have low or zero 
counts (128). 
 
To precisely estimate the county-level effect of each of the five key explanatory variables (using a 
separate model for each) on fatal drug poisonings, the following model specification was used. Assuming 
that the number of fatal drug poisonings within counties follow a Poisson distribution, let 6!,# denote the 
observed count of fatal drug poisonings occurring in the $th county and 7th state during year ' under a 
heterogenous Poisson process: 
6!,#|9!,#~;($<<("(9!,#) 
Where, 
logB9!,#C = log	(D!,# , F!,#) 
F!,# denotes the expected number of fatal drug poisonings under the assumption that statewide overdoses 
are distributed among counties in direct proportion to the population and D!,# is interpreted as the relative 
risk of residing in the $th county during year '. Counties with D!,# > 1 will have higher counts than expected 
based on their population, and counties with D!,# < 1 will have fewer counts than expected. Therefore, the 
log relative rate is: 
log	(D!,#) = 	I + K' + FL;MNOPF!#Q + L′!#S + ∅!# + U!# + V! + W! 
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where I is the statewide intercept and K	is the state temporal trend in fatal drug poisonings over time. L′!,# 
is a matrix of potentially confounding space- and time-varying covariates (identified in Figure 4.1) and S is 
a vector of fixed-effects estimates of the association of those covariates with fatal drug poisonings. 
	FL;MNOPF!# is one of the 5 key explanatory variables (separate model for each) and Q is the effect 
estimate of the association between the explanatory variable and fatal drug poisonings (the effect 
estimate of interest). ∅!# is the CAR random effect and U!# is the nonspatial random effect to control for 
overdispersion. Finally, V! is a county-specific CAR random effect that allows for spatially variant rates of 
change above or below the statewide trend K, and W! is a county-level random effect that allows for 
variation around the intercept I. The posterior distribution of the parameters in the hierarchical Bayesian 
model were estimated via Integrated Nested Laplace Approximation (INLA) in R using the R-INLA 
package (129). This method approximates the median estimate and 95% credibility interval (CI) of the 
posterior distribution that can be interpreted as the point estimate for the incidence rate ratio (RR) and 
95% confidence interval in standard, frequentist, regression, such that a median of 1 indicates evidence 
of no relationship. 
 
Different model specifications were tested in order to identify the best fitting model, including different 
functions for time, state and year fixed effects, and a county-specific random slope for time. The model fit 
was examined using the Deviance Information Criterion (DIC). Better fitting models should have lower 
DIC and small effective number of parameters to estimate (130, 131). The best fitting model included the 
set of pre-determined time-varying covariates, a state fixed effect to account for time-stable differences in 
the explanatory variable, drug-related mortality, and confounders between states, and year fixed effects 
to adjust for the secular trends in the explanatory variable and drug-related mortality. To improve 
interpretability, the five key explanatory variables (i.e., unemployment rate, poverty rate, income 
inequality, Rey index, HDI) were standardized to have a mean of 0 and a standard deviation (SD) of 1, 
using the z-score formula to subtract the mean of each variable from each county-year observation and 




The multiplicative interaction between economic and social conditions and prescription opioid supply on 
the effect of fatal drug poisonings was examined using a two-way cross-product term between 
prescription opioid supply and each of the 5 key explanatory variables (each of the explanatory variables 
examined in a separate model). Results of the five interaction models were examined by estimating as 
the linear combination of the prescription opioid supply coefficient, the socioeconomic condition 
coefficient, and their two-way interactions, with each of the socioeconomic conditions were set at the 25th, 
50th, and 75th percentile. Because additive interaction is of public health interest, additive interaction was 
quantitatively examined by calculating the relative excess risk of interaction (RERI) (132). However, given 
that the results were similar across these two approaches, results from the multiplicative interaction 
models are presented here to evaluate the change in prescription opioid rate ratios across the distribution 





Figure 4.2 shows the rates of fatal drug poisonings attributed to all drugs (Figure 4.2a), all opioids (Figure 
4.2b), prescription opioids only (Figure 4.2c), and heroin (Figure 4.2d) across the 3,109 counties in 2006, 
2010, and 2016. Rates for deaths attributed to any drug, any opioid, and any prescription opioid 
continuously increased from 2006 to 2016. For heroin deaths, rates were lower, with many counties 
recording no heroin-related deaths from 2006 to 2010 and only 25% of counties having a rate of 2.0 per 
100,000 people or more in 2016. The median and interquartile range (IQR) for the 3 single socioeconomic 
measures were 6.0% for unemployment (IQR=4.4, 8.5), 11.4% for poverty (IQR=8.1, 15.7), and for 
income inequality, the Gini coefficient was 0.44 (IQR=0.41, 0.46) (Table 4.1).  
 
4.4.1. Association of economic and social conditions with drug poisoning deaths 
Figure 4.3 and Appendix Table 12 summarize the estimated county-level associations of the three single 
socioeconomic measures and the two composite measures with fatal drug poisonings attributed to all 
drugs, all opioids, prescription opioids only, and heroin, adjusting for potentially confounding variables. A 
1 SD increase in county unemployment rate was associated with a 2% higher rate of fatal drug 
poisonings due to all drugs (RR=1.02; 95% CI=1.01, 1.03), all opioids (RR=1.02; 95% CI=1.01, 1.02), and 
prescription opioids (RR=1.02; 95% CI=1.00, 1.03), but not with heroin-related deaths (RR=0.99; 95% 
CI=0.97, 1.00). A 1 SD increase in families in poverty was associated with a 3% higher rate of drug-
related deaths (RR=1.03; 95% CI=1.02, 1.05), a 2% higher rate of opioid-related deaths (RR=1.02; 95% 
CI=1.00, 1.05), and a 4% higher rate in prescription opioid-related deaths (RR=1.04; 95% CI=1.01, 1.07), 
but a 10% lower rate of heroin-related deaths (RR=0.90; 95% CI=0.84, 0.95). A 1SD increase in income 
inequality was associated with a 10% higher rate of fatal drug poisonings due to all drugs (RR=1.10; 95% 
CI=1.08, 1.12) and all opioids (RR=1.10; 95% CI=1.08, 1.13), a 9% higher rate of prescription opioid-
related deaths (RR=1.09; 95% CI=1.06, 1.12), and a 13% higher rate of heroin-related deaths (RR=1.13; 
95% CI=1.06, 1.19). A 1 SD increase in the Rey index was associated with a 6% higher rate of drug-
related deaths (RR=1.06; 95% CI=1.04, 1.09), an 7% lower rate of opioid-related deaths (RR=1.07; 95% 
CI=1.04, 1.11), and about 2-3% higher rate of prescription opioid- (RR=1.03; 95% CI=0.99, 1.08) and 
heroin-related deaths (RR=1.02; 95% CI=0.95, 1.09). A 1 SD increase in the HDI was associated with a 
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25% lower rate of drug-related (RR=0.75; 95% CI=0.72, 0.78) and opioid-related deaths (RR=0.78; 95% 
CI=0.74, 0.83), a 19% lower rate of prescription opioid-related deaths (RR=0.81; 95% CI=0.76, 0.86), and 
a 8% lower rate of heroin-related deaths (RR=0.92; 95% CI=0.83, 1.03). Finally, a 1 SD increase in 
prescription opioid supply was associated with higher rates of all fatal drug poisoning types (drug-related 
death: RR=1.17; 95% CI=1.16, 1.19; opioid-related death: RR=1.21; 95% CI=1.18, 1.23; prescription 
opioid-related deaths: RR=1.20; 95% CI=1.17, 1.23; and heroin-related death: RR=1.14; 95% CI=1.08, 
1.20). 
 
4.4.2. Interaction between prescription opioid supply and economic and social conditions on fatal 
drug poisonings 
Figures 4.4 to 4.8 and Appendix Table 13 shows the results from the joint effects of prescription opioid 
supply and the five key socioeconomic variables on rates of drug poisoning deaths. Figures 4.4 to 4.8 
present the associations between prescription opioid supply and rates of drug poisoning deaths from any 
drug, any opioid, prescription opioids only, and heroin, at three different levels of the five key 
socioeconomic variables: (1) 25th percentile of the distribution of each socioeconomic condition across the 
study population; (2) 50th percentile; and (3) 75th percentile.  
 
For unemployment rate there was no evidence of multiplicative joint effects on rates of drug poisoning 
deaths due to any of the studied drug types (Figure 4.4). Poverty rate and prescription opioid supply were 
sub-multiplicative for rates of heroin-related deaths, but not any other type of drug poisoning deaths 
(Figure 4.5). Although rates of heroin-related deaths were similar across all three poverty levels in 
counties with below average prescription opioid supply (indicated by values below 0), the association 
between prescription opioid supply and heroin-related deaths increased most rapidly at the 25th percentile 
of the poverty rate distribution in counties with above average prescription opioid supply (indicated by 
values above 0), going from 0.71 (95% CI=0.63, 0.82) at -2 SD to 1.62 (95% CI=1.40, 1.87) at +2 SD, 
compared to the increase in counties at the 50th percentile (-2 SD: RR=0.73; 95% CI=0.66, 0.82; +2 SD: 
RR=1.42; 95% CI=1.26, 1.60) and counties at the 75th percentile (-2 SD: RR=0.75; 95% CI=0.67, 0.85; -2 




Figure 4.6 presents the association between prescription opioid supply and each type of fatal drug 
poisoning deaths at the 25th percentile, 50th percentile, and 75th percentile of the Gini coefficient across 
the study population. Although the RR was below 1.00 for the association between prescription opioid 
supply and all types of fatal drug poisonings when prescription opioid supply is at -2 SD, rates of all types 
of fatal drug poisonings were lower in counties in the 25th percentile versus the 75th percentile. Despite 
beginning at the lowest RR at -2 SD, the association between prescription opioid supply and all types of 
fatal drug poisonings increased most rapidly in counties in the 25th percentile, with counties at each the 
25th percentile, the 50th percentile, and the 75th percentile having similar RRs at +2 SD. Moreover, the 
association between prescription opioid supply and heroin-related deaths had the lowest RR at -2 SD 
(RR=0.60; 95% CI=0.53, 0.69) and had the highest RR at +2 SD (RR=1.39; 95% CI=1.20, 1.61). 
 
Although no multiplicative interaction was found between the Rey index and prescription opioid supply on 
rates of drug poisoning deaths due to any of the studied drug types (Figure 4.7), there was evidence of 
super-multiplicative interaction between prescription opioid supply and HDI on rates of heroin-related 
deaths, but not any of the other types of drug poisoning deaths (Figure 4.8). At the 25th percentile of the 
HDI distribution, the association between prescription opioid supply and heroin-related deaths remained 
remain fairly flat across the prescription opioid supply distribution, going from an RR of 0.96 (95% 
CI=0.82, 1.12) at -2 SD to an RR of 1.14 (95% CI=1.08, 1.22) at +2SD. However, at the 75th percentile of 
the HDI distribution, the association between prescription opioid supply and heroin-related deaths 
increased rapidly, going from the lowest RR at -2 SD (RR=0.61; 95% CI=0.54, 0.7.) to the highest RR at 






Although previous studies have found that worse socioeconomic conditions increase risk of fatal drug 
poisonings at the county level, this is the first study to investigate the hypothesis that worse 
socioeconomic conditions interact with the prescription opioid supply to affect risk of fatal drug 
poisonings. A Bayesian hierarchical space-time approach was used to estimate the independent effect of 
economic and social conditions on fatal drug poisonings and its joint effect with prescription opioid supply.  
 
This study had two major findings. First, rates of fatal drug poisonings are concentrated in counties with 
more socioeconomic disadvantage, and more unequal income distributions, independent of other 
sociodemographic covariates. Although the results related to unemployment and poverty rate are 
consistent with previous findings (42, 44-46, 76), their relationship with fatal drug poisonings was weak—
the exception being the inverse association between poverty rate and heroin-related deaths. In contrast, 
the Rey index, the American Human Development Index and income inequality were all substantial 
predictors of drug poisonings rates. Second, both HDI and income inequality interacted with county-level 
prescription opioid supply to affect drug poisoning rates. However, the results contradict the hypothesis 
that risk of prescription opioid supply on drug-related mortality rates are higher in counties with worse 
socioeconomic conditions than counties with better conditions. Instead, risk of higher prescription opioid 
supply on fatal drug poisoning rates were higher in counties with more equal income distributions and 
higher HDI than counties with less equal income distributions and lower HDI. Taken together, these 
results suggest that not only are income inequality and overall county well-being (as measured by the 
HDI) two key factors by which the geographic distribution of fatal drug poisonings may be understood but 
they are also key factors for understanding the ecological association between prescription opioid supply 
and fatal drug poisonings. 
 
Comparing the estimated effect of each key socioeconomic measure on the four different types of fatal 
drug poisonings revealed consistently different results for drug poisoning deaths from heroin compared to 
those from any drugs, any opioid, and prescription opioids, namely similar effect estimates were found for 
drug poisoning deaths due to any drug, any opioid, and prescription opioid but effect estimates for heroin-
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related deaths often differed in magnitude and even direction. There are a few hypotheses that could 
explain the divergent results for heroin-related deaths. A prime explanation is that heroin is less 
accessible than prescription opioids outside of large urban centers. Previous studies that examine the 
sequence of and trajectories from nonmedical prescription opioid use to heroin use show that the vast 
majority of heroin users report using prescription opioids nonmedically before heroin (133-135). Young 
and new heroin users have described transitioning from prescription opioid pills to heroin as their 
dependency and tolerance made opioid pills prohibitively expensive and large enough quantities difficult 
to obtain (26, 27, 34-38). While the well-established heroin markets can meet the demand of new users 
within large urbanized centers (e.g., the mid-Atlantic, New England, and New York/New Jersey regions), 
heroin access remains limited in more geographically isolated, socioeconomically deprived, rural 
communities. Therefore, the lower heroin poisoning rates across locations with greater poverty, supported 
by these results, suggest that some of the most impoverished counties (e.g., counties in the Southern US 
and North and South Dakota (136, 137))—with widespread access to prescription opioids and limited or 
no access to heroin—may experience both the highest rates of prescription opioid-related deaths and the 
lowest rates of heroin-related deaths. However, the geographic distribution of heroin markets is a 
reasonable but not altogether sufficient explanation of the divergent findings for drug poisoning deaths 
from heroin compared to all other types.  
 
Contrasting the results on heroin-related deaths to all other types of drug poisoning deaths provides 
evidence that the lower rates of heroin poisoning deaths in more impoverished areas is not just due to 
geospatial distribution of heroin markets. Misclassification of socioeconomic conditions may occur if 
conditions at the time of measurement differs from that at the time when the conditions contributed to the 
drug poisoning death. For example, since nearly 80% of people who use heroin reported using 
prescription opioids prior to heroin (138, 139) and the average time from first prescription opioid use to 
heroin use ranges from four to eight years (140-143), it is likely that the aspects of the socioeconomic 
conditions that affect prescription opioid use in one year may not affect heroin use and heroin-related 
deaths for another several years. As such, socioeconomic conditions with high year-to-year variability 
(e.g., unemployment rate, poverty rate) may be more prone to misclassification than those that remain 
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relatively stable over time (e.g., income inequality, the Rey index, the HDI). Therefore, the divergent 
findings for heroin-related deaths compared to all other types of deaths, particularly the associations in 
the opposite direction for unemployment rate and poverty rate, might potentially reflect misclassification of 
socioeconomic conditions, due in part to a combination of the higher year-to-year variability and the 
longer time lag between the exposure to and the effects of certain socioeconomic conditions on 
prescription opioid- versus heroin-related deaths. 
 
The effect of income inequality on health and mortality has been controversial and remains unclear (144-
146). In this study, counties with more unequal income distributions between 1999 and 2016 had higher 
rates of fatal drug poisonings. Research on the relation between income inequality and fatal drug 
poisonings is limited to three studies in the early 2000s from New York City. One study showed no 
association (147) and two studies (41, 47) found income inequality was associated with a small direct 
effect on fatal drug poisonings. Nandi et al (47) showed that levels of police activity and the quality of the 
built environment, measured as the cleanliness of neighborhood sidewalks and buildings in dilapidated 
conditions, mediated the within-neighborhood association between income inequality and fatal drug 
poisonings. This suggest that living in areas with more unequal income distributions may be a direct 
stressor to persons by increasing individual awareness to their perceived low position in the social 
hierarchy (144, 148). However, other U.S. studies support a small direct effect of income inequality on 
health, most often in the range of 20% to 30% increase in risk (144), potentially mediated by social capital 
(e.g., levels of community trust, extent of organizational membership) (149). In county-level analysis of 
U.S. data from 1999 to 2014, Zoorob and Salemi (150) showed that social capital was inversely 
associated with fatal drug poisonings, supporting the idea that social capital may protect communities 
against poisoning deaths. Therefore, more unequal income distributions may both directly increase 
community stress levels by bringing awareness to their relatively low social position on the economic 
hierarchy and indirectly by reducing the social capital necessary for communities to mitigate the 
consequences of this higher stress. This suggests that the association between more unequal income 
distributions and higher rates of fatal drug poisonings after adjusting for other socioeconomic conditions 
(e.g., education, median household income, poverty rate) might potentially reflect the unique effect of 
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relative deprivation on psychosocial stress and social capital that is not captured by common measures of 
absolute deprivation (e.g., poverty rate). 
 
This is the first study to use validated deprivation measures to investigate the geospatial distribution of 
fatal drug poisonings. Despite the widespread use of deprivation indices in epidemiologic research, there 
is no universal measure of ‘deprivation’ nor universal approach for developing a deprivation index. The 
Rey index was developed with the aim of identifying a measure appropriate for use across both urban 
and rural areas. Therefore, the index was constructed of four variables, each representing a fundamental 
dimension of socioeconomic level that has a homogenous meaning over the urban-rural continuum, 
including: median household income, the unemployed rate, the percent blue-collar workers in the labor 
force, and the percent of people greater than or equal to 18 years old with at least a high-school diploma 
(97). In comparison, the HDI index aimed to create a measure to emphasize that people and their 
capabilities for improvement should be the ultimate assessment of deprivation and well-being, not labor 
markets and spending power alone. Therefore, the HDI is a composite measure of ‘average achievement 
in key dimensions of human development: a long and healthy life, being knowledgeable and having a 
decent standard of living’ (105). Since median income and education status are components in both the 
HDI and the Rey index, the differences between the two indices are the health dimension of the HDI, 
measured by life expectancy at birth, and the labor market measures in the Rey index (i.e., percent of 
blue-collar workers in the labor force and the unemployment rate). Therefore, our finding that county HDI 
appeared to have a stronger association with drug poisoning rates than the Rey index, as well as the 
poverty and unemployment rate, suggest that the more common policy levers for improving economic 
conditions (e.g., corporate tax breaks) alone may be less successful than policies that prioritize the broad 
spectrum of the social determinants of health (e.g., education, access to healthcare, safety net spending). 
Numerous policies improve health through increasing income and education, including early life and 
education interventions (151-153), conditional cash transfers (154, 155), negative income taxes (156-
158), and expanded healthcare access (159-161). Future research should investigate the downstream 




There has been no prior study focused on the interaction between prescription opioid supply and 
socioeconomic conditions on rates of fatal drug poisonings. Previous studies considered separately the 
effect of each prescription opioid supply and socioeconomic conditions on fatal drug poisonings, finding 
that changes in prescription opioid supply are more important predictors of the geospatial distribution of 
fatal drug poisonings than socioeconomic conditions (76). However, in the presence of interaction 
between prescription opioid supply and socioeconomic conditions, any calculation of a common relative 
risk associated with prescription opioid supply in a population will depend on the location’s socioeconomic 
conditions. Although this study found that the association between prescription opioid supply and fatal 
drug poisoning rates varied by county income inequality and HDI, the results contradict the hypothesis 
that risk of prescription opioid supply on drug-related mortality rates are higher in counties with worse 
socioeconomic conditions than counties with better conditions. Instead, risk of higher prescription opioid 
supply on fatal drug poisoning rates were higher in counties with more equal income distributions and 
higher HDI than counties with less equal income distributions and lower HDI. This finding suggests that 
higher levels of prescription opioid supply may be more harmful in areas where the local population is 
more socioeconomically advantaged than in less socioeconomically advantaged areas. This may arise for 
several reasons. The diversion of prescription opioids from legal sources to the illicit marketplace may be 
greater in more socioeconomically advantaged counties than in less socioeconomically advantaged 
counties. Nonmedical use and diversion of prescription opioids are responsible for a substantial 
proportion of opioid-related deaths (162, 163). Therefore, if more advantaged counties have higher levels 
of diversion than less advantaged counties, the risk of fatal drug poisoning may be higher in more 
advantaged counties, even at similar levels of prescription opioid supply. Another possible explanation is 
that less advantaged counties experience higher rates of fatal drug poisoning than more advantaged 
counties independent of prescription opioid supply, and thus the effect of prescription opioid supply on 
rates of fatal drug poisoning in less advantaged counties is competing with multiple other causes of 
higher drug poisoning rates, whereas the effects of higher prescription opioid supply on fatal drug 





Substantial funds are expended annually on programs to prevent new onsets of opioid misuse, and 
treatment programs to reduce the community burden of drug addiction. These programs and policies aim 
to mitigate the problems already prevalent in the community without addressing the original economic and 
social conditions within communities that created the “demand” for prescription opioids and the attendant 
consequences. As such, there are important unanswered questions regarding population and contextual 
differences in the effect of prescription opioid supply on fatal drug poisonings. No study to date has 
examined the interaction or effect modification of the prescription opioid supply and fatal drug poisoning 
relationship by drug policy, medical access, or substance use treatment access. This study identified an 
interaction effect between HDI, income inequality, and prescription opioid supply on the risk of fatal drug 
poisonings, but much remains unknown about other factors that may have increased county susceptibility 
to the current drug poisoning crisis. For example, future studies should address whether county-level 
differences in the prevalence of physical disabilities or mental illness, relative to the accessibility of 
rehabilitative services or mental health care, may have precipitated rising rates of prescription opioid 
supply or subsequent increases in fatal drug poisonings. Other factors that may have increased 
susceptibility to prescription opioid supply and fatal drug poisonings include: state-level differences in the 
funding of comprehensive health care for low income persons; community accessibility to addiction 
treatment for low income persons; and community social capital to buffer people in distress from misuse 
and addiction. Understanding the community vulnerabilities that may have facilitated and interacted with 
prescription opioid supply to disproportionately harm some communities over others is necessary to 
identify specific populations and community characteristics that mark high-risk communities. By identifying 
the factors that shape location vulnerability and resiliency, programs and policies can be developed to 
strengthen and empower communities to address existing vulnerabilities and facilitate future community 
capabilities to mitigate future health risks. Moreover, the shifting profile of the epidemic, from prescription 
opioid-related deaths to heroin- and synthetic opioid-related deaths, has raised new questions about the 
changing role of drug supply and its potential interaction with community vulnerabilities. Future research 
with more complete opioid supply data, including local measures of heroin supply and illicitly 
manufactured fentanyl or presence of active drug markets (e.g., Uniform Crime Reporting data from the 
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Federal Bureau of Investigations), will be essential to understanding the changing supply- and demand-
side dynamics on drug poisonings. 
 
This study improves on previous work in this area and extends that work in four ways: (1) there have 
been no prior studies focused on the interaction between prescription opioid supply and socioeconomic 
conditions on rates of fatal drug poisonings; (2) the spatial and temporal dependence across counties and 
over time were included in the model, an approach previously shown to reduce bias and inefficiencies 
when spatial or temporal autocorrelation are present; (3) a directed acyclic graph (DAG) provides a 
transparent approach for identifying the minimum set of potential confounders for accurate estimates; and 
(4) since each socioeconomic measure captures a unique aspect of an area’s socioeconomic well-being 
and each type of fatal drug poisoning may be sensitive to the regional drug markets, the study 
investigated the sensitivity of results to five key markers of socioeconomic conditions (i.e., unemployment 
rate, poverty rate, income inequality, Rey index, and American Human Development Index) and four 
different types of fatal drug poisonings (drug poisonings from any drug, any opioid, prescription opioids 
only, or heroin). As such, results of this study add new insights, and new questions, to the growing 
knowledge base on both the geospatial distribution and the county-level determinants of fatal drug 
poisonings in the U.S. 
 
This study’s findings should be interpreted considering four limitations. First, analyses addressed 
ecological relationships, not the effect of socioeconomic conditions and prescription opioid intake of 
individual in the counties. Second, the associations found at one level of aggregation may not differ from 
association at other geographic units. Although counties are likely more meaningful analytic units than 
boundaries at lower levels of aggregation (e.g., ZIP codes, census blocks), which are often ill defined and 
lack theoretical justification or meaning beyond administrative boundaries (e.g., efficient delivery of mail, 
census enumeration), results at smaller geographic units may have differed. Although the results related 
to socioeconomic conditions and drug poisoning rates are consistent with the findings from previous 
neighborhood-level studies (39, 41, 47), within-county heterogeneity of prescription opioid supply, fatal 
drug poisonings, and confounding factors (residual cross-level confounding or confounding by covariates 
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not considered) may exist. Future studies are needed to explore whether intra-county small area 
neighborhood-level heterogeneity of socioeconomic factors affect the association between prescription 
opioid supply and rates of fatal drug poisoning within counties. Third, administrative mortality data may 
misclassify cause of death and not reliably identify the drugs involved in a fatal opioid poisoning. Although 
state and federal guidelines aim to apply uniform reporting practices about causes of death, previous 
studies have found substantial inconsistencies in the coding of poisoning deaths within- and between-
states (164-166) and over time (167), particularly related to undetermined poisoning deaths (T50.9) (164-
166). To address the sensitivity of estimates to potential misclassification of opioid deaths as 
undetermined poisoning deaths, four different definitions of fatal drug poisoning were examined, including 
the broadest definition—drug-related mortality—that included both intentional and unintentional deaths 
and those where an opioid was not specified on the death certificate. However, the limitations of 
misclassification of data on drug poisoning deaths attributed to heroin are acknowledged given the small 
number of counties with reportable deaths, which could be particularly vulnerable to undercount. Future 
studies could consider investigating the sensitivity of effect estimates to different measures of opioid-
related harm (e.g., non-fatal poisonings, neonatal opioid withdrawal syndrome). Fourth, prescription 
opioid supply was operationalized using a relatively crude measure: opioid prescribing rate per 100 
persons. Although other measures of high-risk prescribing exist (e.g., proportion of population receiving 
prescriptions for opioids from four or more prescribers in a year, proportion of patients with high daily 
morphine milligram equivalents [MME]), opioid prescribing rate per 100 persons has the advantage of 
being the most frequently used measure of prescription opioid supply among previous studies 
investigating the effect of prescription opioid supply and fatal drug poisonings, permitting ready 
comparison to previous results. The fifth limitation is a conceptual one. The study design, while allowing 
for tests of hypotheses suggested by supply- and demand-side effects, did not allow for their relative 
assessment. Either or both processes may be acting, or even taking place simultaneously, to increase 
drug poisonings. Despite recognition of the endogeneity of drug use and the potential value of 
instrumental variable estimation to overcome endogeneity, valid instruments that meets the necessary 
criteria (i.e., it causes drug poisonings indirectly and solely through its effect on drug consumption) are 
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difficult to find. Nevertheless, future studies should seek out candidate instruments to overcome potential 
endogeneity of the supply-demand relationships on drug poisonings. 
 
The rise in opioid analgesic prescribing rates over the past two decades garners much of the public and 
scientific discussion about the root causes of the drug poisoning crisis. However, the substantial 
population-level geographic variation in drug poisoning rates suggest a more complex causal 
architecture. This is the first study to explore the heterogeneous prevalence of the socioeconomic factors 
that interact with prescription opioid supply to create county-level risks of fatal drug poisonings. These 
results suggest that income inequality and overall county well-being (as measured by the HDI) are two 
key factors by which the geographic distribution of fatal drug poisonings may be understood. The results 
provide insight into the way factors related to community vulnerability and resiliency may shape the 
geospatial distribution of fatal drug poisonings in the U.S. By identifying the factors that shape location 
vulnerability and resiliency, programs and policies can be developed to strengthen and empower 
communities to address existing vulnerabilities and facilitate future community capabilities to mitigate 
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4.7. Figures and Tables. 
Table 0.1. Characteristics of 3,109 counties in 49 US Statesa and Washington, D.C., 2006-2016 
Characteristics 
County  State 
Median (IQR)  Median  (IQR) 
Population ≥ 12 year of age 20,281 (8,836 - 
52,197) 
 4,340,759 (1,802,854 - 
6,825,358) 
Population density (per mile2) 44.7 (17.2 - 112.4)  102 (237.7 - 
10,951.9) 
Age (%)      
    0-19 years 26.6 (24.4 - 29.0)  26.8 (25.6 - 28.3) 
    20-44 years 31.9 (30.0 - 33.8)  32.6 (31.6 - 33.9) 
    45-64 years 25.4 (23.6 - 26.9)  25.7 (24.9 - 26.6) 
    ≥ 65 years 15.4 (13.1 - 18.1)  14.5 (13.3 - 15.8) 
Sex (%)      
    Male 49.3 (48.6 - 50.0)  49.1 (48.8 - 49.7) 
    Female 50.8 (50.0 - 51.4)  50.1 (50.3 - 51.3) 
Race/ethnicity (%)      
    Non-Hispanic white 82.1 (63.6 - 92.3)  72.2 (58.9 - 80.9) 
    Non-Hispanic black 1.8 (0.3 - 10.1)  7.2 (2.6 - 15.4) 
    Hispanic 2.3 (1.0 - 6.8)  7.4 (3.5 - 11.9) 
    Other race/ethnicity 3.7 (1.6 - 9.6)  7.5 (4.5 - 11.0) 
Economic and social conditions      
    Unemployed (%) 6.7 (4.5, 9.5)  6.2 (4.7 - 8.2) 
    Families living below the poverty line (%) 11.7 (8.4, 16.0)  9.8 (8.1 - 12.1) 
    Income inequality (Gini coefficient) 0.44 (0.41, 0.46)  0.46 (0.44, 0.47) 
    Rey index 0.05 (-0.23, 0.34)  -0.15 (-0.27, 0.02) 
    American human development index 4.23 (3.63, 4.76)  5.10 (4.68, 5.67) 
PDMP = Prescription drug monitoring program; IQR = interquartile range 
a Alaska was excluded from the analysis due to changes in the boundaries of multiple counties over the analytical period  
b Per-capita prescription opioid rates were compiled by IQVIA Xponent, provided by the Centers for Disease Control (CDC), 
calculated as the total number of opioid prescriptions dispensed in a county in a given year and county (numerator) over the annual 
resident population estimates derived from the Population Estimates Program, U.S. Census Bureau. 





Figure 0.1. Directed acyclic graph for the effect of unemployment rate on fatal drug poisonings 
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Figure 0.2. County-level rates of fatal drug poisonings attributed to all drugs (a), any opioid (b), prescription opioids only 











Continue: Figure 4.2. Continued: County-level rates of fatal drug poisonings attributed to all drugs (a), any opioid (b), 












Figure 0.3. County-level associations between economic and social conditions and rates of fatal drug poisonings related to 
all drugsa, all opioidsb, prescription opioids onlyc, and illicit opioidsd in 3,109 counties in 49 US Statese and Washington, 
D.C., 2006-2016 
 
Alaska was excluded from the analysis due to changes in the boundaries of multiple counties over the analytical period. Definitions of abbreviations: RR = rate ratio, computed as the 
exp(!) of the median posterior estimate; CI = credibility interval; SD = standard deviation; HDI = human development index. County-level models included state fixed effect, unit-
specific trends, conditional-autoregressive (CAR) spatial random effect, and adjusted for population density (1,000s of people per square mile); age distribution (% 0-19 years, % 20-44 
years, % 45-64 years); racial/ethnic distribution (% non-Hispanic white, % non-Hispanic black, % Hispanic); gender distribution (% male); education (% of people ages 24 years or 
older with a high school degree or less, % some college), median household income, poverty rate, and urbanicity.a Drug poisoning deaths were identified using International 
Classification of Diseases, 10th Revision (ICD-10) underlying cause of death (UCOD) codes for unintentional poisoning (X40-X44), intentional poisonings (X60-X64), homicidal 
poisoning (X85), poisonings with unclear intent (Y10-Y14). b Opioid poisoning deaths were drug poisoning deathsa identified using ICD-10 MCODs for opium (T40.0), heroin (T40.1), 
natural or semi-synthetic opioid (T40.2), methadone (T40.3), synthetic opioid (T40.4), and unspecified narcotic (T40.6). c Prescription opioid-related deaths were drug poisoning 
deathsa identified using ICD-10 MCODs for natural and semisynthetic opioids (T40.2) or methadone (T40.3) and not heroin (T40.1). d Heroin-related deaths were drug poisoning 
deathsa identified using ICD-10 MCODs for heroin (T40.1). e Income inequality measured as the Gini coefficient. f Rey index is defined as the first component of a principal component 
analysis of the median household income, % of high school graduates in the population aged 15 years and older, % blue-collar workers, and unemployment rate. g The human 
development index is a composite score of overall well-being in a county based on health (measured as life expectancy at birth), education (school enrollment for the population ages 3 
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Figure 0.4. County-level association between prescription opioid supply and fatal drug poisonings related to any drug, any 
opioid, prescription opioids only, and heroin, across county level unemployment rate, 2006-2016 
 
 
Unemployment rate levels at the 25th (p25), 50th (p50), and 75th percentile (p75) of the distribution of unemployment across the 34,199 county-year 





Figure 0.5. County-level association between prescription opioid supply and fatal drug poisonings related to any drug, any 
opioid, prescription opioids only, and heroin, across county level poverty rate, 2006-2016 
 
Poverty rate levels at the 25th (p25), 50th (p50), and 75th percentile (p75) of the distribution of poverty across the 34,199 county-year observations.  





Figure 0.6. County-level association between prescription opioid supply and fatal drug poisonings related to any drug, any 
opioid, prescription opioids only, and heroin, across county level income inequality, 2006-2016 
 
 
Income inequality measured by the Gini Coefficient. Levels of income inequality at the 25th (p25), 50th (p50), and 75th percentile (p75) of the 
distribution across the 34,199 county-year observations. Horizontal red line indicates a rate ratio (RR) of 1.00 (no association). 95% CI indicates 




Figure 0.7. County-level association between prescription opioid supply and fatal drug poisonings related to any drug, any 
opioid, prescription opioids only, and heroin, across county level score on the Rey Index, 2006-2016 
 
 
Rey Index levels at the 25th (p25), 50th (p50), and 75th percentile (p75) of the distribution of index values across the 34,199 county-year 





Figure 0.8. County-level association between prescription opioid supply and fatal drug poisonings related to any drug, any 
opioid, prescription opioids only, and heroin, across county level score on the Human Development Index, 2006-2016 
 
 
Human Development Index levels at the 25th (p25), 50th (p50), and 75th percentile (p75) of the distribution of index values across the 34,199 






Drug poisoning deaths are one of the most pressing public health issues in the U.S., and their causes are 
likely a mix of both supply- and demand-side factors. While many trace the root of the drug poisoning 
crisis to the unprecedented, 4-fold, increase in opioid prescribing between 1999 and 2012, it is difficult to 
understand the drug poisoning crisis fully from changes in the prescription opioid supply alone, without 
considering the factors that drive demand for opioid drugs, in terms of both the people who use opioid 
analgesics for pain relief and the people who use opioids nonmedically for other reasons. The goal of this 
dissertation was to test the independent and joint effects of supply- and demand-side factors, 
operationalized as prescription opioid supply and socioeconomic conditions, on fatal drug poisoning in the 
U.S. Addressing these aims was motivated by 1) the lack of a previous systematic literature review 
focused on the effect of supply- and demand-side factors of the current drug poisoning crisis in the U.S.; 
2) inconsistencies in the literature on the relationship between prescription opioid supply and fatal drug 
poisonings and lack of understanding about the source of these inconsistencies (e.g., methodological 
differences between studies, bias from methodological deficiencies); and 3) the absence of research 
testing the joint effect of supply and demand on fatal drug poisonings. This dissertation aimed to address 
these gaps in the literature in three parts. First, a comprehensive systematic review of the literature was 
conducted to critically evaluate the evidence on the ecological relationship of prescription opioid supply 
and socioeconomic conditions on rates of fatal drug poisonings. Although this review provides evidence 
for the independent effects of each prescription opioid supply and socioeconomic conditions on fatal drug 
poisonings, the gap in the literature on the joint effects of prescription opioid supply and socioeconomic 
conditions was clear, with no study examining the interaction between supply- and demand-side factors 
on rates of fatal drug poisonings. Second, I conducted an empirical test of the county-level effect of 
prescription opioid supply on fatal drug poisonings, and investigated the sensitivity of the findings to the 
level of geographic aggregation of the analysis, source of prescription opioid supply data, and level of 
adjustment for confounding and spatial autocorrelation in the data. Third, I estimated both the 
independent effect of socioeconomic conditions on fatal drug poisonings and the joint effect of 
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prescription opioid supply and socioeconomic conditions on fatal drug poisonings at the county-level. The 
primary results of these studies are summarized and implications discussed below.  
 
5.2. Summary of Results 
For the systematic literature review in Chapter 2, 17 met the inclusion criteria: 5 studies investigated the 
effect of prescription opioid supply only, 9 studies investigated the effect of economic conditions only, and 
2 studies investigated the independent effect of each prescription opioid supply and economic conditions, 
but not their joint effect, on drug-related mortality. Three main findings deserve discussion. First, there 
was ample evidence of an ecological association between worse socioeconomic conditions and higher 
levels of fatal drug poisonings. Despite consistent findings, the key construct, socioeconomic conditions, 
was not well defined, and studies used a variety of different indicator variables and indices (composite 
measures). The most common single indicators were unemployment rate (1-3), median household 
income (3-5), and poverty rate (1, 3, 5). Three different indices included: the index of economic conditions 
(3), poverty index (6), and economic distress index (7, 8). Although consistent findings across varying 
measures may be useful for demonstrating robustness, the heterogeneity of measures used across the 
studies prevented meta-analysis of results. Second, greater prescription opioid supply was associated 
with higher rates of fatal drug poisonings in most of the studies (3, 8-11), but 2 studies reported 
contradictory findings: 1 study (12) showing no effect of prescription opioid supply on drug-related 
mortality and 1 study (13) showing a negative effect of prescription opioid supply on drug-related mortality 
(e.g., locations with higher levels of prescription opioid supply were associated with fewer drug-related 
deaths). The divergent findings in these two studies could be partially explained by methodological 
differences or methodological deficiencies. For example, whereas the 4 nationally representative studies 
uniformly found that area prescription opioid supply was positively associated with fatal drug poisonings 
(3, 8-10), the 2 studies reporting contradictory findings focused on single U.S. states (12, 13). Because 
effect measures are as much an assessment of the prevalence of component causes (i.e., those causes 
that interact with the exposure of interest to cause the outcome) as they are a measure of a causal effect 
of an exposure (14), the average effect of prescription opioid supply on fatal drug poisonings may be 
positive in nationally representative data, despite the effect of prescription opioid supply on fatal drug 
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poisonings being null or negative in particular states. However, the two divergent results came from 
models with limited or no confounder adjustment, suggesting that methodological deficiencies may 
explain these results. Because it cannot be determined whether methodological differences or 
deficiencies explain the observed divergent findings in this literature, future studies are needed to 
investigate the sensitivity of results to the different methodological differences and deficiencies across 
studies. Third, although two studies estimated the independent effect of prescription opioid supply and 
socioeconomic conditions in a model adjusting for the other exposure, there were no studies that 
examined the joint effect of prescription opioid supply and socioeconomic conditions on fatal drug 
poisonings. Thus, the gap in the literature on the interaction between prescription opioid supply and 
socioeconomic conditions on fatal drug poisonings is clear. 
 
The analysis in Chapter 3 aimed to estimate the county-level effect of prescription opioid supply on fatal 
drug poisonings. To overcome some limitations in previous studies and investigate the potential source of 
the previously documented divergent findings, this study included several sensitivity tests, investigating 
the sensitivity of results to: 1) type of fatal drug poisoning (drug poisoning deaths from any drug, any 
opioid, prescription opioid only, or heroin); 2) geographic unit used to aggregate data (county- versus 
state-level analysis); 3) measures of prescription opioid supply (rate of opioid prescriptions per 100 
persons versus morphine milligram equivalents per capita); and 4) inadequate adjustment for 
confounding or spatial autocorrelation. A hierarchical Bayesian Poisson conditional autoregressive model 
was used to evaluate the county-level association between prescription opioid supply and fatal drug 
poisonings in 3,109 U.S. counties from 2006-2016. This Bayesian spatiotemporal modeling approach 
borrows strengths across counties and years to produced smoothed yearly county level estimates, 
allowing examination of spatial and temporal variation in rare outcomes such as counts of fatal drug 
poisonings (15, 16). Also, a Directed Acyclic Graph (DAG) was used to identify adjustment variables for 
this analysis. In this analysis, when the models adjusted for the minimum set of potential confounders 
identified by the DAG, greater area-level supply of prescription opioids were consistently associated with 
higher rates of fatal drug poisonings. To investigate the potential source of this heterogeneity in the 
literature, a transparent and rigorous analysis strategy was applied, holding constant the adjustment for 
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two potential sources of bias (i.e., inadequate adjustment for potential confounding and/or spatial 
autocorrelation) and varying the definition of the outcome, the level of aggregation, and the type of 
measure of the main predictor. Although results were similar across these methodological sources of 
variation, removing adjustment variables from the model caused the estimates to attenuate and reverse in 
direction, such that higher levels of prescription opioid supply were associated with fewer fatal drug 
poisonings, suggesting that previous heterogeneity in study findings may arise from inadequate 
adjustment for potential confounding.  
 
Taken together, these results indicate that greater prescription opioid supply increases rates of fatal drug 
poisonings attributed to all types of drugs, all opioids, prescription opioids only, and heroin. The 
underlying mechanism by which prescription opioid supply may increase fatal drug poisonings is likely to 
vary by drug poisoning type. The effect of prescription opioid supply on prescription opioid-related deaths 
may be a combination of the direct effect of medical use of opioid pain relievers on drug poisonings and 
the indirect effect the oversupply of prescription opioids has on driving nonmedical use and attendant 
drug poisonings. In contrast, the effect of prescription opioid supply on rates of heroin-related deaths may 
operate by increasing the prevalence of opioid dependence or addiction in a population, normalizing 
opioid use, and increasing demand for heroin. Because the estimated effect of a greater prescription 
opioid supply is in the same direction for fatal drug poisonings from prescription opioids only and heroin, it 
follows that higher levels of prescription opioid supply will be similarly associated with fatal drug 
poisonings from all drugs and all opioids.  
 
Finally, Chapter 4 used annual county-level data from 3,109 U.S. counties from 49 states (2006-2016) to 
test the independent effect of county deprivation level on fatal drug poisoning rates and its joint effect with 
prescription opioid supply. Five key variables were used to assess the county deprivation level, including: 
three indicator variables (unemployment, poverty rate, income inequality) and two economic and social 
indices (Rey index, American Human Development Index [HDI]). Fatal drug poisonings were categorized 
into four types based on whether the death involved any drug (drug-related death), any opioid (opioid-
related death), any prescription opioid but not heroin (prescription opioid-related death), and heroin 
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(heroin-related death). Multiplicative interaction was tested using a two-way cross-product term between 
prescription opioid supply and each of the five key explanatory variables (each of the explanatory 
variables examined in a separate model). 
 
This analysis shows that higher rates of fatal drug poisonings are concentrated in counties with greater 
socioeconomic deprivation and less equal income distributions. However, there was substantial variation 
in the importance of different socioeconomic factors on drug poisoning rates, as indicated by the 
magnitude of their associations. Although the results related to unemployment and poverty rate, and their 
respective magnitudes of association, are in line with previous findings (1-3, 5, 6), their relationship with 
fatal drug poisonings was weak—the exception being an estimated protective effect of poverty rate on 
heroin-related deaths. Conversely, HDI and income inequality were substantial predictors of drug 
poisoning rates. In addition to HDI and income inequality each being each independently associated with 
fatal drug poisoning rates, there was evidence of super-multiplicative interaction between both HDI and 
income inequality and county-level prescription opioid supply on fatal drug poisoning rates. Specifically, 
the effect of higher prescription opioid supply on rates of fatal drug poisonings was greater in counties 
with higher HDI and more equal income distributions than counties with lower HDI and less equal income 
distributions. The finding that fatal drug poisoning rates were higher in counties with more unequal 
income distributions is in accordance with what has been previously observed in studies of New York City 
in the early 2000s (17, 18). Although this is the first study to investigate the effects of HDI on fatal drug 
poisonings in national data, the relationship between higher HDI and lower mortality rates is well 
documented in the literature (19-23). Finally, the relationships between county socioeconomic conditions 
and fatal drug poisonings differed for heroin-related deaths compared to all other types of drug poisoning 
deaths. For example, higher poverty was associated with lower rates heroin-related deaths but higher 
rates of all other types of drug poisoning deaths. This difference in effect estimates for heroin-related 
deaths compared to all other types of fatal drug poisoning is in accordance with what has been previously 
observed for the joint effect of ZIP code economic features and urbanicity on fatal drug poisonings from 
heroin versus prescription opioids (24), and may reflect geospatial differences in the availability of 




5.3. Limitations and Strengths 
The analysis presented in this dissertation has several limitations. The systematic literature review 
conducted in Chapter 2 has limitations in terms of both the study results that are summarized and the 
review itself. Despite the substantial burden of drug poisoning mortality in the U.S., at the time of this 
review, only 17 studies were identified that met inclusion criteria for this review, with 6 studies 
investigating prescription opioid supply only, 9 studies investigating socioeconomic conditions only, and 
two studies investigating both. The limited number of studies and the methodological differences among 
studies in terms of their analytical sample, years of data, exposure and outcome measures, and 
identification strategy precluded a formal meta-analysis of results.  
 
The empirical analyses conducted for Chapter 3 and 4 had their own, similar, limitations. The 
administrative mortality data used for this analysis have been found to have substantial inconsistencies in 
the coding of poisoning deaths across states (25-27) and over time (28), particularly related to 
undetermined poisoning deaths (T50.9) (25-27). However, our findings were robust to four different 
definitions of fatal drug poisoning, including the broadest definition—drug-related mortality—that included 
deaths where an opioid was not specified on the death certificate. Few counties recorded a heroin-related 
death from 2006 to 2010 and only 25% of counties had a rate of 2.0 per 100,000 people or more in 2016. 
Heroin-related deaths were concentrated in a small number of counties that tended to be more urban and 
more populous than counties with no heroin-related deaths. Although the Bayesian hierarchical 
framework applied in Chapters 3 and 4 allow the borrowing of information across space-time units, which 
is an effective method for addressing the data sparsity for heroin-related deaths, the parameters will be 
less precise from the models of heroin-related deaths compared to the other, more common, types of 
fatal drug poisonings. Future studies should consider the use of weakly informative priors as a way to 
potentially reduce estimation error (29) or the results from this study could serve as informative priors in 
future analyses (30, 31). It is possible that counties do not represent meaningful community boundaries. 
Although counties provide more meaningful community boundaries than the state, within-county 
heterogeneity of prescription opioid supply, fatal drug poisonings, and confounding factors may exist. 
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While future studies may consider replicating this analysis in more disaggregated data, boundaries at 
lower levels of aggregation (e.g., ZIP codes, census blocks) are often ill defined and lack theoretical 
justification or meaning beyond administrative boundaries (e.g., efficient delivery of mail, census 
enumeration). Fourth, prescription opioid supply was operationalized using a relatively crude measure: 
opioid prescribing rate per 100 persons. Although other measures of high-risk prescribing exist (e.g., 
proportion of population receiving prescriptions for opioids from four or more prescribers in a year, 
proportion of patients with high daily morphine milligram equivalents [MME]), opioid prescribing rate per 
100 persons is the most frequently used measure of prescription opioid supply among previous studies 
investigating the effect of prescription opioid supply and fatal drug poisonings. Finally, specific to Chapter 
4, since no single social or economic indicator or composite measure can completely capture the totality 
of a location’s socioeconomic conditions, three county-level indicators (i.e., poverty rate, unemployment 
rate, and income inequality) and two county-level measures of socioeconomic deprivation (i.e., the Rey 
index and HDI) were used. Although the ability for composite measures to simultaneously model the 
effect of multiple socioeconomic indicators provides an advantage over any single indicator variable (e.g., 
unemployment rate), their results can be difficult to interpret and convey to non-scientists and policy 
makers.  
 
Despite these limitations, this study had multiple important strengths. Chapter 2 provides a systematic 
review of the literature on a topic of great importance that has captured the attention of public health 
researchers and policymakers, but which has not been systematically reviewed. Chapter 3 is the first 
study to systematically investigate the source of previous divergent results on the relationship between 
prescription opioid supply and drug poisonings. In doing so, this study identified the consistency of this 
effect estimate to several common sources of methodological differences across studies (i.e., definition of 
fatal drug poisoning, level of aggregation, type and source of data on prescription opioid supply) and 
found that inadequate adjustment for potential confounding may explain the previous heterogeneity in 
study findings on the topic. Chapter 4 is the first analysis to test the joint effects of prescription opioid 
supply and socioeconomic conditions on rates of fatal drug poisonings. Moreover, this study improved 
upon previous analyses examining the effect of socioeconomic conditions on fatal drug poisonings by 
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applying a more appropriate statistical approach to model spatial dependencies and additionally 
considering the sensitivity of results to multiple key markers of socioeconomic conditions. Chapters 3 and 
4 both contribute important findings regarding supply- and demand-side factors of the current drug 
poisoning crisis. While Chapter 3 provided additional evidence that prescription opioid supply is a key 
factor underlying the current drug poisoning crisis, these findings do not suggest that supply reductions 
will lower the rate of fatal drug poisonings because drug use and its consequences lie at the intersection 
of supply- and demand-side forces. Findings from Chapter 4 demonstrate that the effects of prescription 
opioid supply are closely linked to a location’s socioeconomic conditions. By studying the interaction of 
supply- and demand-side factors, new information is learned about the characteristics of high-risk 
locations that can be used to identify vulnerable communities and inform efficient interventions that can 
mitigate future crises. Studies on the interaction of supply- and demand-side factors may also enable us 
to predict the local effects of state and federal policy. For example, a supply-side intervention—such as 
prescription drug monitoring programs and abuse deterrent drug formulations—causes the supply of 
prescription opioids on the illicit market to be reduced, while the demand for these drugs remains 
unchanged. This example illustrates the limits of simplistic interventions that focus on a single dimension 
of this multidimensional crisis. Because this study is the first to investigate the interaction of supply- and 
demand-side factors underlying this current crisis, this dissertation contributes to a greater understanding 
about the determinants of county-level drug poisoning rates and their geospatial distribution across the 
U.S. However, the drug poisoning crisis is complex, and it cannot be understood without an explanation 
of the way that the various parts interact. As such, more work is needed to integrate the information 
learned about these ecological factors with the societal, behavioral, and biological processes that underly 








5.4. Implications and Future Directions 
The findings from this dissertation help to build the evidence base for intervention and for future research 
into the ecological factors that shape the geographic distribution of drug use and its consequences.  
 
With regards interventions, the review conducted in Chapter 2 found that prescription opioid supply and 
socioeconomic conditions are each associated with increased risks of fatal drug poisonings. The fact that 
no study was identified that tested for an interaction between prescription opioid supply and 
socioeconomic conditions suggest a substantial gap in the literature. Chapter 3 provides further evidence 
of the role of prescription opioid supply in the geospatial distribution of drug poisoning deaths. Despite the 
results here indicating an association between area-level prescription opioid supply and fatal drug 
poisonings, they do not suggest that supply reductions will lower the rate of fatal drug poisonings. Recent 
years have seen a marked increase in the number of papers documenting the unintended consequences 
of supply-side interventions as on heroin-related poisonings (32-35). A supply-side intervention—such as 
prescription drug monitoring programs, abuse deterrent drug formulations—causes the market supply to 
decline while leaving drug demand unaffected. This shift illustrates the idea that to compensate for the 
unmet demand for prescription opioids created by a supply-side intervention, some people who use 
prescription opioids, whether for medical or nonmedical purposes, finding their preferred drug too costly 
or difficult to obtain may transition to heroin. This suggests that investing in supply-side interventions, 
without an adequate understanding of the mix of factors that closely link drug demand to supply, may 
offset the intended reductions in prescription opioid-related deaths with unintended increases in heroin-
related deaths. As such, an improve understanding of supply-demand dynamics is needed.  
 
Chapter 4 provides evidence that the effects of prescription opioid supply on fatal drug poisoning deaths 
are closely linked to county-level economic and social conditions. Although previous studies have 
examined the independent contribution of local socioeconomic conditions and of changes in the 
prescription opioid supply in drug-related mortality (3, 8), this dissertation provides the first evidence of an 
interaction between local supply- and demand-side factors on drug poisoning rates. As such, a singular 
focus on either supply- or demand-side factors, without consideration of the interaction between supply 
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and demand, is problematic for policy and research. For research, it is well known that the effect of a 
cause will vary among populations as a function of each population’s underlying distribution of component 
causes. This suggests that, if true, the efficacy of supply reduction may be larger in locations with less 
socioeconomic deprivation, indicated by higher HDI and a more equal income distribution, whereas it may 
be more important to address the social and structural factors that interact with supply to drive drug 
demand.  
 
This dissertation also has several implications for future research studies. The findings from the 
systematic literature review conducted in Chapter 2 can be used to inform researchers about the 
characteristics of a location’s socioeconomic conditions and prescription opioid supply that are associated 
with fatal drug poisonings. In order to inform policymakers about the opportunities for intervention, an 
interdisciplinary group of drug user unions, epidemiologist, health geographers, and psychiatrist with 
substance use expertise could make use of the findings from this review to set priorities for a research 
agenda that would produce important, accurate, and useful science on the underlying dynamics of the 
drug poisoning crisis. Future studies that investigate the ecological effects of prescription opioid supply 
and socioeconomic conditions on fatal drug poisonings could agree to use a more standardized set of 
methods to increase the comparability across studies. They could also make an increased effort to 
identify potential sources of fixed and time-varying confounding and seek opportunities to exploit 
exogenous variation in key variables to overcome confounding using a quasi-experimental framework 
(e.g., instrument variable, regression discontinuity design, difference-in-differences). Chapter 3 
contributes to a more complete understanding of confounding and its contribution to the divergent results 
identified by the systematic review on the prescription opioid supply—fatal drug poisonings relationship. 
Future research studies could improve upon my analysis by evaluating alternative models than the one 
purposed in the DAG or incorporating several competing models in the estimation process using 
Bayesian Model Averaging (36, 37). Chapter 4 identified evidence of interaction between economic and 
social conditions and prescription opioid supply, contributing to a more complete understanding of the role 
that community factors in general and socioeconomic factors in particular play in shaping the geographic 
distribution of fatal drug poisonings. Future research studies could improve upon this analysis by 
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exploring other potential sources of community vulnerability and resilience that may interact with supply-
side factors to cause drug-related morbidity and mortality. For example, future studies should address 
whether county-level differences in the prevalence of physical disabilities or mental illness, relative to the 
accessibility of rehabilitative services or mental health care, may have precipitated rising rates of 
prescription opioid supply or subsequent increases in fatal drug poisonings. Other factors that may have 
increased susceptibility to prescription opioid supply and fatal drug poisonings include: state-level 
differences in the funding of comprehensive health care for low income persons; community accessibility 
to addiction treatment for low income persons; and community social capital to buffer people in distress 
from misuse and addiction. Understanding the community vulnerabilities that may have facilitated and 
interacted with prescription opioid supply to disproportionately harm some communities over other 
communities is necessary for identifying specific populations and community characteristics that mark 
high-risk communities. By identifying the factors that shape location vulnerability and resiliency, programs 
and policies can be developed to strengthen and empower communities to address existing vulnerabilities 
and facilitate future community capabilities to mitigate future health risks. 
 
The U.S. drug poisoning crisis is among the greatest threats to public health in the U.S. The causes of the 
crisis are complex, multifaceted, and not yet completely understood. This dissertation increased our 
understanding of the independent and joint effects of supply- and demand-side factors in shaping the 
geospatial distribution of drug poisoning rates in the U.S. The systematic literature review in Chapter 2 
suggests the importance of prescription opioid supply and socioeconomic conditions in fatal drug 
poisonings. The empirical analyses in Chapters 3 and 4 suggest that current focus on isolating 
independent and actionable causes of the drug poisoning crisis is insufficient and future research should 
focus on understanding the interplay of factors that work together to drive drug poisoning rates. By 
understanding the interactions that underly drug poisoning rates, interventions could be tailored to the 
most vulnerable populations and mitigate any unintended consequences. Given the longstanding public 
health burden of the drug poisoning crisis, efforts to understand and address this crisis remain 
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Systematically review the literature related to the geographic distribution of drug poisoning death, with
particular attention given to the range of statistical models commonly applied to investigated the geographic
patterning of drug poisoning death rates.
 
Searches
The systematic review will be conducted by searching 5 online databases (EconLit, EMBASE, MEDLINE and
MEDLINE In-process and Other Non-Indexed Citations, PsycINFO, and Web of Science Core Collection)
and Google Scholar for titles and abstracts of articles, published in English, that examined an association
between contextual factors and opioid-related morbidity and mortality.
EMBASE example
1. 'mortality'/exp OR 'death'/exp OR 'sudden death'/exp or 'decedent' OR 'death certificate' OR 'death' OR
'fatal'
2. drug overdose'/exp OR ('drug related' OR drug OR opioid OR heroin) NEXT/5 (mortality OR death OR
overdose OR poison*)
3. 'street drug'/exp OR 'drug'/exp OR 'substance use'/exp OR 'drug dependence'/exp OR addiction/exp OR
'opiate agonist'/exp OR 'analgesic agent'/exp OR 'prescription drug'/exp OR 'prescription drug misuse'/exp
OR 'prescription drug diversion'/exp OR 'drug abuse'/exp OR 'cocaine'/exp OR 'methamphetamine'/exp OR
'amphetamine'/exp
4. 'illicit drug' OR 'prescription opi*' OR 'crack cocaine' OR 'heroin' OR 'oxycontin'
5. #3 OR #4
6. 'spatial analysis/exp OR 'spatial autocorrelation analysis'/exp OR 'spatial regression'/exp OR
'spatiotemporal analysis'/exp OR 'patio temporal dynamics'/exp OR spatiotemporal pattern'/exp OR
'geospatial analysis'/exp OR 'geographic information system'/exp OR 'small-area analysis'/exp
7. 'contextual effect' OR 'spatial epidemiology' OR 'spatiotemporal analysis' OR 'geographic mapping' OR
'census tract' OR 'geospatial' OR 'hot spot' OR 'spatial autocorrelation' OR 'geocod*' OR ArcMap OR
'Bayesian hierarchical' OR 'empirical Bayes prediction'
8. #6 OR #7 
9. #1 AND #5 AND #9
10. #2 AND #8
11. #9 OR #10
12. #11 AND [humans]/lim AND [english]/lim 
 
Types of study to be included
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I will include observational studies that provide quantitative evidence of one or more contextual determinants
of drug-related mortality. This will include any epidemiological or observational study, including: longitudinal
and retrospective studies, cohort, case-control, or cross-sectional studies. I will exclude commentaries or
opinion papers without results on the effect of the exposure on outcome of interest, or studies in which
contextual factors are treated as control variables used for confounding adjustment, instead of treated as a
primary or secondary variable of interest.
 
Condition or domain being studied
Drug poisonings, defined as accidental poisoning deaths, intentional self-poisonings, poisonings by other,
and undetermined intent with one or more drugs involved in the death.
 
Participants/population
Inclusion: Population-based sample of persons aged 12 years or older. 




I will include observational studies that provide quantitative evidence of one or more contextual determinants
of drug-related mortality. Contextual determinants will be defined as factors that operate “above” the







Population-based samples in any county, published in English
 
Main outcome(s)
Rate of drug-related mortality, measured using either fatality records or hospital records. Drug poisonings are
defined in the underlying cause of death files with ICD-10 codes: X40-X44 (accidental poisoning deaths),





Data extraction (selection and coding)
All the resulting study titles and abstracts will be exported to DistillerSR, a web interface developed to
systematize the review process. Duplicates will be removed using DistillerSR. After removing the duplicates,
all titles and abstracts will be screened for eligibility, and those considered relevant will advance to the full-
text review. I will include observational studies published in English if they estimated the association between
a contextual factor and opioid-related morbidity and mortality in a single U.S. state or in a set of states. No
restrictions will be placed on sample size or population age. 
Articles determined to meet the inclusion criteria will be summarized using a standardized article assessment
form that captures data on study design; years and source of study population, including inclusion and
exclusion criteria; sample size; missing data; outcome data source; exposure data source; analytic strategy;
and results, including point estimates and confidence intervals (CIs) or P values. 
 
Risk of bias (quality) assessment
Included papers will be assessed for risk of bias using a modified version of the Cochrane Risk of Bias In
Non-randomized Studies-on Interventions (ROBINS-I) assessment tool. The ROBINS-I assesses risk of bias
within 8 specific bias domains (confounding, selection of participants, classification, deviation from intended
interventions, missing data, measures of outcomes, selection of reported results, and overall bias), grading
each domain as low, moderate, serious, or critical. The ROBINS-I, developed by Cochrane to assess
intervention studies, will be modified to evaluate exposure assessment, instead of the current category on
deviation from the intended intervention.
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Strategy for data synthesis
Study-level aggregate data (i.e., not individual participant data) will be synthesized. Substantial
heterogeneity in the primary contextual determinant of interest across studies is likely to prevent a formal
meta-analysis. Instead, I will perform a qualitative assessment and narrative (descriptive) synthesis using
methods outlined by the Agency for Healthcare Research and Quality (AHRQ). Evidence to support the
effect of each type of contextual factor will be considered using the strength of evidence (SOE) tool from
AHRQ. For this tool, researchers rate the evidence for each research question based on 6 domains: risk-of-
bias (low, moderate, serious); directness (direct, indirect); consistency of estimates (inconsistent, consistent);
precision of estimates (precise, imprecise); overall SOE (insufficient, low, moderate, high); and publication
bias (none detected, potential bias). Two researchers will independently rate each of these 6 domains, and
all disputes will be resolved through discussion.
 
Analysis of subgroups or subsets
US versus specific states. Different types of drugs involved in poisonings (e.g., any opioid, prescription
opioid, heroin)
 




Organisational affiliation of the review
Columbia University, Mailman School of Public Health
https://www.mailman.columbia.edu/academics/departments/epidemiology
 
Review team members and their organisational affiliations
Mr David Fink. Columbia University
Ms Julia Schleimer. University of California, Davis
 
Type and method of review
Epidemiologic, Narrative synthesis, Systematic review
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Appendix Document 2. Study selection form for systematic review 
Inclusion and Exclusion criteria 
 
1. Does the outcome consist of a fatal drug event (e.g., drug-poisoning death, drug overdose)?  
 
No -> STOP. Excluded (Not relevant to topic) 
Yes -> Proceed to 2. 
 
2. Is the study either (a) about the geographic distribution of events or (b) an ecological study?  
 
No -> STOP. Excluded (Not relevant to topic) 
Yes -> Proceed to 3. 
 
3. Is the article of any following study designs or publication types? 
 
Case report 
Case series study 
Review 
Opinion/Editorial 




No -> Include study for full-text review.  
Yes -> STOP. Excluded (Excluded study design or publication type) 







Appendix Document 3. Data extraction form for systematic review 
Study population: 
 






2. What years are included? 
 
From: _____ To:_____  
 





e. ZIP code 
f. Census tract 
g. Other 
 
4. Sample restrictions 
a. Age (text) 
 
Study’s outcome variable: 
 
5. What is outcome? (Check all that apply) 
a. Any opioid 





6. Type of death? (Check all that apply) 
a. Unintentional (e.g., overdose) 




Study’s primary exposure of interest: 
 
7. Exposure(s) of interest? 
b. Prescription supply 
c. Economic factor 
d. Demographic factor 
e. Other 
f. Descriptive study without exposure of interest 
 
8. Source of data on primary exposure of interest?  [TEXT] 
 
Study’s statistical approach: 
 
9. Statistical analysis 
a. Did the study need to consider spatial autocorrelation?  
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i. Yes (<= county-level data) 
ii. No (state or national data) 
 
b. Did the study consider spatial autocorrelation? 
i. Yes [Continue to 9.c] 
ii. No   [Continue to 9.f] 
 
c. Global or local or both 
i. Global (is there clustering? Moran’s I) 
ii. Local (identify specific clusters; Getis-Ord Gi  
 
d. Spatial relation (spatial weights) 
i. Inverse distance 
ii. K nearest neighbors 
iii. Dulaunay triangulation 
iv. Other unknown 
 
e. How did the analysis deal with spatial autocorrelation? 
i. Residual 









iv. Population size 
v. Residential density 
vi. Urbanicity 
vii. Farmland 
viii. Median home value 
ix. Renter occupied housing 
x. Households with divided income 
xi. English speaking 
xii. Native 
xiii. Percent without earnings 
xiv. Median age 
xv. Percent black 
xvi. Percent white 
xvii. Percent Hispanic 
xviii. Percent Asian 
xix. Percent other race 
xx. Percent with < HS 
xxi. Percent female headed 
xxii. Number of MDs 
xxiii. Number of hospitals 
xxiv. Percent on Medicare 
xxv. Percent on Medicaid 
xxvi. Number in jail 
xxvii. Number in juvenile detention 
xxviii. Number homeless 
xxix. Median arrests for drug sale 













10. Description of spatial distribution? [TEXT] 
 











Appendix Table 1. Search Strategy for spatial studies investigating the effect of prescription 
opioid supply and socioeconomic conditions on drug-related deaths. 
MEDLINE (via PubMed), Searched on January 11, 2019 (No Limits on Years) 
Search No. Search terms # of Results 
#1 mortality/ OR fatal outcome/ OR decedent OR ‘death certificate’ OR 
death OR fatal 
1,111,746 
#2 ‘street drugs’/ OR ‘substance-related disorders’/ OR ‘substance 
abuse’/ OR ‘substance addiction’/ OR ‘analgesics, opioid’/ OR 
narcotic/ OR ‘opiate alkaloids’/ OR ‘prescription drug’/ OR 
‘prescription drug diversion’/ OR prescription drug misuse’/ OR 
‘prescription drug overuse’/ OR ‘drug misuse’/ OR cocaine/ OR 
‘crack cocaine’/ OR amphetamines/ OR ‘Illicit drug’ OR ‘street drug’ 
OR ‘drug misuse’ OR addiction OR ‘ prescription drug’ OR ‘prescription 
opioid’ OR ‘OxyContin’ OR ‘amphetamines’ OR ‘methamphetamines’ 
OR ‘heroin’ OR ‘narcotic’ OR ‘cocaine’ OR ‘crack cocaine’ 
488,030 
#3 ‘spatial analysis’/ OR ‘spatial regression’/ OR ‘models, spatial 
interaction’/ OR ‘spatio-temporal analysis’/ OR ‘geographic 
mapping’/ OR ‘contextual effect’ OR ‘spatial epidemiology’ OR ‘spatial 
analysis’ OR ‘census tract’ OR ‘geographic’ OR ‘geography’ OR 
‘mapping’ OR ‘spatial’ OR ‘geospatial’ OR ‘hotspots’ OR ‘geographic 
information system’ OR ‘geocod*’ OR ‘GeoDa’ OR ‘WinBugs’ OR 
‘ArcMap’ OR ‘Bayesian Hierarchical’ OR ‘empirical Bayes prediction’ 
OR ‘small area analysis’ 
741,975 
#4 #1 AND #2 AND #3 229 
 
 144 
#5 #4 NOT (‘case reports’/ OR ‘systematic review’/ OR comment/ OR 
commentary/ OR ‘editorial comment’/ OR letter reply/ OR OR 
‘systematic review’ OR ‘case study’) 
225 
#6 #5 AND English 212 
Embase, Searched on January 11, 2019 (No Limits on Years) 
Search No. Search terms # of Results 
#1 mortality/ OR death/ OR ‘sudden death’/ ‘decedent’ OR ‘death 
certificate’ OR death OR fatal 
2,125,777 
#2 ‘drug overdose’/ OR (‘drug related’ OR drug OR opioid OR heroin) 
NEXT/5 (mortality OR death OR overdose OR poison*) 
56,552 
#3 ‘street drug’/ OR drug/ OR ‘substance use’/ OR ‘drug dependence’/ 
OR addiction/ OR ‘opiate agonist’/ OR ‘analgesic agent’/ OR 
‘prescription drug’/ OR ‘prescription drug misuse’/ OR 
‘prescription drug diversion’/ OR ‘drug abuse’/ OR cocaine/ OR 
methamphetamine/ OR diamorphine/ OR amphetamine 
4,315,079 
#4 ‘Illicit drug’ OR ‘prescription opi*’ OR ‘crack cocaine’ OR ‘heroin’ OR 
‘oxycontin’ 
43,046 
#5 #3 OR #4 4,316,731 
#6 ‘spatial analysis’/ OR ‘spatial autocorrelation analysis’/ OR ‘spatial 
regression’/ OR ‘spatiotemporal analysis’/ OR ‘spatiotemporal 
dynamics’/ OR ‘spatiotemporal pattern’/ OR ‘geospatial analysis’/ 




#7 ‘contextual effect’ OR ‘spatial epidemiology’ OR ‘spatio-temporal 
analysis’ OR ‘geographic mapping’ OR ‘census tract’ OR ‘geospatial’ 
OR ‘hot spot’ OR ‘spatial autocorrelation’ OR geocod* OR ArcMap OR 
‘Bayesian hierarchical’ OR ‘empirical Bayes prediction’ 
20,031 
#9 #6 OR #7 37,592 
#10 #1 AND #5 AND #9 243 
#11 #2 AND #9 66 
#12 #10 OR #11 282 
#13 #12 AND [humans]/lim AND [english]/lim 237 
PsychINFO, Searched on January 11, 2019 (No Limits on Years) 
Search No. Search terms # of Results 
#1 “Death and Dying”/ or Suicide/ or (death or decedent or ‘death 
certificate’ or mortality).mp.  
133,692 
#2 ((drug or opioid or heroin) adj5 (mortality or death or overdose or 
poison*)).mp.  
2,464 
#3 ‘Drug Usage’/ or Drugs/ or ‘Drug Abuse’/ or Opiates/ or 
‘Prescription Drugs’/ or Addiction/ or ‘Drug Dependency’/ or ‘Drug 
Addiction’/ or ‘Prescription drugs’/ or Opiates/ or ‘Analgesic 
Drugs’/ or ‘Heroin Addiction’/ or Heroin/ or ‘Crack Cocaine’/ or 
Cocaine/ or Methamphetamine/ or amphetamine/ or (‘street drug’ or 




heroin or prescription opioid or Cocaine Methamphetamine 
amphetamine).mpe. 
 
#4 Geography/ or ‘Contextual Associations’/ or Neighborhoods/ or 
(spatial or ‘spatial analysis’ or ‘spatial autocorrelation’ or spatiotemporal 
or ‘contextual effect’ or ‘geospatial’ or ‘spatial analysis or spatial 
regression' or spatiotemporal or spatio-temporal or ‘geographic 
mapping’ or ‘census tract’ or ‘hot spot’ or geocod* or ArcMap or 
Bayesian hierarchical or empirical Bayes prediction or Winbugs or JAG 
or small area).mp. 
  
119,615 
#5 1 and 3 and 4 186 
#6 2 and 4 27 
#7 5 or 6 197 
#8 Limit 7 to (human and English language) 101 
EconLit, Searched on January 11, 2019 (No Limits on Years) 
Search No. Search terms # of Results 
#1 Drug overdose or drug fatality or drug mortality or drug death or drug-
related mortality or drug-related death or drug-related fatality or opioid 
death or opioid overdose or opioid fatality or heroin mortality or heroin 
overdose  
71 
Web of Science, Searched on January 11, 2019 (No Limits on Years) 
 
 147 
Search No. Search terms # of Results 
#1 TS=(death OR decedent OR 'death certificate' OR mortality' OR 'death 
and dying' OR suicide)  
Indexes=SCI-EXPANDED, SSCI, ESCI Timespan=All years 
1,538,946 
#2 (TI=((drug NEAR/5 mortality) OR (drug NEAR/5 death) OR (drug 
NEAR/5 overdose) OR (drug NEAR/5 poison*))) OR (TI=((opioid 
NEAR/5 mortality) OR (opioid NEAR/5 death) OR (opioid NEAR/5 
overdose) OR (opioid NEAR/5 poison*))) OR (TI=((heroin NEAR/5 
mortality) OR (heroin NEAR/5 death) OR (heroin NEAR/5 overdose) 
OR (heroin NEAR/5 poison*))) AND LANGUAGE: (English)  
Indexes=SCI-EXPANDED, SSCI, ESCI Timespan=All years 
5,143 
#3 ((TS=street drug) OR (TS=illicit drug) OR (TS=substance use) OR 
(TS=drug dependence) OR (TS=addiction) OR (TS=opiate agonist) OR 
(TS=analgesic) OR (TS=prescription drug) OR (TS=prescription drug 
misuse) OR (TS=prescription drug diversion) OR (TS=prescription 
opioid) OR (TS=drug abuse) OR (TS=cocaine) OR (TS=crack cocaine) 
OR (TS=methamphetamine) OR (TS=diamorphine) OR (TS=heroin) 
OR (TS=amphetamine) OR 
(TS=OxyContin)) AND LANGUAGE: (English)  
Indexes=SCI-EXPANDED, SSCI, ESCI Timespan=All years 
434,488 
#4 ((TS=spatial) OR (TS=spatial analysis) OR (TS=spatial autocorrelation) 
OR (TS=spatial regression) OR (TS=spatiotemporal) OR 
(TS=geospatial) OR (TS=geographic information system) OR 
(TS=small-area analysis) OR (TS=small area estimation) OR 




epidemiology) OR (TS=spatio-temporal) OR (TS=geographic mapping) 
OR (TS=census tract) OR (TS=hot spot) OR (TS=geocod*) OR 
(TS=ArcMap) OR (TS=Bayesian hierarchical) OR (TS=empirical Bayes 
prediction) OR (TS=WinBUGS) OR (TS=JAG) OR (TS=ArcGIS) OR 
(TS=geography) OR (TS=geographic) OR 
(TS=GeoDa)) AND LANGUAGE: (English)  
Indexes=SCI-EXPANDED, SSCI, ESCI Timespan=All years 
 
#5 #1 AND #3 AND #4 617 
#6 #2 AND #3 AND #4 81 
#7 #5 OR #6 642 
Notes. Medline: ‘MeSH’ terms in bold, ‘key-words’ in lowercase. Embase: ‘EMTREE’ terms in bold, ‘key-
words’ in lowercase. PsychINFO: Exploded terms in bold; ‘key words’ in lowercase; adj5 = records where 
the terms joined by the operator are within 5 words of each other; mp = search in title, abstract, heading 
word, table of contents, key concepts, original title, tests, and measures; m_titl = search in title. Web of 
Science: TS=Topic; TI=Title; NEXT/5=records where the terms joined by the operator are within 5 words 











Appendix Table 2. Description of 7 included studies estimating the association between per-capita prescription opioid 
supply and drug-related mortality 




Type of drug 
poisoning Included covariates Study results ROB 
Author, Year 









Vital statistics: Deaths 













related deaths (UCD: 
X40-44, X60-64, X85, 
Y10-14; MCOD: T40.2) 
Age distribution Descriptive:  
Spatial clustering of prescription 
opioid-related deaths was 





For every 10,000 prescriptions 
increased, the number of opioid 
mortalities decreased by 0.12% (p 
< 0.001) 
Serious –  






varying factors.  
Author, Year 









Vital statistics: Deaths 














written and then 
submitted to be 
filled under 





(UCD: X40-44, X60-64, 
X85, Y10-14; MCOD: 
N/A) 





status, density of 
substance abuse 
centers, and the 
percentage of opioid 
prescription filled under 
Medicare Part D in the 
county. 
Association:  
Counties in which a greater 
proportion of Medicare Part D 
prescriptions were for opioids had 
substantially increased odds of 
high overdose mortality: 
 
3-4.9% vs. <3%: 2.33 
(95%CI=1.68, 3.23) 
 
5-7.9% vs. <3%: 15.18 
(95%CI=11.02, 20.92) 
 
≥8% vs. <3%: 65.81 
(95%CI=46.51, 93.10) 
Serious -  
Measure of PO 
supply is selective 
and may depend on 
size and health of 
Medicare population 
in a county; 
Outcome measure 
was categorized into 
a 3-level variable, 
without explanation, 















Appendix Table 2 - Continued 




Type of drug 
poisoning Included covariates Study results ROB 
Author, Year 






















44, Y10-14; MCOD: 
N/A) 
None Association:  
No significant (p < 0.05) space-time 
clusters of prescription opioid sales 
and unintentional drug poisonings 
were identified. 
Serious –  

























Vital statistics: Deaths 
50 US states and 














poisonings (UCD: X42, 
X44, Y12, Y14; 
MCOD: N/A) 
Distribution of age and 
race/ethnicity 
Association:  
Several drugs correlated significantly 
(p<0.05) with drug poisoning 
mortality, including: hydromorphone (r 
= 0.46; p = 0.05), Methadone (r = 
0.66; p < 0.0001), Morphine (r = 0.46; 
p = 0.05), OxyContin® (r = 0.58; p = 
0.002), Oxycodone, other (r = 0.73; p 
< 0.0001), and total MME (r = 0.73; p 
< 0.0001). 







used to assess 
association; study 









Appendix Table 2 - Continued 




Type of drug 
poisoning Included covariates Study results ROB 
Author, Year 









Vital statistics: Deaths 













(UCD: X40-44 X60-64, 
X85, Y10-14, Y352; 
MCOD: T40.1, T40.2, 
T40.) 




White, age, percentage 
of persons ≥25 years 
old with some college or 
who were college 
graduates, percentage 
of female headed 
households, foreign-
born persons, number 
of hospital beds and 
active non-federal 
physicians, urban-rural 
continuum code, state 
prescription drug 
monitoring programs, 
and legalized medical or 
recreational cannabis.  
Association:  
Annual per-capita MME was 
associated with 0.006 (SE=0.0003) 
opioid analgesic death rate at the 
county level. At the national level, 
per-capita MME was associated with 
0.007 opioid analgesic death rate. 
 
Opioid prescribing explained about 
78% of the rise of associated deaths. 
 
Adding county-level covariates to the 
model reduced the MME coefficient 
around one third, 0.0036864 for 
county-level and 0.0037462 for 
national-level   




digit ZIP code level 
















Vital statistics: Deaths 















proportion of population 
White 
Association:  
3-digit ZIP code areas with high 
oxycodone orders (in 2004) were 
associated with a higher number of 
fentanyl-related deaths (in 2006) (b = 
1.41; SE=0.42; p < 0.01) 
Serious –  













Appendix Table 2 - Continued 




Type of drug 
poisoning Included covariates Study results ROB 
Author, Year 









Vital statistics: Deaths 
48 contiguous US 







prescription rate per 




(UCD: X40-44, X60-64, 
Y10-14, drug-induced 
deaths,4 findings of 
drugs in the blood,5 
mental and behavioral 





white, and percent 
military veterans. 
Association:  
A 1SD increase in 
logged opioid 
prescribing (2009-2011) 
is associated with an 
increase of 2.41 








(logged), in 2009-2011, 
is associated with an 
increase of 1.95 
(SE=0.29, p<.001) 
deaths from 2014-2016 
Serious - Inadequate 
adjustment of time-
invariant and time-
varying factors; No 
adjustment for spatial 
autocorrelation. 
UCD=Underlying Cause of Death; MCOD=Multiple Cause of Death; SD=Standard deviation; SE=Standard error; CI=Confidence interval 
1 QuintilesIMS TDW is a proprietary sample of retail (non-hospital) pharmacies dispensing approximately 88% of all retail prescriptions in the US. 
Opioid prescription rates include prescriptions dispensed for butrans (buprenorphine), codeine, fentanyl, hydrocodone, hydromorphone, 
methadone, morphine, oxycodone, oxymorphone, propoxyphene, tapentadol, and tramadol. Methadone dispensed through substance use 
treatment programs are not included in this dataset (Centers for Disease Control and Prevention, 2017) 
2 Medicare Part D represents two-thirds of Medicare prescriptions.  
3 Automation of Reports and Consolidation Orders System (ARCOS) is a centralized database, maintained by the Drug Enforcement Agency 
(DEA), which tracks the sale of controlled substances in grams to hospitals, pharmacies, and practitioners. Manufacturers and distributors are 
required to report inventories, acquisitions, and dispositions of all Schedule I and II drugs, Schedule II narcotic drugs, and gamma-hydroxybutyric 
acid (GHB).  ARCOS reports data at the 3-digit ZIP code level. 
4 Drug-induced diseases includes ICD-10 codes: D52.1, D59.0, D61.1, E06.4, E16.0, E24.2, E66.1, G21.1, G24.0, G25.1, G25.4, G25.6, G44.4, 
G62.0, G72.0, I95.2, J70.2-70.4, K85.3, L10.5, L27.1, M10.2, M32.0, M80.4, M81.4, M83.5, M87.1, R50.2 
5 Findings of drugs in the blood includes ICD-10 codes: R78.1-78.5 
6 Mental and behavioral disorders due to drugs includes ICD-10 codes: F11.0-11.5, F11.7-11.9, F12.0-12.5, F12.7-12.9, F13.0-13.5, F13.7-13.9, 





Appendix Table 3. Description of 11 included studies estimating the association between socioeconomic and social 
conditions and drug-related mortality 




Type of drug 
poisoning Included covariates Study results ROB 
Author, Year 









Vital statistics: Deaths 




Census ZIP code 
tabulation area 
Exposure:  



















(both prescription and 
illicit use) opioid 
overdose 
Age and race/ethnicity 
distribution 
Association:  
Higher percent of residents below 
federal poverty level and higher 
median household income associated 
with higher rates of both prescription 
opioid- and heroin-related deaths. 
 
Higher percent of residents 25 years 
or older with 4-year college degree 
associated with reductions in rates of 
prescription opioid-related overdose 
deaths. 
Serious –  





















Vital statistics: Deaths 













64, X85, Y10-14, 




included in the model. 
Association:  
County-level analysis: A 1% rise in 
county unemployment rate was 
associated with a 0.19 per 100,000 
residents (SE=0.05; p < 0.001) 
increase in opioid fatalities. 
 
State-level analysis: A 1% rise in 
state unemployment rate was 
associated with a 0.35 per 100,000 
residents (SE=0.11; p < 0.001) 
increase in opioid fatalities. 











Appendix Table 3 - Continued 




Type of drug 
poisoning Included covariates Study results ROB 
Author, Year 









Vital statistics: Deaths 























related deaths (UCD: 
X40-44, X60-64, X85, 




deaths (UCD: X40-44, 
X60-64, X85, Y10-14, 
Y35.2; MCOD: T40.1, 
T40.4) 




White, age, percentage 
of persons ≥25 years 
old with some college or 
who were college 
graduates, percentage 
of female headed 
households, foreign-
born persons, number 
of hospital beds and 
active non-federal 
physicians, urban-rural 
continuum code, state 
prescription drug 
monitoring programs, 
and legalized medical or 
recreational cannabis. 
Association:  
A 1 standard deviation increase in 
index of economic conditions was 
associated with a 0.79 per 100,000 
(SE=0.44; p < 0.1) faster growth in 
overdose mortality and a 0.31 per 
100,000 (SE=0.17; p < 0.1) and -0.10 
per 100,000 (SE=0.31; p > 0.1) 
change in opioid analgesic and heroin 
death rates, respectively. 
Low –  














Vital statistics: Deaths 
45 US states, 1999-












(not explicitly defined) 
 
Opioid-related deaths 
(not explicitly defined) 
Share of person 21-55 
years with a bachelor’s 
degree, baseline prime 
age (21-55 years) 
female labor force 
participation rate, 
baseline share of the 
population that is 
foreign born 
Association:  
A 1% decline in the manufacturing 
employment share of prime age 
workers between 2000 and 2016 was 
associated with a 0.04 per 1,000 and 
0.02 per 1,000 increase in drug- and 
opioid-related deaths, respectively, 
between pooled 1999-2003 and 
pooled 2012-2016. 








ability to assess 




Appendix Table 3 - Continued 




Type of drug 
poisoning Included covariates Study results ROB 
Author, Year 









Vital statistics: Deaths 
from New York City, 

























Substantial clustering of opioid 




Moderate spatial correlation was 
found between rates of fatal 
analgesic poisonings and income 
inequality (I = 0.17; P = 0.02), family 
fragmentation (I = 0.14; P = 0.04), 
and housing dilapidation (I = 0.18; P 
= 0.02). 







varying factors  
Author, Year 









Vital statistics: Deaths 















or boarded up 
Deaths from drug 
dependence (ICD-9 
code: 304)  
Proportion of population 
foreign born, between 
the ages of 25 and 34, 
the ratio of males to 
females, the percentage 
of the population Black, 
and the percentage of 
the population of 
Hispanic origin 
Association:  
A 1 standard deviation increase in 
poverty index was associated with a 
21.7% (95% CI=13.4%, 30.5%) in 
deaths from drug dependence. 
 
Drug dependence mortality was 
positively associated with boarded up 
houses (b = 0.17; SE=0.05; p < 
.0001), and inversely associated with 
percent homeowners (b = -0.007; 
SE=0.001; p < .0001) 
Moderate – 
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Type of drug 
poisoning Included covariates Study results ROB 
Author, Year 









Vital statistics: Deaths 
from New York City, 

















included in the 
ecological analyses 
Association:  
36% of the association between the 
distribution of income (Gini 
coefficient) and the rate of fatal drug 
poisonings was explained by the 
direct effect of income inequality on 
the rate of fatal drug poisonings (path 
coefficient=0.21), with the remaining 
64% of the association being indirect, 
mediated by environmental disorder, 
police activity, and quality of built 
environment.  





















Vital statistics: Deaths 
from New York City, 









and percent of 
income earned 
by lowest 









included in the 
ecological analyses 
Descriptive:  
Neighborhoods with greater income 
inequality had higher rates of fatal 
drug poisonings compared to 
neighborhoods with less income 
inequality. A threshold effect was 
found with rates of fatal drug 
poisonings increasing more rapidly 
above Gini coefficient 0.45 and below 
39% of income earned by the lowest 
70% of households. 
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Type of drug 
poisoning Included covariates Study results ROB 
Author, Year 









Vital statistics: Deaths 
48 contiguous US 









 (UCD: X40-44, X60-
64, Y10-14, drug-
induced deaths,4 
findings of drugs in the 
blood,5 mental and 
behavioral disorders 












population ≥65 years), 
percentage of residents 
in military or veterans.  
Descriptive: 
Substantial clustering of drug-related 




A 1 SD increase in economic distress 
index was associated with a 6.4% 
(SE= 1.68; p < 0.001) increase in the 
drug-related mortality. 
 
Compared with diversified 
economies, mining dependent 
counties had a 13% (SE=4.03; 
p=0.001) higher average rate of drug-
related mortality, public sector 
dependent (-11.8%; SE=2.59; 
p<0.001), manufacturing dependent 
(-3.53%; SE=1.90; p=0.06), and 
farming dependent (-6.62%; 
SE=3.69; p=0.09) counties were 
associated with lower rates. 
Moderate - 
Counties with fewer 
than 10 drug-
related deaths were 
suppressed (623 
counties [20%]), 
















Vital statistics: Deaths 
48 contiguous US 
states and Washington 











 (UCD: X40-44, X60-
64, Y10-14, drug-
induced deaths,4 
findings of drugs in the 
blood,5 mental and 
behavioral disorders 





44, X60-64, Y10-14, 
drug-induced deaths,4 
findings of drugs in the 
blood,5 mental and 
behavioral disorders 
due to drugs6; MCOD: 
T40.0-T40.4, T40.6) 
for percentage 65 or 
older, percent non-




A 1 standard deviation increase in 
economic distress in 2000 is 
associated with a 3.17 per 100,000 
(95% CI = 1.68, 3.72) population 
increase in county-level drug mortality 
rates in 2014-2016. 
 
County-level economic dependence 
on mining (3.23; 95% CI = 1.13, 5.33) 
and services (2.32; 95% CI = 0.85, 
3.79) were associated with higher 
rates of drug-related mortality, and 
manufacturing (-1.26; 95% CI = -0.24, 
-2.28), public sector employment (-
1.80; 95% CI =  -0.45, -3.15), and 
farming (-1.81; 95% CI = -0.32, -3.30) 
were associated with lower rates. 
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Type of drug 
poisoning Included covariates Study results ROB 
Author, Year 









Vital statistics: Deaths 













 (UCD: X40-44, X60-




percent of population 
over 65 years, and 
metropolitan status 
Descriptive: 
Substantial clustering of drug-related 
mortality rates (Moran’s I: 0.49), 
poverty rate (0.58), Unemployment 
rate (0.62), and employment-to-




A 1% increase in a county’s poverty 
rate, unemployment rate, and 
employment-to-poverty ratio were 
associated with a 1.7% (95% CI = 
1.3%, 2.1%), 4.6% (95% CI = 3.6%, 
5.6%), and 0.5% (95% CI = 0.3%, 
0.7%) increase in drug-poisoning 
deaths, respectively. 








UCD=Underlying Cause of Death; MCOD=Multiple Cause of Death; SD=Standard deviation; SE=Standard error; CI=Confidence interval 
1 Index of socioeconomic deprivation was calculated using a Principle Components Analysis of 5 indicator variables: (1) Manual workers; (2) Unemployment; (3) Temporary workers; 
(4) Low education level: percentage of people aged 16 years and over with less than 5  years of schooling or with 5 years of schooling or more who did not complete basic compulsory 
education; (5) Low education level in young people 16-29 years). 
2 Index of economic conditions was calculated from 5 county-level indicator variables: (1) Unemployment rate, averaged over 3-years; (2) Poverty rate, averaged over 3-years; (3) 
Median home price, averaged over 5-years; (4) Median household income; and (5) exposure to Chinese import competition.  
3 Standardized poverty index summed 4 census tract-level indicator variables: (1) Poverty rate; (2) Median family income (reverse coded); (3) Percentage of households receiving 
public assistance income; and (4) Unemployment rate. 
4 Economic distress indicator included 8 count-level indicator variables: (1) Poverty rate, among ages 25-54 years; (2) Unemployment/not in labor force, among ages 25-54; (3) 
Disability rate, among ages 21-64; (4) Less than 4-year college degree among ages 25 or older; (5) Households with supplemental security income; (6) Households with public 
assistance income; (7) Gini coefficient of income inequality; and (8) Uninsured, among ages 18-64 years. 
5 Drug-related deaths included: Accidental poisonings (ICD-10 codes: X40-X44), intentional self-poisoning (ICD-10 codes: X60-X64); Poisoning of undetermined intent by exposure to 
drug (ICD-10 codes: Y10-Y14); Drug-induced diseases includes (ICD-10 codes: D52.1, D59.0, D61.1, E06.4, E16.0, E24.2, E66.1, G21.1, G24.0, G25.1, G25.4, G25.6, G44.4, G62.0, 
G72.0, I95.2, J70.2-70.4, K85.3, L10.5, L27.1, M10.2, M32.0, M80.4, M81.4, M83.5, M87.1, R50.2); Drugs in the blood (ICD-10 codes: R78.1-78.5); Mental and behavioral disorders 
due to drugs (ICD-10 codes: F11.0-11.5, F11.7-11.9, F12.0-12.5, F12.7-12.9, F13.0-13.5, F13.7-13.9, F14.0-14.5, F14.7-14.9, F15.0-15.5, F15.7-15.9, F16.0-16.5, F16.7-16.9, F18.0-
18.5, F18.7-18.9, F19.0-19.5, F19.7-19.9) 
6 Economic distress index is a standardized (z-score) factor-weighted index that combines 6 indicator variables from 2000 Census: (1) Poverty (percentage); (2) State-to-county 
median household income (ratio); (3) Households receiving public assistance income (percentage); (4) Persons age 25 or older without a 4-year college degree (percentage); (5) Not-




Appendix Table 4. Risk of bias assessment in included studies 
Criteria for ROB 
assessment in 
included studies 
Study, Year (Reference) 
 Romeiser, 2019 (79) Zoorob & Salemi, 
2017 (80) 
Modarai, 2013 (77) Paulozzi, 2006 (78) 
Bias in selection of 
participants into the 
study 
Serious – Study limited 
to a single state (New 
York), over a three-
year period, unlikely to 
represent U.S. effect.  
Low – Selection of 50 
states and Washington 
D.C.  
Serious – Study limited 
to a single state (North 
Carolina), unlikely to 
represent U.S. effect 
Serious – Study limited 
to a single year (2002) 
Bias due to missing 
data 
Low – No missing data 
were reported. 
Moderate – Data on 
drug-related mortality 
was suppressed in 
counties with fewer 
than 10 deaths each 
year.  
Low – No missing data 
were reported. 
Low – No missing data 
were reported. 
Bias in data 
collection methods 
Low – No bias 
detected in data 
collection methods. 
Serious – Information 
loss due to 
categorizing drug-
related mortality rates 
into a three-level 
variable. 
 
Measure of PO supply 
is selective and may 
depend on size and 
health of Medicare 
population in a county. 
Low – No bias 
detected in data 
collection methods. 
 
Low – No bias 
detected in data 
collection methods. 
Bias due to 
confounding 
Serious - Analysis 
adjusted for only age, 
failing to account for 
other potential 
confounding variables.  
Moderate –  





status, density of 
substance abuse 
centers. 
Serious –  
Analysis failed to 





Serious –  
Analysis adjusted for 
only age and 
race/ethnicity, failing to 
account for other 
potential confounding 
variables.  
Bias in analyses Moderate -  
Spatial autocorrelation 
was handled with 
smoothed residuals, a 
sub-optimal approach. 
Serious –  
Outcome measure was 
categorized into a 3-
level variable, without 
explanation, loss of 
information probable; 




Serious –   
Analysis investigated 
co-occurring clustering 
of opioid sales and 
drug poisonings, 
instead of estimating 
an association 
between the variables 
of interest; Lack of 
theoretical justification 
for conducting analysis 
at 3-digit ZIP code. 
Serious –  
Association between 
per-capita prescription 
opioid supply and 
drug-related mortality 
rates were assessed 
using a correlation 
coefficient only. 
Overall bias Serious - Sample 
unlikely to represent 
U.S. population; 
Inadequate adjustment 
of time-invariant and 
time-varying factors; 
No adjustment for 
spatial autocorrelation 
Serious - Inadequate 
adjustment of time-
varying factors; No 
adjustment for spatial 
autocorrelation 
Serious - Sample 
unlikely to represent 
U.S. population; 
Inadequate adjustment 
of time-invariant and 
time-varying factors; 
No adjustment for 
spatial autocorrelation 
Serious - Inadequate 
adjustment of time-
invariant and time-
varying factors;  




Appendix Table 4 - Continued 
Criteria for ROB 
assessment in 
included studies 
Study, Year (Reference) 
 Ruhm, 2019 (91) Hempstead, 2014 (76) Monnat, 2019 (90) Marshal, 2018 (86) 
Bias in selection of 
participants into the 
study 
Low – Selection of 50 
states and Washington 
D.C. 
Serious – Study limited 
to a single state (New 
Jersey) in a single year 
(2006) 
Moderate - Selection 
of 48 contiguous states 
and Washington D.C. 
Serious - Data limited 
to a single county over 
only a five-year period  
Bias due to missing 
data 
Low – No missing data 
were reported. 
Low – No missing data 
were reported. 
Moderate - Analyses 
excluded counties with 
fewer than 1000 non-
Hispanic white adults 
in 2016 
Low – No missing data 
were reported. 
Bias in data 
collection methods 
Moderate –  
ARCOS3 reports data 
on prescription opioids 




dispensed at 3-digit 
ZIP code were 
distributed within each 
county by population 
size. 
Moderate –  
Prescription opioid 
supply is limited to a 
single opioid 
(oxycodone). 
Serious - Data on the 
exposure and 
covariates came from 
different years (e.g., 
2008-2012 American 
Community Survey, 
2000 Census, 2004 
Urban-rural codes, 
2009-2011 prescribing 
rates) and time 
difference between 
these measures and 
the outcome will vary 
by year. 
Low – No bias 
detected in data 
collection methods. 
Bias due to 
confounding 
Low – Robust 
adjustment for time-
fixed and time-varying 
confounders. 
Serious –  
Analysis adjusted for 
only median income 
and proportion white, 
failing to account for 
other potential 
confounding variables. 
Serious - Model 
adjusts for percentage 
65 or older, percent 
non-Hispanic white, 
and percent military 





Serious - Analysis 
adjusted for only age 
and race/ethnicity, 
failing to account for 
other potential 
confounding variables. 
Bias in analyses Moderate –  
No adjustment for 
potential spatial or 
temporal 
autocorrelation. 
Moderate –  
No adjustment for 




Moderate –  
Measure of average 
opioid prescribing of 
neighboring counties 
was included for each 
county-year; No 
explicit adjustment for 
spatial autocorrelation.  
Moderate -  
No adjustment for 
potential spatial or 
temporal 
autocorrelation. 
Overall bias Moderate – Per-capita 
prescription supply 
transformed from 3-
digit ZIP code level to 
county-level; No 
adjustment for spatial 
autocorrelation 
Serious - Sample 
unlikely to represent 
U.S. population; 
Inadequate adjustment 
of time-invariant and 
time-varying factors; 
No adjustment for 
spatial autocorrelation 
Serious - Inadequate 
adjustment of time-
invariant and time-
varying factors; No 
adjustment for spatial 
autocorrelation 
Serious - Sample 
unlikely to represent 
U.S. population; 
Inadequate adjustment 
of time-invariant and 
time-varying factors; 
No adjustment for 
spatial autocorrelation 





Appendix Table 4 - Continued 
Criteria for ROB 
assessment in 
included studies 
Study, Year (Reference) 
 Hollingsworth, 2017 
(85) Charles, 2018 (82) Cerda, 2013 (81) Hannon, 2006 (84) 
Bias in selection of 
participants into the 
study 
Low – Selection of 50 
U.S. states and D.C. 
Moderate –  
Selection of 45 U.S. 
states, unknown which 
states were excluded 
and why. 
Moderate – Study 
limited to a single state 
(New York), over a 
three-year period, 
unlikely to represent 
U.S. effect. 
Moderate – Study 
limited to a single state 
(New York), over a 
three-year period, 
unlikely to represent 
U.S. effect. 
Bias due to missing 
data 
Low – No missing data 
were reported. 
Low – No missing data 
were reported. 
Moderate – 
Approximately 10% of 
deaths had a missing 
address of injury and 
were excluded. 
Moderate – 
Approximately 8% of 
census tracts were 
excluded due to 
missing data on deaths 
or small population 
counts (n < 500). 
Bias in data 
collection methods 
Low – No bias 
detected in data 
collection methods. 
Serious –  
Drug and opioid 
deaths were not 
defined in the paper. 
 
Low – No bias 
detected in data 
collection methods. 
Moderate - deaths 
were identified using 
ICD-9 code 304, death 
from drug 
dependence. Deaths 
from drug dependence 
may undercount 
overall drug-related 
deaths. However, the 
study cites a New York 
City Department of 
Health study 
suggesting that New 
York City examiners 
place about 97% of 
drug abuse deaths into 
this single category 
(ICD-9: 304) 
Bias due to 
confounding 
Serious – No 
covariates were 
included in the model.  
Serious –  
Analysis adjusted for 
share of person 21-55 
years with a bachelor’s 
degree, baseline prime 
age female labor force 
participation rate, 
baseline share of the 
population that is 
foreign born; Analysis 
applied a shift share 
instrument.  
Serious – No potential 
confounding variables 
were included when 
estimating the spatial 
correlation between 
neighborhood 
measures and fatal 
drug poisoning rates   
Moderate -  
Proportion of 
population foreign 
born, between the 
ages of 25 and 34, the 
ratio of males to 
females, the 
percentage of the 
population Black, and 
the percentage of the 
population of Hispanic 
origin. 
Bias in analyses Serious –  
State and year fixed-






clustered at the county 
level fail to address 
spatial autocorrelation.  
Serious –  
The paper provided 
insufficient information 
on the analytical 
approach to determine 
the quality of the 
analysis.  
Moderate – Models 
were unadjusted for 
potential confounding; 
Estimates of spatial 
correlation did not 
include standard errors 
or other estimates of 
precision. 
Low –  
Models included a 
spatial lag variable, 
calculated using a 2-
stage least squares 
approach, to address 
potential bias from 
spatial autocorrelation.  
Overall bias Serious - Inadequate 
adjustment of time-
invariant and time-
varying factors; No 
adjustment for spatial 
autocorrelation 
 





of methods limited 
ability to assess risk of 
bias  
Serious - Sample 
unlikely to represent 
U.S. population; 
Inadequate adjustment 
of time-invariant and 
time-varying factors 
Moderate - Sample 
unlikely to represent 
U.S. population; 
Inadequate adjustment 
of time-invariant and 
time-varying factors 




Appendix Table 4 - Continued 
Criteria for ROB 
assessment in 
included studies 
Study, Year (Reference) 
 Nandi, 2006 (89) Galea, 2003 (88) Monnat, 2018 (87) Ghertner, 2018 (83) 
Bias in selection of 
participants into the 
study 
Moderate – Study 
limited to a single state 
(New York), over a 
three-year period, 
unlikely to represent 
U.S. effect. 
Moderate – Study 
limited to a single state 
(New York), over a 
three-year period, 
unlikely to represent 
U.S. effect. 
Moderate – Selection 
of 48 U.S. states and 
D.C. 
Low – Selection of 50 
U.S. states and D.C.  
Bias due to missing 
data 
Moderate – Decedents 
without residential 
information or 
classified as homeless 
were excluded. 
Moderate – Decedents 
without residential 
information or 
classified as homeless 
were excluded. 
Moderate – Counties 
with fewer than 10 
drug-related deaths 
were suppressed (623 
counties [20%]), 
missing data were 
imputed. 
Low – No missing data 
were reported. 
Bias in data 
collection methods 
Moderate – Inexact 
proxies of 
neighborhood 
conditions were used, 
such as mean number 
of misdemeanor 
arrests as proxies for 
police activity. 
Low – No bias 
detected in data 
collection methods. 
Low – No bias 
detected in data 
collection methods. 
Low – No bias 
detected in data 
collection methods. 
Bias due to 
confounding 
Serious – No potential 
confounders were 
included in the 
ecological analysis. 
Serious – No potential 
confounders were 








residents in military or 
veterans; analysis did 
not consider any 
potentially confounding 
policy indicators 









Bias in analyses Serious – No 
adjustment for 
potential confounding; 
No adjustment for 
potential spatial or 
temporal 
autocorrelation. 
Serious – No 
adjustment for 
potential confounding; 
No adjustment for 
potential spatial or 
temporal 
autocorrelation. 
Low – Spatial 2-stage 
least squares 
autoregressive models 
were used to account 
for correlated residuals 
between neighboring 
counties by fitting the 
model with a 
correlation parameter 
of the residuals. 
Serious - State fixed 




standard errors at the 
county-level does not 
address spatial 
autocorrelation.   
Overall bias Serious – Sample 
unlikely to represent 
U.S. population; 
Inadequate adjustment 
of time-invariant and 
time-varying factors; 
No adjustment for 
spatial autocorrelation 
Serious - Sample 
unlikely to represent 
U.S. population; 
Inadequate adjustment 
of time-invariant and 
time-varying factors; 
No adjustment for 
spatial autocorrelation 
Moderate - Inadequate 
adjustment of time-
varying factors 
Serious - Inadequate 
adjustment of time-
invariant and time-
varying factors; No 
adjustment for spatial 
autocorrelation 






Appendix Table 5. Description of the prescription opioid supply datasets 
 Automation of 
Reports and 
Consolidated Orders 
System (ARCOS)  Xponent  Medicare Part D 
Years 2000-2018  2006-2018  2013-2018 
Data source Administrative data  Survey data  Administrative data 













 Retail (non-hospital) pharmacies, 
paid for by commercial 
insurance, Medicaid, Medicare, 
or cash or its equivalent. 
 Medicare Part D prescription 
drug claims prescribed by 
health care providers 
Exclusion 
criteria 
Methadone sales from 
opioid treatment 
programs 
 Mail order pharmacy data. 
Cough and cold formulations 
containing opioids; 
buprenorphine products used to 
treat opioid use disorder; 

















tapentadol, and tramadol 
 






















Grams of drug 
distributed, converted 
to morphine milligram 
equivalents (MME) 
 Number of opioid prescriptions 
per 100 residents 
 Opioid prescribing rate: The 
number of Opioid claims 
divided by the Overall Claims 
and multiplied by 100 







Appendix Table 6. Estimated effect of county-level per-capita opioid prescribing rate on 
drug-related deaths in 49 U.S. Statesa and Washington, D.C., 2006-2016, comparing 
listwise deletion to imputation of per-capita opioid prescribing rate in counties with 
missing data 
 
Drug-related deathb  
Drug-related deathsb 
5 imputed sets 
Medianc (95% CI)  Medianc (95% CI) 
Opioid prescribing rate (1 SD) 1.17 (1.16-1.19)  1.17 (1.15-1.19) 
Unemployment (1 SD) 1.02 (1.01, 1.03)  1.02 (1.01-1.03) 
Population density 1.03 (1.02-1.06)  1.04 (1.02-1.07) 
Race/ethnicity      
    Non-Hispanic white (%) 0.65 (0.55-0.77)  0.63 (0.54-0.75) 
    Non-Hispanic black (%) 0.54 (0.43-0.69)  0.54 (0.43-0.69) 
    Hispanic (%) 0.61 (0.48-0.77)  0.60 (0.47-0.75) 
Male (%) 0.20 (0.09-0.44)  0.23 (0.11-0.51) 
Age      
    0-19 years (%) 0.81 (0.48-1.34)  0.76 (0.45-1.27) 
    20-44 years (%) 1.72 (1.06-2.80)  1.65 (1.01-2.69) 
    45-64 years (%) 5.74 (2.53-13.06)  5.62 (2.46-12.85) 
Urbanicity      
   2 versus 1 1.00 (0.95-1.05)  1.00 (0.95-1.05) 
   3 versus 1 1.01 (0.96-1.07)  1.01 (0.96-1.07) 
   4 versus 1 0.96 (0.90-1.01)  0.95 (0.90-1.01) 
   5 versus 1 0.93 (0.87-1.01)  0.93 (0.86-1.00) 
   6 versus 1 0.90 (0.86-0.95)  0.90 (0.86-0.95) 
   7 versus 1 0.88 (0.83-0.94)  0.88 (0.83-0.94) 
   8 versus 1 0.84 (0.78-0.90)  0.85 (0.79-0.92) 
   9 versus 1 0.84 (0.78-0.91)  0.87 (0.80-0.94) 
Medical marijuana law 1.22 (1.19-1.24)  1.22 (1.20-1.24) 
PDMP, must access 1.03 (1.02, 1.05)  1.03 (1.01-1.05) 
Definitions of abbreviations: CI = credibility interval; SD = standard deviation; PDMP = prescription drug monitoring program. 
a Alaska was excluded from the analysis due to changes in the boundaries of multiple counties over the analytical period  
b Drug poisoning deaths were identified using International Classification of Diseases, 10th Revision (ICD-10) underlying cause of 
death (UCOD) codes for unintentional poisoning (X40-X44), intentional poisonings (X60-X64), homicidal poisoning (X85), 
poisonings with unclear intent (Y10-Y14) 
c Median is the rate ratio, computed as the exp	(&) of the median posterior estimates. Additional adjustments included state and 
year fixed effects, and interaction between county and year (modeled with an exchangeable prior). County-level models included 







Appendix Table 7. Estimated effect of county-level per-capita opioid prescribing rate on 
opioid-related deaths in 49 U.S. Statesa and Washington, D.C., 2006-2016, comparing 
listwise deletion to imputation of per-capita opioid prescribing rate in counties with 
missing data 
 
Opioid-related deathb  
Opioid-related deathsb 
5 imputed sets 
Medianc (95% CI)  Medianc (95% CI) 
Opioid prescribing rate (1 SD) 1.20 (1.18-1.23)  1.20 (1.18-1.22) 
Unemployment (1 SD) 1.02 (1.01-1.03)  1.02 (1.01-1.03) 
Population density 1.06 (1.03-1.09)  1.06 (1.03-1.09) 
Race/ethnicity      
    Non-Hispanic white (%) 0.81 (0.63-1.05)  0.78 (0.61-1.00) 
    Non-Hispanic black (%) 0.48 (0.34-0.69)  0.47 (0.32-0.68) 
    Hispanic (%) 0.89 (0.62-1.28)  0.85 (0.59-1.22) 
Male (%) 0.26 (0.08-0.88)  0.28 (0.08-0.96) 
Age      
    0-19 years (%) 1.49 (0.68-3.28)  1.58 (0.72-3.58) 
    20-44 years (%) 3.49 (1.64-7.40)  3.34 (1.57-7.10) 
    45-64 years (%) 24.38 (6.74-88.35)  28.4 (7.82-103.4) 
Urbanicity      
   2 versus 1 0.94 (0.88-1.01)  0.94 (0.88-1.01) 
   3 versus 1 0.88 (0.81-0.95)  0.88 (0.82-0.95) 
   4 versus 1 0.86 (0.79-0.93)  0.86 (0.79-0.93) 
   5 versus 1 0.79 (0.70-0.89)  0.79 (0.70-0.88) 
   6 versus 1 0.81 (0.75-0.87)  0.81 (0.75-0.87) 
   7 versus 1 0.80 (0.73-0.88)  0.80 (0.73-0.88) 
   8 versus 1 0.83 (0.74-0.93)  0.85 (0.76-0.96) 
   9 versus 1 0.80 (0.71-0.90)  0.82 (0.73-0.93) 
Medical marijuana law 1.18 (1.15-1.21)  1.18 (1.15-1.21) 
PDMP, must access 1.03 (1.01-1.06)  1.04 (1.01-1.06) 
Definitions of abbreviations: CI = credibility interval; SD = standard deviation; PDMP = prescription drug monitoring program. 
a Alaska was excluded from the analysis due to changes in the boundaries of multiple counties over the analytical period  
b Drug poisoning deaths were identified using International Classification of Diseases, 10th Revision (ICD-10) underlying cause of 
death (UCOD) codes for unintentional poisoning (X40-X44), intentional poisonings (X60-X64), homicidal poisoning (X85), 
poisonings with unclear intent (Y10-Y14) and multiple cause of death codes (MCOD) for opium (T40.0), heroin (T40.1), natural or 
semi-synthetic opioid (T40.2), methadone (T40.3), synthetic opioid other than methadone (T40.4), or other unspecified narcotics 
(T40.6). 
c Median is the rate ratio, computed as the exp	(&) of the median posterior estimates. Additional adjustments included state and 
year fixed effects, and interaction between county and year (modeled with an exchangeable prior). County-level models included 








Appendix Table 8. Estimated effect of county-level per-capita opioid prescribing rate on 
prescription opioid-related deaths in 49 U.S. Statesa and Washington, D.C., 2006-2016, 
comparing listwise deletion to imputation of per-capita opioid prescribing rate in 
counties with missing data 
 
Prescription opioid-
related deathb  
Prescription opioid-
related deathsb 
5 imputed sets 
Medianc (95% CI)  Medianc (95% CI) 
Opioid prescribing rate (1 SD) 1.20 (1.17-1.23)  1.20 (1.17-1.22) 
Unemployment (1 SD) 1.02 (1.00-1.03)  1.00 (1.00-1.03) 
Population density 1.05 (1.02-1.08)  1.05 (1.02-1.08) 
Race/ethnicity      
    Non-Hispanic white (%) 1.07 (0.79-1.43)  1.03 (0.77-1.39) 
    Non-Hispanic black (%) 0.41 (0.27-0.62)  0.40 (0.27-0.61) 
    Hispanic (%) 0.75 (0.49-1.13)  0.72 (0.48-1.09) 
Male (%) 0.22 (0.05-0.87)  0.24 (0.06-0.98) 
Age      
    0-19 years (%) 1.15 (0.47-2.83)  1.14 (0.46-2.80) 
    20-44 years (%) 3.43 (1.45-8.14)  3.18 (1.34-7.55) 
    45-64 years (%) 9.69 (2.23-42.20)  10.12 (2.32-44.11) 
Urbanicity      
   2 versus 1 0.98 (0.91-1.06)  0.98 (0.90-1.06) 
   3 versus 1 0.94 (0.86-1.02)  0.94 (0.86-1.03) 
   4 versus 1 0.92 (0.84-1.00)  0.91 (0.84-1.00) 
   5 versus 1 0.86 (0.75-0.97)  0.85 (0.74-0.97) 
   6 versus 1 0.89 (0.82-0.97)  0.89 (0.82-0.97) 
   7 versus 1 0.86 (0.77-0.95)  0.86 (0.77-0.95) 
   8 versus 1 0.90 (0.79-1.02)  0.92 (0.80-1.04) 
   9 versus 1 0.89 (0.78-1.02)  0.92 (0.46-1.05) 
Medical marijuana law 1.12 (1.08-1.17)  1.12 (1.08-1.17) 
PDMP, must access 1.00 (0.97-1.03)  1.00 (0.97-1.03) 
Definitions of abbreviations: CI = credibility interval; SD = standard deviation; PDMP = prescription drug monitoring program. 
a Alaska was excluded from the analysis due to changes in the boundaries of multiple counties over the analytical period  
b Drug poisoning deaths were identified using International Classification of Diseases, 10th Revision (ICD-10) underlying cause of 
death (UCOD) codes for unintentional poisoning (X40-X44), intentional poisonings (X60-X64), homicidal poisoning (X85), 
poisonings with unclear intent (Y10-Y14) and multiple cause of death codes (MCOD) for natural or semi-synthetic opioid (T40.2) or 
methadone (T40.3) and not heroin (T40.1). 
c Median is the rate ratio, computed as the exp	(&) of the median posterior estimates. Additional adjustments included state and 
year fixed effects, and interaction between county and year (modeled with an exchangeable prior). County-level models included 








Appendix Table 9. Estimated effect of county-level per-capita opioid prescribing rate on 
heroin-related deaths in 49 U.S. Statesa and Washington, D.C., 2006-2016, comparing 







5 imputed sets 
Medianc (95% CI)  Medianc (95% CI) 
Opioid prescribing rate (1 SD) 1.14 (1.08-1.20)  1.13 (1.07-1.19) 
Unemployment (1 SD) 0.99 (0.97-1.00)  0.99 (0.97-1.01) 
Population density 1.06 (1.02-1.11)  1.03 (1.02-1.11) 
Race/ethnicity      
    Non-Hispanic white (%) 1.51 (0.79-2.90)  1.48 (0.78-2.85) 
    Non-Hispanic black (%) 5.19 (2.32-11.62)  5.21 (2.33-11.67) 
    Hispanic (%) 4.17 (1.90-9.14)  4.06 (1.85-8.92) 
Male (%) 0.08 (0.00-1.50)  0.08 (0.01-1.49) 
Age      
    0-19 years (%) 0.76 (0.45-1.28)  0.77 (0.27-2.23) 
    20-44 years (%) 1.65 (1.01-2.69)  1.74 (0.64-4.72) 
    45-64 years (%) 5.67 (2.48-12.98)  7.10 (1.39-36.45) 
Urbanicity      
   2 versus 1 0.93 (0.81-0.93)  0.93 (0.81-1.07) 
   3 versus 1 0.64 (0.55-0.64)  0.65 (0.55-0.76) 
   4 versus 1 0.69 (0.58-0.69)  0.69 (0.59-0.81) 
   5 versus 1 0.54 (0.41-0.54)  0.54 (0.41-0.71) 
   6 versus 1 0.48 (0.41-0.48)  0.48 (0.41-0.57) 
   7 versus 1 0.43 (0.35-0.43)  0.44 (0.35-0.54) 
   8 versus 1 0.45 (0.33-0.45)  0.46 (0.34-0.61) 
   9 versus 1 0.32 (0.22-0.32)  0.33 (0.23-0.47) 
Medical marijuana law 1.05 (1.00-1.10)  1.05 (1.01-1.10) 
Recreational marijuana law      
PDMP, must access 1.04 (1.00-1.09)  1.05 (1.01-1.09) 
Definitions of abbreviations: CI = credibility interval; SD = standard deviation; PDMP = prescription drug monitoring program. 
a Alaska was excluded from the analysis due to changes in the boundaries of multiple counties over the analytical period  
b Drug poisoning deaths were identified using International Classification of Diseases, 10th Revision (ICD-10) underlying cause of 
death (UCOD) codes for unintentional poisoning (X40-X44), intentional poisonings (X60-X64), homicidal poisoning (X85), 
poisonings with unclear intent (Y10-Y14) and multiple cause of death codes (MCOD) for heroin (T40.1). 
c Median is the rate ratio, computed as the exp	(&) of the median posterior estimates. Additional adjustments included state and 
year fixed effects, and interaction between county and year (modeled with an exchangeable prior). County-level models included 








Appendix Table 10. County-level association between rate of opioid prescribinga and drug-related deathb attributed to any drug, any 
opioid,c prescription opioids,d and heroine in 3,109 counties in 49 U.S. Statesf and Washington, D.C., 2006-2016 
 Drug-related 
Deathb 






Mediang 95% CI  Mediang 95% CI  Mediang 95% CI  Mediang 95% CI 
Opioid prescribing rate (1 SD) 1.17 (1.16-1.19)  1.20 (1.18-1.23)  1.20 (1.17-1.23)  1.14 (1.08-1.20) 
Unemployment (1 SD) 1.02 (1.01, 1.03)  1.02 (1.01-1.03)  1.02 (1.00-1.03)  0.98 (0.97-1.00) 
Population density 1.03 (1.02-1.06)  1.06 (1.03-1.09)  1.05 (1.02-1.08)  1.06 (1.02-1.11) 
Race/ethnicity            
    Non-Hispanic white (%) 0.65 (0.55-0.77)  0.81 (0.63-1.05)  1.07 (0.79-1.43)  1.57 (0.82-3.01) 
    Non-Hispanic black (%) 0.54 (0.43-0.69)  0.48 (0.34-0.69)  0.41 (0.27-0.62)  5.46 (2.44-12.23) 
    Hispanic (%) 0.61 (0.48-0.77)  0.89 (0.62-1.28)  0.75 (0.49-1.13)  4.31 (1.96-9.45) 
Male (%) 0.20 (0.09-0.44)  0.26 (0.08-0.88)  0.22 (0.05-0.87)  0.09 (0.00-1.68) 
Age            
    0-19 years (%) 0.81 (0.48-1.34)  1.49 (0.68-3.28)  1.15 (0.47-2.83)  0.76 (0.45-1.28) 
    20-44 years (%) 1.72 (1.06-2.80)  3.49 (1.64-7.40)  3.43 (1.45-8.14)  1.65 (1.01-2.69) 
    45-64 years (%) 5.74 (2.53-13.06)  24.38 (6.74-88.35)  9.69 (2.23-42.20)  5.67 (2.48-12.98) 
Urbanicity            
   2 versus 1 1.00 (0.95-1.05)  0.94 (0.88-1.01)  0.98 (0.91-1.06)  0.93 (0.81-1.07) 
   3 versus 1 1.01 (0.96-1.07)  0.88 (0.81-0.95)  0.94 (0.86-1.02)  0.65 (0.55-0.76) 
   4 versus 1 0.96 (0.90-1.01)  0.86 (0.79-0.93)  0.92 (0.84-1.00)  0.69 (0.59-0.81) 
   5 versus 1 0.93 (0.87-1.01)  0.79 (0.70-0.89)  0.86 (0.75-0.97)  0.54 (0.41-0.71) 
   6 versus 1 0.90 (0.86-0.95)  0.81 (0.75-0.87)  0.89 (0.82-0.97)  0.48 (0.41-0.56) 
   7 versus 1 0.88 (0.83-0.94)  0.80 (0.73-0.88)  0.86 (0.77-0.95)  0.44 (0.35-0.54) 
   8 versus 1 0.84 (0.78-0.90)  0.83 (0.74-0.93)  0.90 (0.79-1.02)  0.45 (0.33-0.60) 
   9 versus 1 0.84 (0.78-0.91)  0.80 (0.71-0.90)  0.89 (0.78-1.02)  0.33 (0.23-0.46) 
Medical cannabis law 1.22 (1.19-1.24)  1.18 (1.15-1.21)  1.12 (1.08-1.17)  1.05 (1.00-1.10) 
Recreational cannabis law 0.91 (0.87-0.96)  0.88 (0.82-0.94)  0.95 (0.87-1.03)  0.80 (0.70-0.91) 
PDMP, must access 1.03 (1.02, 1.05)  1.03 (1.01-1.06)  1.00 (0.97-1.03)  1.04 (1.00-1.08) 
Definitions of abbreviations: CI = credibility interval; SD = standard deviation; PDMP=prescription drug monitoring program (mandatory provider review). 
Alaska was excluded from the analysis due to changes in the boundaries of multiple counties over the analytical period. Median estimates an incidence rate ratio, computed as the 
exp(!) of the median posterior estimate. County-level models included state fixed effect, unit-specific trends, and modeled spatial autocorrelation using a conditional-autoregressive 
(CAR) spatial random effect.  
a Per-capita prescription opioid rates were compiled by IQVIA Xponent, provided by the Centers for Disease Control (CDC), calculated as the total number of opioid prescriptions 
dispensed in a county in a given year and county (numerator) over the annual resident population estimates derived from the Population Estimates Program, U.S. Census Bureau. 
b Drug-related deaths were identified using International Classification of Diseases, 10th Revision (ICD-10) underlying cause of death (UCOD) codes for unintentional poisoning (X40-
X44), intentional poisonings (X60-X64), homicidal poisoning (X85), poisonings with unclear intent (Y10-Y14).  
c Opioid poisoning deaths were drug poisoning deathsa identified ICD-10 multiple cause of death codes (MCOD) for opium (T40.0), heroin (T40.1), natural or semi-synthetic opioid 




d Prescription opioid-related deaths were drug poisoning deathsa identified using ICD-10 MCOD for natural and semisynthetic opioids (T40.2) and methadone (T40.3) and not heroin 
(T40.1). 
e Heroin-related death were drug poisoning deathsa identified using ICD-10 MCOD for heroin (T40.1) 
f Alaska was excluded from the analysis due to changes in the boundaries of multiple counties over the analytical period  
g Median is the rate ratio, computed as the exp	(!) of the median posterior estimates. Additional adjustments included state and year fixed effects, and interaction between county and 
year (modeled with an exchangeable prior). County-level models included state fixed effect, unit-specific trends, and modeled spatial autocorrelation using a conditional-autoregressive 








Appendix Table 11. Sensitivity analysis: Inclusion of synthetic opioid deaths as 
prescription opioid-related deaths and heroin-related deaths 
 Effect of 1SD increase in opioid prescribing ratef 
 County-level analysis  State-level analysis 
 Mediang (95% CI)  Mediang (95% CI) 
Prescription opioid-related death     
    Including deaths from synthetic opioidsa,b 1.21 (1.18-1.23)  1.12 (1.07-1.17) 
    Excluding deaths from synthetic opioidsa,c 1.20 (1.17-1.23)  1.10 (1.05-1.16) 
      
Heroin-related death      
    Including deaths from synthetic opioidsa,d 1.15 (1.11-1.19)  1.08 (1.01-1.15) 
    Excluding deaths from synthetic opioidsa,e 1.14 (1.08-1.20)  1.24 (1.12-1.36) 
SD = standard deviation 
3,109 counties within 49 US states, 2006-2016. Alaska was excluded from the analysis due to changes in the 
boundaries of multiple counties over the analytical period.  
a Drug poisoning deaths were identified using International Classification of Diseases, 10th Revision (ICD-10) 
underlying cause of death (UCOD) codes for unintentional poisoning (X40-X44), intentional poisonings (X60-X64), 
homicidal poisoning (X85), poisonings with unclear intent (Y10-Y14).  
b Prescription opioid-related deaths were drug poisoning deathsa identified ICD-10 multiple cause of death codes 
(MCOD) for natural and semisynthetic opioids (T40.2) and methadone (T40.3) and not heroin (T40.1). 
c Prescription opioid-related deaths including synthetic opioids were prescription opioid-related deathsb including ICD-
10 MCOD for synthetic opioids (T40.6).  
d Heroin-related death were drug poisoning deathsa identified using ICD-10 MCOD for heroin (T40.1). 
e Heroin-related death including synthetic opioids were heroin-related deathsd including synthetic opioid-related 
deaths (T40.6).  
f Per-capita prescription opioid rates were compiled by IQVIA Xponent, provided by the Centers for Disease Control 
(CDC), calculated as the total number of opioid prescriptions dispensed in a county in a given year and county 
(numerator) over the annual resident population estimates derived from the Population Estimates Program, U.S. 
Census Bureau 
g Models adjusted for the following area-specific covariates: population density (1,000s of people per square mile); 
urbanicity, age distribution (% 0-19 years, % 20-44 years, % 45-64 years); racial/ethnic distribution (% non-Hispanic 
white, % non-Hispanic black, % Hispanic); gender distribution (% male); median household income; % of families in 
poverty; % of people ages 16 years or older unemployed. Models were also adjusted for State’s status on medical 
marijuana laws, must access prescription drug monitoring program, year fixed effect, unit-specific random trend. 
County-level models included state fixed effect and modelled spatial autocorrelation using a conditional-
autoregressive (CAR) spatial random effect. Median estimates an incidence rate ratio, computed as the exp(!) of the 





Appendix Table 12. County-level association between socioeconomic and social conditions and drug-related deatha 
attributed to any drug, any opioid,b prescription opioids,c and heroind in 3,109 counties in 49 US Statese and Washington, 
D.C., 2006-2016 
 Outcome: Type of Fatal Drug Poisoning 
All drugsa  All opioidsa,b  Prescription opioid onlya,c  Heroind 
RR (95% CI)  RR (95% CI)  RR (95% CI)  RR (95% CI) 
Unemployment ratef (1 SD) 1.02 (1.01-1.03)  1.02 (1.01-1.02)  1.02 (1.00-1.03)  0.99 (0.97-1.00) 
Random effects            
    County 0.002 (0.002-0.002) 0.006 0.006-0.007  0.006 0.006-0.007  0.02 (0.01-0.02) 
    Spatial 0.18 (0.17-0.19)  0.43 0.34-0.53  0.51 0.44-0.59  1.34 (1.10-1.68) 
    Noise 0.05 (0.05-0.06)  0.11 0.08-0.14  0.13 0.10-0.16  0.05 (0.02-0.12) 
    ! = spatial / (spatial + noise) 0.76   0.79   0.79   0.95  
            
Poverty rateg (1 SD) 1.03 (1.02-1.05)  1.02 (1.00-1.05)  1.04 (1.01-1.07)  0.90 (0.84-0.95) 
Random effects            
    County 0.002 (0.002-0.002) 0.006 (0.006-0.007) 0.006 (0.006-0.007) 0.02 (0.01-0.02) 
    Spatial 0.19 (0.19-0.20)  0.43 (0.35-0.53)  0.50 (0.40-0.61)  1.18 (0.99-1.43) 
    Noise 0.06 (0.05-0.06)  0.11 (0.08-0.14)  0.12 (0.09-0.16)  0.09 (0.05-0.16) 
    ! = spatial / (spatial + noise) 0.78   0.79   0.80   0.92  
            
Income inequalitye,f (1 SD) 1.10 (1.08-1.12)  1.10 (1.08-1.13)  1.09 (1.06-1.12)  1.13 (1.06-1.19) 
Random effects            
    County 0.002 (0.002-0.002) 0.007 (0.006-0.007) 0.006 (0.006-0.007) 0.02 (0.01-0.02) 
    Spatial 0.14 (0.13-0.14)  0.41 (0.33-0.52)  0.50 (0.40-0.61)  1.20 (1.03-1.44) 
    Noise 0.06 (0.06-0.07)  0.10 (0.08-0.14)  0.12 (0.09-0.16)  0.09 (0.04-0.15) 
    ! = spatial / (spatial + noise) 0.68   0.79   0.80   0.92  
            
Rey Indexh (1 SD) 1.06 (1.04-1.09  1.07 (1.04-1.11)  1.03 (0.99-1.08  1.02 (0.95-1.09) 
Random effects            
    County 0.002 (0.002-0.002) 0.007 (0.006-0.007) 0.006 (0.006-0.007) 0.02 (0.01-0.02) 
    Spatial 0.14 (0.12-0.18)  0.37 (0.30-0.45)  0.12 (0.09-0.15)  1.21 (1.02-1.47) 
    Noise 0.05 (0.04-0.06)  0.11 (0.08-0.13)  0.44 (0.35-0.53)  0.07 (0.03-0.13) 
    ! = spatial / (spatial + noise) 0.75   0.78   0.78   0.94  
            
HDI Indexh (1 SD) 0.75 (0.72-0.78)  0.78 (0.74-0.83)  0.81 (0.76-0.86)  0.92 (0.83-1.03) 
Random effects            
    County 0.002 (0.002-0.002) 0.006 (0.006-0.007) 0.006 (0.006-0.007) 0.02 (0.01-0.02) 
    Spatial 0.16 (0.13-0.19)  0.41 (0.33-0.51)  0.48 (0.39-0.59)  1.38 (1.19-1.64) 
    Noise 0.05 (0.04-0.06)  0.11 (0.08-0.14)  0.12 (0.09-0.16)  0.05 (0.01-0.10) 
    ! = spatial / (spatial + noise) 0.75   0.79   0.80   0.96  
            
Prescription opioid supplyi,f (1SD) 1.17 (1.16-1.19)  1.21 (1.18-1.23)  1.20 (1.17-1.23)  1.14 (1.08-1.20) 
Random effects            




    Spatial 0.15 (0.13-0.19)  0.38 (0.30-0.46)  0.44 (0.36-0.54)  0.15 (0.13-0.19) 
    Noise 0.05 (0.04, 0.06)  0.10 (0.07-0.13)  0.12 (0.09-0.15)  0.05 (0.04-0.06) 
    ! = spatial / (spatial + noise) 0.76   0.79   0.79   0.76  
Definitions of abbreviations: RR = rate ratio, computed as the exp(!) of the median posterior estimate; CI = credibility interval; SD = standard deviation; HDI = human development 
index. Alaska was excluded from the analysis due to changes in the boundaries of multiple counties over the analytical period. Median estimates an incidence rate ratio, computed as 
the exp(!) of the median posterior estimate. County-level models included state fixed effect, unit-specific trends, and modeled spatial autocorrelation using a conditional-
autoregressive (CAR) spatial random effect. All models adjusted for state’s status on medical and recreational cannabis laws and must access prescription drug monitoring programs. 
a Drug poisoning deaths were identified using International Classification of Diseases, 10th Revision (ICD-10) underlying cause of death (UCOD) codes for unintentional poisoning 
(X40-X44), intentional poisonings (X60-X64), homicidal poisoning (X85), poisonings with unclear intent (Y10-Y14). b Opioid poisoning deaths were drug poisoning deathsa identified 
using ICD-10 MCODs for opium (T40.0), heroin (T40.1), natural or semi-synthetic opioid (T40.2), methadone (T40.3), synthetic opioid (T40.4), and unspecified narcotic (T40.6). c 
Prescription opioid-related deaths were drug poisoning deathsa identified using ICD-10 MCODs for natural and semisynthetic opioids (T40.2) or methadone (T40.3) and not heroin 
(T40.1). d Heroin-related death were drug poisoning deathsa identified using ICD-10 MCODs for heroin (T40.1). e Income inequality measured as the Gini coefficient. f Models included 
population density (1,000s of people per square mile); age distribution (% 0-19 years, % 20-44 years, % 45-64 years); racial/ethnic distribution (% non-Hispanic white, % non-Hispanic 
black, % Hispanic); gender distribution (% male); education (% of people ages 24 years or older with a high school degree or less, % some college), median household income, 
poverty rate, and urbanicity. g Models included population density; age distribution; racial/ethnic distribution; gender distribution; education, median household income; and urbanicity. h 
Models included population density; age distribution; racial/ethnic distribution; gender distribution; education; and urbanicity. i  Per-capita prescription opioid rates were compiled by 
IQVIA Xponent, provided by the Centers for Disease Control (CDC), calculated as the total number of opioid prescriptions dispensed in a county in a given year and county 




Appendix Table 13. Fatal drug poisoning: main effects and Interaction effects of per-capita prescription opioid supply and 
economic and social conditions on fatal drug poisonings due to all drugs, all opioids, prescription opioids only, and illicit opioids 
in 3,109 counties in 49 US Statese and Washington, D.C., 2006-2016 
 Outcome: Type of Fatal Drug Poisoning 
All drugsa  All opioidsa,b  Prescription opioids onlya,c  Illicit opioids
a,d 
RR (95% CI)  RR (95% CI)  RR (95% CI)  RR (95% CI) 
Exposure: Unemploymentg ratef           
Prescription opioid supplye (1 SD) 1.17 (1.16-1.19)  1.20 (1.17-1.22)  1.20 (1.17-1.23)  1.15 (1.05-1.21) 
Unemployment rate (1 SD) 1.02 (1.01-1.03)  1.01 (1.00-1.02)  1.01 (1.00-1.03)  0.99 (0.97-1.00) 
Supply x Unemployment 1.00 (1.00-1.01)  1.01 (1.00-1.02)  1.00 (0.99-1.01)  1.00 (0.98-1.03) 
            
Exposure: Poverty rateh            
Prescription opioid supplye (1 SD) 1.18 (1.16-1.19)  1.20 (1.18-1.23)  1.19 (1.16-1.22)  1.17 (1.10-1.24) 
Poverty rate (1 SD) 1.03 (1.01-1.05)  1.02 (1.00-1.05)  1.04 (1.01-1.07)  0.89 (0.84-0.95) 
Supply x Poverty 0.99 (0.98-1.00)  1.00 (0.99-1.02)  1.01 (0.99-1.02)  0.92 (0.88-0.97) 
            
Exposure: Income inequalityf,g            
Prescription opioid supplye (1 SD) 1.18 (1.16-1.20)  1.21 (1.19-1.24)  1.20 (1.17-1.23)  1.16 (1.09-1.23) 
Income inequality (1 SD) 1.09 (1.07-1.11)  1.10 (1.07-1.13)  1.08 (1.05-1.08)  1.13 (1.07-1.20) 
Supply x Income inequality 0.96 (0.95-0.97)  0.95 (0.94-0.97)  0.98 (0.96-1.00)  0.91 (0.87-0.95) 
            
Exposure: Rey indexi            
Prescription opioid supplye (1 SD) 1.17 (1.16-1.19)  1.20 (1.17-1.22)  1.19 (1.17-1.22)  1.14 (1.08-1.21) 
Rey index (1 SD) 1.06 (1.04-1.09)  1.07 (1.03-1.11)  1.03 (0.98-1.08)  1.01 (0.95-1.09) 
Supply x Rey index 1.00 (0.99-1.01)  1.00 (1.01-1.02)  1.01 (0.99-1.02)  1.02 (0.99-1.05) 
            
Exposure: HDI indexi            
Prescription opioid supplye (1 SD) 1.16 (1.15-1.18)  1.19 (1.16-1.22)  1.21 (1.17-1.24)  1.16 (1.10-1.23) 
HDI (1 SD) 0.79 (0.76-0.81)  0.80 (0.76-0.84)  0.83 (0.78-0.88)  0.93 (0.83-1.04) 
Supply x HDI 1.01 (1.00-1.02)  1.00 (0.98-1.02)  1.03 (1.01-1.03)  1.15 (1.10-1.21) 
Definitions of abbreviations: RR = rate ratio, computed as the exp(!) of the median posterior estimate; CI = credibility interval; SD = standard deviation; HDI = human development 
index. 
Notes: The dependent variable is the number of drug-related deaths in a county attributed to all drugs, all opioids, prescription opioids, or heroin. All models were adjusted for the 
following county-level covariates:  population density (1,000s of people per square mile); age distribution (% 0-19 years, % 20-44 years, % 45-64 years); racial/ethnic distribution (% 
non-Hispanic white, % non-Hispanic black, % Hispanic); gender distribution (% male); education (% of people ages 24 years or older with a college degree). Models were also 
adjusted for State’s status on medical marijuana laws, must access prescription drug monitoring program, and state and year fixed effects. All the exposure variables have been 


























Appendix Figure 4. Directed acyclic graph for the effect of American Human Development index on fatal drug poisonings 
 
 
 
